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This project investigates the possibility to develop organometallic complexes of transition 
metals possessing biomedical applications, so as to develop potential theranostic agents. 
Specifically, this work describes the development of tripodal systems and their related metal 
complexes with relevance for prostate cancer diagnosis using cellular imaging techniques.  
Chapter 1 presents the context of this work. The concept of coordination compounds possessing 
biomedical applications is introduced, and a literature review regarding the latest transition 
metal complexes displaying biological activities is presented. Molecular imaging techniques 
are described together with examples of metal complexes designed for imaging applications. 
An overview of cellular hypoxia and its role in tumour development is given, along with a 
description of prostate cancer, its features and how these can be exploited in diagnosis and 
therapy. 
Chapter 2 describes the syntheses of tripodal systems based upon a hexasubstituted benzene 
scaffold, and their potential for biomedical applications is probed. In this chapter, two series of 
nitrogen-based and one series of anthracene-thiosemicarbazone-based tripodal systems were 
successfully synthesised and characterised spectroscopically, and their biological activity 
probed with MTT assay and confocal microscopy experiments on PC3 prostate cancer cells.  
Chapter 3 describes the development of a series of tripodal N-heterocyclic carbene-based 
compounds with the potential to act as ligands for a variety of transition metals. In this chapter, 
the synthesis and characterisation of nine tripodal systems, which incorporate unsymmetrical 
imidazole arms is described. Crystals suitable for X-ray diffraction were successfully obtained 
for four compounds described hereby, allowing an appreciation of how these systems present 
dynamic conformational equilibria, and are able to form polymeric associations via network of 
interactions between the tripodal systems and their anions. 
Chapter 4 describes the syntheses of novel tripodal systems with unsymmetrical substituents, 
so to develop ligands capable of binding metals as well as other functionalities. The 
unsymmetrical tripodal systems presented in this work are based upon the tripodal NHC-based 
compound 76 described in Chapter 3, in which one of the three NHC arms is modified either 





Chapter 5 describes the complexation attempts between a series of transition metals that have 
known biomedical potential and selected tripodal systems discussed in the previous chapters. 
Two anthracene-thiosemicarbazone based tripodal systems, previously reported in Chapter 2, 
were metallated by exploiting microwave technology to obtain rhenium and ruthenium 
complexes. The development of metal complexes of group 11 transition metals and tripodal 
NHC-based ligands reported in Chapter 3 is discussed and their biological activities are probed 
in PC3 cells using MTT assays and confocal microscopy experiments. 
Chapter 6 summaries the work described throughout the thesis and future work emerging from 
the project results. 
Chapter 7 contains all the experimental details and characterisation data for the compounds 
obtained in this work. 
The Appendices provide supporting spectroscopic data and X-ray diffraction data for the 
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1.1. Coordination chemistry for cancer therapy and other 
biomedical applications 
In 1893, the Swiss chemist Alfred Werner (1866−1919) was the first to propose the correct 
geometry of transition metal complexes when he described the structure of 
hexamminecobalt(III) chloride.1, 2 This seminal work led to the establishment of coordination 
chemistry, the branch of inorganic chemistry that studies coordination complexes. Generally, a 
coordination compound consists of a molecule composed of a central atom or ion, usually a 
metal, surrounded by molecules or anions, known as ligands.3 The ligands are attached to the 
central atom by dative bonds, also known as coordinate bonds, in which both electrons in the 
bond are supplied by the same atom on the ligand. 
A coordination complex whose centre is a metal atom is called a metal complex. The use of 
transition metal complexes as chemotherapeutic agents began with the discovery of the 
anticancer activity of the platinum(II)-based drug cisplatin in 1965 (Figure 1.1).4 Since then, 
the use of metal complexes for sensing and medicinal purposes has been increasing noticeably.5-
7  
 
Figure 1.1. Structural representation of cisplatin. 
One of the main characteristics of coordination complexes is their capacity to undergo a process 
called “ligand exchange” which denotes a chemical reaction whereby one ligand in a complex 
ion is replaced by a different one.8 A typical example regarding the way in which this ligand 
exchange may be used in medicinal chemistry is the mode of action of cisplatin: this complex 
exchanges its chloride substituents with N7-guanine residues of DNA strands, causing the 
formation of crosslinks between the two DNA strands. 
A different way to exploit the ligand exchange effect in coordination complexes is the 
possibility to bind the metal with a releasable ligand that presents a medicinal effect on its own. 
A suitable example is the recent development of carbon monoxide-releasing molecules 






(CO) to the site of interest. Even though carbon monoxide holds the bad reputation of a “silent 
killer”, its diverse effects as a second messenger (like nitric oxide, NO) include reduction of 
inflammation, heart protection from reperfusion damage following surgery and improvement 
of organ functionality after transplantation.9, 10 Some representative examples of CORMs are 
shown in Figure 1.2. 
 
Figure 1.2. Some examples of currently investigated CORMs. [Ru(CO)3Cl2]2 (1), [Ru(CO)3Cl(glycinate)] (2), and 
the biocompatible vitamin B12-rhenium complex B12-ReCORM-2 (3).9, 11 
Organometallic complexes, which are chemical compounds containing one or more metal-
carbon bonds, are a class of chemical compounds widely used in homogenous catalysis. For 
this reason, several research groups have started to develop organometallic complexes that are 
able to catalyse chemical reactions in cells.12-14 One of the first studies in this direction comes 
from Sadler and co-workers,15 by using a series of ruthenium-arene ethylenediamine complexes 
4 (Figure 1.3) that catalyse a redox reaction involving glutathione. The result is a net increase 
of reactive oxidative species (ROS), which is found to be highly toxic towards human lung and 
ovarian cancer cells. 
 






Following the discovery of several radioisotopes, the development of organometallic 
compounds has become a crucial part of radiochemistry. These complexes usually consist of a 
radioisotope linked to a simple chelator, which can be further attached to a targeting molecule 
to increase the specificity for the tissue of interest. An example of how such a strategy can be 
applied comes from a paper by Schibli and co-workers: in their work, the group synthesised a 
series of biomolecules containing the targeting molecule folic acid, functionalised with a 
tridentate picolylamine-monoacetic acid chelating system which ultimately binds an atom of 
99mTc (see compound 5 displayed in Figure 1.4).16 The resulting radiopharmaceuticals were 
able to accumulate in cancer cells where the folate receptor is overexpressed, thus allowing the 
visualization of the tumours.17 
 
Figure 1.4. Structural representation of compound 5. 
With the aim of developing treatment strategies that are minimally invasive and considerably 
less toxic, the emerging field of photodynamic therapy (PDT) has seen an extensive application 
of coordination compounds. PDT involves a combination of three elements: light, 
photosensitiser and a substrate.18 Upon light irradiation, the photosensitiser at ground singlet 
state (S0) may be excited to the first excited singlet state (S1) and then undergoes intersystem 
crossing (ISC) to reach the first excited triplet state (T1) (see Figure 1.5). The excited 
photosensitiser directly interacts with substrates (typically oxygen) to produce ROS, which in 







Figure 1.5. Generation of reactive oxygen species due to absorption of electromagnetic radiation by a 
photosensitiser molecule. The absorption leads to population of excited singlet states, which are rapidly converted 
into an S1 population via internal conversion (IC). The excited photosensitiser can return to the ground state (S0) 
by release of energy as heat (IC) or by fluorescence. Alternatively, through intersystem crossing (ISC), the 
molecule moves to the metastable triplet T1 state, which then allows energy or charge transfer to other molecules 
such as oxygen. Adapted from Ref.20 with permission from the Royal Society of Chemistry. 
Cyclic tetrapyrrolic molecules (such as porphyrins) are good examples of fluorophores and 
photosensitisers.21 A wide range of metals have been used to form complexes with 
photosensitiser macrocycles, particularly transition metals, although a number of 
photosensitisers coordinated to group 13 and group 14 metals have also been synthesised.22, 23 
The nature of the central metal ion greatly influences the photophysical properties of the 
photosensitiser.24-26 For example, the zinc phthalocyanine photosensitiser (ZnPcS4, Figure 1.6) 
has a singlet oxygen quantum yield of 0.70 in water;21 nearly twice that of most other metallated 
phthalocyanines. ZnPcS4 was found to be active against several cancer cell lines,27 as well as 
pathogenic microorganisms such as Staphylococcus aureus and Candida albicans.26 
 






The versatility of coordination complexes can also be exploited to develop combination 
agents,28 a class of compounds obtained by combining two or more active agents to form a 
molecule capable of modulating multiple targets simultaneously. An example of such a 
compound is the bifunctional heterobimetallic copper-ruthenium complex 6 (Figure 1.7) 
developed by Reedijk and co-workers.29 
 
Figure 1.7. Structural representation of the bifunctional heterobimetallic copper-ruthenium complex 6. 
Compound 6 is composed of the DNA-cleaving agent copper terpyridine (Cu(terpy)), linked by 
a flexible bridge to a high affinity ruthenium metallo-intercalator. The bimetallic combination 
agent 6 demonstrated a superior DNA-cleavage activity compared to the Cu(terpy) agent alone. 
Overall, coordination complexes display numerous properties that can be used to design drugs 
that present both therapeutic and diagnostic capabilities, thus becoming a powerful tool for 







1.1.1. N-Heterocyclic carbene complexes with biomedical applications 
N-Heterocyclic carbenes (NHCs) are cyclic compounds containing a divalent carbon atom 
bound to at least one nitrogen atom within the heterocycle.30 There were many attempts to 
isolate such species over the 20th century and, in 1991 Arduengo et al. reported the isolation 
and characterisation of the first free carbene unit incorporated into a nitrogen heterocycle.31 N-
heterocyclic carbenes (NHC, Figure 1.8) contain the lone pair of electrons of the carbon atom 
stabilised by two geminal nitrogen atoms within the heterocyclic ring. Their electronegativity 
withdraws σ-electron density away from the carbene, while at the same time the nitrogen atoms 
donate π-electron density into the empty p orbital of the sp2 hybridised carbon.32 
 
Figure 1.8. General structure of an N-heterocyclic carbene (A) and representation of the electronic stabilising 
effects (B). 
Thanks to these stabilising effects, NHCs have become extremely popular for complexing 
various transition metals. Many research articles show that NHC complexes are used as 
catalysts in a variety of chemical transformations, such as Suzuki coupling, Diels-Alder 
reactions and many others.33-35 In the last 20 years though, the application of NHC-based metal 
complexes in the area of medicinal chemistry has seen a steady increase, with their position 
being reinforced by the discoveries of tuneable biological activity. The application of NHC-
metal complexes as antimicrobial agents is a good example, with the gold imidazoline 
derivative 7 (Figure 1.9) being active against several bacterial species.36 
 







However, most progress made in this field has been achieved by using the innate antimicrobial 
properties of silver and its carbene complexes.37 Several research groups have successfully 
developed silver-based NHC chemotherapeutics that have shown minimum inhibitory 
concentration (MIC) values against bacteria under 10 µg/ml. In a study led by Youngs et al., 
two pyridine-linked pincer silver NHC complexes 8 (Figure 1.10) were even more active than 
AgNO3 against several bacterial strains.38 Another study conducted by Roland and Jolivalt et 
al. in 2011 reported a series of halido Ag(I)-NHC complexes 9 (Figure 1.10) that were found 
to be active even against S. aureus MsrA (a bacterial strain with constitutive resistance to 
erythromycin).39 
 
Figure 1.10. Structural representations of the pyridine-linker silver(I)-NHC complex 8 and the halido-silver(I) 
NHC complex 9. 
Although most antimicrobial metal complexes are silver-based, the use of gold-based NHC 
complexes is predominant in cancer therapy. Gold-based biomolecules have also been tested in 
various inflammatory diseases, such as rheumatoid arthritis, and they have been found to 
interfere with common biochemical pathways that are also relevant for cancer.40 
One of the first studies that analysed the cytotoxic activity of some dinuclear gold(I) NHC 
complexes reported the induction of mitochondrial membrane swelling triggered by 
intracellular Ca2+ increase.41 The study, conducted by Berners-Price and co-workers and 
published in 2008, revealed that gold(I) NHC complexes, such as compound 10 (Figure 1.11), 
act as mitochondria-targeted agents by interacting with selenoproteins (such as thioredoxin 
reductase) as preferential targets.42 The antimitochondrial activity of these Au(I)-NHC 
complexes could also be due to their delocalised cationic charge and their lipophilicity. Such 
attributes allow the gold complexes to accumulate in the mitochondria of the cancer cells which 







Figure 1.11. Structural representation of the dinuclear gold(I) NHC complex 10. 
Aiming to investigate the uptake and intra-cellular distribution in the PC3 human prostate 
cancer cell line of gold(I) NHC complexes Gautier, Cisnetti and co-workers developed the 
Au(I)-NHC complex 11 bearing a fluorescent coumarin moiety (Figure 1.12).44 This 
functionalised Au-NHC complex was synthesised by a straightforward synthetic route, 
combining an ‘auto-click’ reaction with a transmetallation process. Interestingly, a significant 
blue fluorescence was detected in the cytoplasm but not in the nucleus after 18 hours incubation 
of PC3 prostate cancer cells with 10 µM of the compound 11. Furthermore, compound 11 
appears to specifically localise in the mitochondria in a similar manner to the mitochondria-
targeted Au(I)-NHC complexes 12 and 13 developed by Li and co-workers (Figure 1.12).45 
 
Figure 1.12. Structural representations of the gold(I) NHC complex 11 and the mitochondria-targeted Au(I)-NHC 
complexes 12 and 13. 
A series of amino-functionalised Au(I)-NHC complexes (such as compound 14, Figure 1.13) 
were tested for their antiproliferative activity in the PC3 prostate cancer cell line by Gornitzka 
and co-workers.46 The observed anti-tumour effects were attributed to the lipophilic properties 






again highlighting the intriguing anti-mitochondrial properties of gold and its complexes. 
Moreover, compound 14 was found to be insensitive to normal primary human umbilical vein 
endothelial cells (HUVECs) at the highest concentration tested (5 µM). All these results 
indicate that 14 is active against multiple cancer cell lines while having restricted effects on 
normal human endothelial cells. 
 
Figure 1.13. Structural representation of the gold(I) NHC complex 14. 
However, selenoproteins are not the only targets of gold NHC complexes. A study from Barrios 
and co-workers reported that various gold(I) NHC complexes are capable of strongly inhibiting 
several protein tyrosine phosphatases (PTP), which are involved in several pathways relevant 
not only to cancer but also  diseases such as diabetes and obesity.47 Another paper by Che et al. 
reported a series of gold(III) NHC complexes (e.g. compound 15, Figure 1.14) that are capable 
of interacting with topoisomerase I, thus producing DNA strand breaks.48 
 
Figure 1.14. Structural representation of the gold(III) NHC complex 15. 
In the last few years, various research groups have studied the possibility of developing 
anticancer metal NHC complexes with other transition metals.49 A significant number of 
platinum-based NHC complexes have been studied and showed good activity against cancer 
cell lines.50-53 For example, a comparative study between the cis-platinum NHC complex 16 
(Figure 1.15) and cisplatin showed that two compounds had similar antiproliferative activity, 
and a strong interaction between compound 16 and DNA strains was observed. However, the 
study also outlined that compound 16 shares a similar level of interaction with glutathione to 







Figure 1.15. Structural representation of the cis-platinum based NHC complex 16. 
A series of trans-platinum NHC complexes such as compound 17 (Figure 1.16) have been 
investigated and their antiproliferative activity was found to be comparable to cisplatin.55 
Cyclometalated platinum(II) NHC complexes, such as compound 18 (Figure 1.16), displayed 
strong cytotoxic activity and useful fluorescent properties, which allowed a completely 
different biological profile to be discovered. Trans-platinum complexes were found to be potent 
inhibitors of the anti-apoptotic protein survivin, thus promoting the activation of caspase-3, a 
protease which plays a fundamental role in programmed cell death.56 
 
Figure 1.16. Examples of trans-platinum(II) NHC complexes: compounds 17 and 18. 
As well as being widely known for their anti-infective properties, silver-based NHC complexes 
have also demonstrated cytotoxic effects in cancer cells. Compound 19 (Figure 1.17) 
demonstrated IC50 values comparable to cisplatin.57 A study published in 2012 by Eloy and co-
workers demonstrates that silver NHC complexes such as compound 20 (Figure 1.17) act as 
antimitochondrial agents: these complexes can trigger membrane depolarization, damage of the 
endoplasmic reticulum and liberation of apoptotic inducing factor (AIF) from the matrix, 
ultimately causing apoptosis in cancer cells.58 
 






Although the vast majority of studies on the antiproliferative activity of group 11 transition 
metals involved the use of gold, several copper(I) NHC complexes have also been investigated. 
An extensive study by Tacke et al. involved nine symmetrically substituted (21a-i) Cu(I)-NHC 
bromide complexes and one unsymmetrically substituted (21j) derivative (Figure 1.18). These 
complexes were synthesised via the transmetallation reaction of p-benzyl substituted 
imidazolium halides with Cu(I) bromide dimethylsulfide over Ag(I) oxide.59 The Cu(I)-NHC 
bromido complexes (21a-i) showed high cytotoxicity against MCF-7 breast cancer and Caki-1 
renal cancer cell lines with IC50 values in the micromolar and sub-micromolar range. 
 
Figure 1.18. Structural representations of Cu(I)-NHC complexes 21a-j. 
A study in 2015 from Gandin and co-workers on 1,2,4-triazolium-based group 11 NHC-based 
metal complexes led to the development of the Cu(I)-NHC complex 22 (Figure 1.19). The 
newly synthesised copper(I) complex was assessed for cytotoxicity in various human cancer 
cell lines, including cisplatin-sensitive and resistant cells. Compound 22 was found to be 
between 3- to 7-fold more effective than cisplatin against A431 cervical, A549 lung, HCT-15 
colon and BxPC3 pancreatic cancer cells.60 
 
Figure 1.19. Structural representation of the 1,4-bis(4-nitrobenzyl)-1H-1,2,4-triazol-4-ium bromide-based Cu(I)-
NHC complex 22. 
Interestingly, 22 displayed higher cytotoxicity than its corresponding gold and silver complexes 






analyses suggested that compound 22 could enter and consequently accumulate in cancer cells 
leading to cell death through the impairment of the ubiquitin-proteasome degradation pathway. 
This study reinforces the rationale that the biological activity of specific NHC complexes may 
be properly tuned and modified by the nature of the metal centre, thus giving useful direction 
to the development of clinically relevant NHC-based metal complexes. 
A more recent study conducted by Bertrand and co-workers on a series of complexes of cyclic 
(alkyl)(amino)carbene (CAAC) of group 11 metals found that Cu(I)-NHC complexes such as 
compound 23, and the bis-carbene complex [(Me2CAAC)2Cu(I)]+ 24 (Figure 1.20), displayed 
noticeable cytotoxicity against a panel of cancer cell lines (including the cisplatin-resistant 
A549 lung cancer cells), with IC50 in the low sub-micromolar range.61 
 
Figure 1.20. Structural representations of the Cu(I)- CAAC complex 23 and the bis-carbene [(Me2CAAC)2Cu(I)]+ 
complex 24. 
Further mechanistic studies revealed that compound 23 was able to induce about the same 
amount of reactive oxygen species (ROS) production as the positive control H2O2. ROS 
overproduction can induce cellular stress, which ultimately leads to cell death.62 Interestingly, 
the cationic bis-CAAC complex 24 did not trigger ROS formation, suggesting that the higher 
steric hindrance, as well as the lack of readily available coordination sites on the metal centre 
of 24, might play a role in the generation of ROS compared to the more labile NHC ligand of 
the compound 23. 
The latest study on the cytotoxic activity of copper complexes, conducted by Gaillard and 
collaborators., involved a panel of cationic Cu(I)-NHC bearing 2,2′-dipyridylamine (dpa)-type 
ligands.63 These metal complexes were previously investigated for their emissive properties as 







Figure 1.21. Structural representations of the neutral Cu(I)-NHC complex 25 and the cationic complex 
[Cu(I)(NHC)(dpa)]+[PF6]- compound 26. 
From the comparative study between the neutral complexes (e.g. compound 25, Figure 1.21), 
previously screened by Gautier and co-workers,65 and the cationic Cu(I)(NHC)(dpa) 
complexes, compound 26 emerged as the most active against a panel of four cancer cell lines 
and with IC50 values lower than the commercial drugs, Etoposide and 5-fluorouracil. These 
results indicate that copper complexes are currently an attractive area of investigation in the 
pursuit for novel, potent anticancer compounds based on earth-abundant elements. 
The antiproliferative activity of palladium-based NHC complexes has been investigated and 
some promising results have also been obtained.66 The antiproliferative activity of compounds 
27 and 28 (Figure 1.22) may be related to the electron donating nature of their substituents and 
also appears to depend upon their stereochemistry, with the trans- derivatives being more 
cytotoxic than the cis-.67 The mechanism of action of such complexes has been proposed in a 
paper by Ray et al.: it appears that compound 28 triggers an overexpression of the mitotic 
protein cyclin B1, thus arresting the cell cycle at the G2-M transition phase, as well as blocking 
mitosis by avoiding the translocation of the cell division cycle protein 2 (cdc2) into the nucleus. 
 
Figure 1.22. Structural representations of the palladium-NHC complexes 27 and 28. 
Ruthenium NHC complexes with biological activity have been successfully identified in 






catalysts (such as compounds 29 and 30, Figure 1.23) were screened as antiproliferative 
agents.70 However, limiting factors such as poor solubility in biological system contributed to 
their weak efficiencies against tumour proliferation. Compound 30 instead displayed significant 
antiproliferative effects with IC50 values of 9.9 µM against MCF-7 breast adenocarcinoma, as 
well as strong inhibiting efficiency against the tumour biomarkers cathepsin B (catB) and 
thioredoxin reductase (TrxR). 
Following these first results, research conducted by Ott and co-workers involved a series of 
arene-ruthenium(II) benzimidazolylidene carbene complexes such as compound 31 (Figure 
1.23). These compounds displayed greater activity against catB and TrxR, as well as noticeable 
antiproliferative effects. Furthermore, mechanistic studies confirmed the interaction between 
the ruthenium centre and thioselenols through ligand exchange reactions. 
 
Figure 1.23. Structural representations of ruthenium-NHC complexes. 
Another recently studied class of metal-carbene complexes in the ‘metals in medicine’ field 
involves those having iridium(III) as the metal core. These complexes are characterised by an 
octahedral configuration, which allows wider structural modification, thus allowing greater 
possibilities for the design of new biomolecules.71 
In 2014 Mao and co-workers developed a series of phosphorescent cyclometallated Ir(III) 
complexes containing bis-NHC ligands 32 (Figure 1.24) that showed remarkable 
antiproliferative activity, acting as antimitochondrial agents. Furthermore, their photophysical 
properties might be exploited for diagnosis and therapy at the same time.72 For example, the 
group was able to monitor the cellular localisation of the complexes via confocal microscopy 
in HeLa cells, demonstrating that 32 was able to cross the cellular membrane and localise in the 
mitochondria, where it demonstrated a high degree of co-localisation with the conventional 







Figure 1.24. General structural representation of the cyclometalated Ir(III) complexes 32. 
 
Figure 1.25. Determination of intercellular localisation of complex 32 by confocal microscopy. HeLa cells were 
incubated with the mitochondrial dye MTR (100 nM) for 20 min and then co-incubated with 32 (20 μmol) for 10 
min at 37°C. The Ir(III) complex 32 was excited at 405 nm and the emission was collected at 520±20 nm. MTR 







In recent years several groups have begun to investigate the biological properties of the group 
7 transition metal rhenium. The profound interest in this research area is due to the fact that 
rhenium is cheaper than most of the noble metals previously described and its two isotopes, 
186Re and 188Re, can be easily produced and employed for radiotherapeutic purposes.73-75 
However, the synthesis of the first radiolabelled 188Re(V) N‐heterocyclic carbene complex 
(compound 33, Figure 1.26) was reported by the groups of Reiner and Kühn only in 2014, 
following the development of the “cold” analogue by Lum and co-workers.76, 77 
 
Figure 1.26. Structural representation of the radiolabelled cationic 188Re(V)-bis-NHC complex 33. 
Following the synthesis of compound 33, the Reiner group conducted a series of stability tests 
under various conditions, starting with water at 37 °C in a pH range from 5 to 8, with phosphate 
buffered saline solutions (37 °C; pH: 5, 6 and 7), and also bovine serum (which is reasonably 
similar to the in vivo environment). Although its “cold” precursor was found to be rather stable 
in such media, compound 33 was found to undergo decomposition. 
Investigation of the luminescent properties of the Re(CO)3-NHC complexes have been carried 
out by several research groups. In 2012, Li and co-workers, inspired by the pioneering works 
of Wrighton and Morse,78 reported the syntheses of a panel of rhenium(I) tricarbonyl chloride 
complexes with pyridine-functionalized N-heterocyclic carbenes (such as compounds 34 and 
35, Figure 1.27). These were obtained following the transmetallation reaction of a set of ligand 
precursors with rhenium(I) pentacarbonyl chloride over Ag2O. The complexes exhibit blue-
green emission characterised by metal-to-ligand charge-transfer transitions (MLCT) influenced 
by the strong electron donor capability of the bound NHC.79 
 
Figure 1.27. Structural representations of the Re(CO)3Cl pyridine-functionalised N-heterocyclic carbene 






In parallel with this work, an extensive study carried out by Brown, Stagni and Massi et. al. 
thoroughly investigated the photophysics and photochemistry of related rhenium(I) tricarbonyl 
complexes of general formula fac-[Re(CO)3(NˆC)X] such as compounds 36, 37 and 38 (Figure 
1.28).80, 81 
 
Figure 1.28. Structural representations of the fac-[Re(CO)3(NˆC)X] compounds 36, 37 and 38. X = Cl, Br. 
It was demonstrated that the coordinated NHC ligands of 36-38 act as π*-acceptors, thus directly 
influencing the energy of the LUMO level, in a similar fashion to the well-known diimine-
based rhenium complexes.82, 83 Moreover, compound 37 was found to undergo photochemical 
CO dissociation after excitation to its lowest excited state,84 which makes such complexes an 
interesting benchmark for new phosphorescent rhenium(I) carbonyl-based complexes as 
photoactivated CO-releasing molecules for the treatment of inflammation-related pathologies.85 
More recently, an extensive study carried out by Barnard and co-workers investigated the 
synthesis and characterisation of several rhenium and technetium tricarbonyl complexes with 
NHC ligands, suitable for both biological imaging and sensor applications (compounds 39 and 
40, Figure 1.29).86 The Barnard group reported the successful radiolabelling of one such 
complex (compound 41, Figure 1.29) with 99mTc via a Ag(I) transmetallation reaction by 
treating the ligand precursor with Ag2O, followed by the addition of [99mTc(H2O)3(CO)3]+.87 
 
Figure 1.29. Structural representations of a carboxylic acid-functionalised fac-[Re(CO)3(NˆC)Cl] complex 
coupled with the benzyl ester-protected glycine (compound 39), fac-[Re(CO)3(NˆC)OBn] compound 40 and the 






In order to further enhance the complex stability of rhenium and technetium tricarbonyl 
complexes, the same group prepared a number of bidentate, bis-bidentate and tridentate NHC 
pro-ligands and their corresponding Re(I) complexes (Figure 1.30).88 Although these 
complexes represent building blocks for the development of more biologically relevant metal 
complexes, mainly due to the poor stability of the bidentate complexes,89 the tridentate complex 
44 was stable in the presence of metal-binding amino acids (L-histidine or L-cysteine) and 
showed no evidence for displacement of the tridentate NHC ligand. 
 
Figure 1.30. Structural representations of the bidentate (compound 42), bis-bidentate (compound 43) and 
tridentate (compound 44) rhenium tricarbonyl complexes developed by Barnard and co-workers. 
A study in 2017 published by Simpson and co-workers investigated the anticancer properties 
of rhenium and ruthenium complexes containing NHC ligands conjugated to the nonsteroidal 
anti-inflammatory drug (NSAID) indomethacin (compounds 45-a and 46-a, Figure 1.31).90 
 






The antitumoral activity of these complexes was probed against a panel of pancreatic cancer 
cell lines. The ruthenium complexes (compounds 46 and 46a, Figure 1.31) were found to be 
inactive against the pancreatic cancer cell lines, while their rhenium analogues demonstrated 
remarkable antiproliferative activity. Moreover, it was demonstrated that the cytostatic activity, 
promoted by the metal, was triggered by the arrest of the cell cycle at the G2/M phase, 
associated with inhibition of the phosphorylation of the Aurora-A kinase gene, which is usually 
overexpressed in several cancers.91 
Finally, a study, conducted in 2018 by Luengo et al, involved the synthesis and application of 
the first cationic heterobimetallic complex of the type fac-[Re(CO)3(NHC)(LAuPPh3)]+ 
(compound 47 , Figure 1.32). The aim was to couple the valuable emissive properties of the 
previously described compound 34,78 with the antiproliferative activity of gold, so as to 
generate a multimodal agent suitable for both imaging and therapeutic purposes. Compound 47 
exhibited remarkable antiproliferative activity against the A549 lung tumour cell line. 
Moreover, confocal microscopy experiments showed that 47 was able to penetrate the cellular 
membrane and localise throughout the cytoplasm (Figure 1.33), further demonstrating the 
appealing properties of transition metal complexes for the development of multimodal agents 
suitable for biomedical applications. 
 
Figure 1.32. Structural representation of the heterobimetallic Re(I)/Au(I) complex 47. 
 
Figure 1.33. Images of compound 47 incubated with A459 cells and Draq5 (a nuclear dye used as an internal 






Over the last few years, research on the medical applications of metal NHC complexes has 
brought us many different ligands and metals. Considering the wide chemical diversity amongst 
the various complexes described, it is highly unlikely that a unique target for metal NHC 
complexes exists.  
Overall, the possibility to tune the biological activity of both ligands and metals, as well as the 
useful characteristics of some transition metals to be used as imaging agents, confers this recent 
class of compounds with exciting possibilities for NHC-metal complexes in medicinal 
chemistry. One of the main aims of this thesis is to investigate new carbene-based ligands for 
their capacity to bind transition metals forming new coordination complexes with relevance in 







1.2. Molecular imaging of cancer 
Molecular imaging is a set of various techniques that allows the in vivo characterisation and 
quantification of biological processes at a cellular level. It exploits chemical tracers as well as 
intrinsic tissue features in order to obtain “images” that can give crucial information for 
detection and progression of a disease and evaluation of the treatment.92 The key features of 
some of the most important molecular imaging techniques are summarised in Figure 1.34. 
 
Figure 1.34. A summary of techniques used for molecular imaging.92 
 
1.2.1. Magnetic Resonance Imaging (MRI) 
Magnetic resonance imaging (MRI) relies on the principles of nuclear magnetic resonance 
(NMR), a spectroscopic technique that allows chemical and physical information to be obtained 
regarding the structure of a molecule. MRI produces images based on spatial variations in the 
phase and frequency of radiofrequencies (RF) being absorbed and emitted by the imaged object.  
The human body is composed primarily of water and fat, both rich in hydrogen atoms, which 
therefore constitutes up to 63% of the human body.93 The nuclei of hydrogen atoms (protons) 
are comparable to small magnets, each possessing its own magnetic moment which is randomly 
oriented. By applying a strong, external magnetic field, the protons assume a non-random 
alignment, resulting in a measurable magnetic moment in the direction of the external magnetic 
field. Upon application of RF pulses, it is possible to reconstruct images deriving from the 






The main advantages of MRI over other imaging techniques include a very high spatial 
resolution, especially due to a superior soft tissue contrast resolution and multiplanar imaging 
capabilities.94 Since MRI does not require the use of ionising radiation, this technique is widely 
used in hospitals and clinics for medical diagnosis, staging of disease and follow-up, without 
exposing the body to potentially harmful radiation. The main disadvantage of MRI is its very 
low sensitivity, usually around 10-3 mol/L to 10-5 mol/L, well below that of other imaging 
techniques such as PET and SPECT.95  
The use of contrast agents in MRI allows enhancement of the signal for certain types of tissues, 
organs or molecules by altering the longitudinal and transverse relaxation time (T1 and T2) of 
water protons. This is achieved by using paramagnetic metal ions such as gadolinium (Gd3+).96 
The enhanced sensitivity makes it possible to take advantage of the great spatial and temporal 
resolution of the MRI imaging modality, thus allowing a detailed picture of the biological 
microenvironment to be acquired at a cellular and molecular level. An example of such an agent 
is shown below in Figure 1.35: the ferrocene-conjugated complex Gd-DTPA, developed by 
Kim and co-workers in 2010,97 which demonstrated high relaxivity as well enhanced thermal 
and kinetic stability in the target tissue. 
 
Figure 1.35. Structural representation of the ferrocene-conjugated Gd-DTPA, used as MRI contrast agent. 
Adapted from citation97 
 
1.2.2. Positron Emission Tomography (PET) 
Positron emission tomography is a technique that exploits compounds (drugs or biomolecules) 
attached to a positron emitting radioisotope (Table 1.1). The antiparticle generated undergoes 
an annihilation process with an electron from a nearby molecule, thus producing two γ-rays that 
move in opposite direction. The event is detected, and a 3D image of the tracer concentration 






Table 1.1. Most common radioisotopes used in PET and SPECT. The average energy of the positron (β+) is given 
along with the percentage of decays in which the β+ is emitted. The energy of γ-rays that occur in more than 1% 
of decays is given along with the percentage of decays in which that γ-ray is emitted.99 
Isotope Half-life β+ Energy (MeV) γ Energy (MeV) 
11C 20.4 min 0.385 (99.8%)  
13N 9.97 min 0.492 (99.8%)  
15O 122 s 0.735 (99.9%)  
18F 110 min 0.250 (100%)  
38K 7.64 min 1.216 (99.3%) 2.167 (99.8%) 
62Cu 9.74 min 1.315 (97.6%)  
64Cu 12.7 h 0.278 (17.9%)  








124I 4.18 d 
0.686 (11.3%) 
0.974 (11.3%) 
1.691 (10.4%), 7.228 (10.0%), 1.509 
(3.0%), 1.376 (1.7%), 1.325 (1.43%) 
 
In order to obtain the best outcome from PET imaging, the choice of the radiotracer is crucial. 
In recent years, many radiolabelled compounds have been synthesised in order to improve their 
localisation and the detection of cancers.100-102 The most commonly used radiotracer for PET 
imaging is 18F-fluorodeoxyglucose (18F-FDG - Figure 1.36). This radiolabelled analogue of 
glucose was developed as a tracer selective for high-glucose-utilising cells such as brain, kidney 
and cancer cells. In the context of prostate cancer, 18F-FDG use is generally limited to the 
detection of primary forms of this disease because of the small size and slow growth rate of the 
prostate gland. However, 18F-FDG may be used for the detection of hidden metastatic lesions 
in patients with biochemical recurrence (a state characterised by an increasing level of prostate-
specific antigen), and also the evaluation of the treatment response in advanced prostate 
cancer.103 
 






Another characteristic shared by many types of tumour cells is increased lipogenesis followed 
by abnormal cellular membrane synthesis. 11C-acetate, 11C-choline and 18F-fluorocholine have 
been synthesised in order to target phospholipid biogenesis.104 Acetate is incorporated in the 
synthesis of fatty acids by fatty acid synthetase, which is found to be overexpressed in several 
malignancies.105  11C-acetate may therefore be useful in detecting lymphatic metastases and in 
the localisation of tumour recurrences. Choline is transported into the cells via its dedicated 
transporter and it is used as a building block for the biosynthesis of phosphatidylcholine (a 
component of the cellular membrane) through the action of choline kinase, which is upregulated 
in prostate cancer cells.105 Various studies have reported that choline-based radiotracers may 
be exploited for the detection of metastatic diseases in patients with biochemical relapse who 
are subject to increasing prostate-specific antigen (PSA) levels (Figure 1.38).106-108 
 
Figure 1.37. Structural representations of 11C-acetate (48), 11C-choline (49) and 18F-fluorocholine (50). 
 
Figure 1.38. Instance of a PET-positive pelvic nodal area in a patient with biochemical relapse following prostate 
radiotherapy and androgen ablation therapy. (a) PET/CT scan with 18F-FDG. (b) PET/CT scan with 18F-choline.109 
Among many upregulated pathways in prostate cancer cells, the overexpression of various 
amino acid transport systems are emerging as suitable targets for PET imaging. Anti-1-amino-
3-18F-fluorocyclobutane-1-carboxylic acid (anti-18F-FACBC, Figure 1.39) is a synthetic amino 
acid analogue that accumulates in prostate cancer cells following the overexpression of the ACS 
(Alanine, Cysteine & Serine) transport system.110 A study from Nanni and co-workers proposed 








Figure 1.39. Structural representation of anti-18F-FACBC. 
Surface receptors that are generally upregulated in cancer cells are emerging as attractive targets 
for therapy and diagnosis. For example, various Prostate-Specific Membrane Antigen (PSMA)-
based radiotracers have been developed, including peptidomimetic PSMA inhibitors and 
radiolabelled antibodies.112 Promising derivatives include the bombesin-based ligand 68Ga-
DOTA-CHCO-Gly-4-aminobenzyl-Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH2 51 that binds to 
the overexpressed Gastrin-Releasing Peptide (GRP) receptor, the 89Zr-5A10 monoclonal 
antibody 52 that targets free Prostate-Specific Antigen (PSA) and the 1-(2’-deoxy-2’-fluoro-b-
D-arabinofuranosyl)thymidine 53, specific for thymidine kinase, which was developed for 
assessing cellular proliferation and as a cellular stress marker.113 All these recent approaches 
are currently under investigation in the preclinical stages for the molecular imaging of prostate 
cancer with PET. 
 
Figure 1.40. Structural representations of 68Ga-DOTA-CHCO-Gly-4-aminobenzyl bombesin analogue (51), 89Zr-







1.2.3. Single-Photon Emission Computed Tomography (SPECT) 
In the same manner as PET, SPECT imaging makes use of a radioisotope that emits one or 
more γ-rays of characteristic energies which are directly measured by an instrument.114 The 
advantages of this technique, compared to PET, are lower cost, thanks to the longer half-lives 
of the radioisotopes used (e.g. t1/299mTc = 6 hours), and the possibility of using different isotopes 
in the same study (Table 1.1). In contrast, SPECT imaging suffers from lower spatial resolution 
and the use of heavier isotopes may alter the biochemical properties of the labelled compound. 
In clinical practice, SPECT has been used to detect bone metastases in patients with advanced 
prostate cancer. Various radiolabelled phosphonates (for example the 99mTc-diphosphonate 
represented in Figure 1.41) have been developed and used in diagnosis.115, 116 
 
Figure 1.41. Structural representation of 99mTc-diphosphonate. 
 
1.2.4. Optical imaging 
Optical imaging (OI) is a non-invasive imaging technique that allows one to follow the 
biodistribution of fluorescent molecules in living organisms.117 OI makes use of an external 
excitation light source (usually a laser) that excites a selected fluorescent probe which emits 
light at a longer wavelength of lower energy. This type of imaging is particularly useful for 
monitoring the targeted accumulation of fluorophore-labelled drugs thanks to its high 
sensitivity and resolution, as well as the possibility to perform multimodal imaging by coupling 
OI with other imaging techniques, such as computed tomography and PET. Lack of deep tissue 
penetration, auto-fluorescence and diffusive scattering phenomena and the lack of anatomical 
information are the main limitation of OI. 
While the majority of optical imaging applications are in preclinical research (using techniques 
such as confocal microscopy), it is possible to exploit OI for clinical purposes.118 A paper 
published by Dam et al reported a methodology to exploit the near-infrared fluorescent dye 
derivative named Folate-FITC (compound 54 shown in Figure 1.42), which consists of 






in ovarian cancer cells). In this pilot study, the folate-FITC in an intravenously injected 
formulation enhances the fluorescence imaging over the time course from 2 to 8 h after injection 
(Figure 1.42). This could be used to help surgeons to detect and remove malignant lesions while 
keeping as much healthy tissue as possible.119 
 
Figure 1.42. Left: Structural representation of Folate-FITC (54). Right: Colour image (a) of a representative area 
in the abdominal cavity (b) with the corresponding tumour-specific fluorescence image.119 
As mentioned before, OI displays excellent sensitivity, and it is particularly suitable for non-
invasive imaging of drug localisation in superficial tumours. Unfortunately, due to the 
excessive light scattering effect of deep tissues, such a technique is usually restricted to 
superficial tissues where the light can easily penetrate. 
Chen and co-workers120 reported a near infrared fluorescence (NIRF) labelled high-density 
lipoprotein (HDL) nanoparticle 55 to assess both active specific targeting to blood vessels in 
tumours and passive accumulation (due to the enhanced permeability and retention effect). The 
results showed that nanoparticles functionalised with a specific targeting system accumulate 
immediately after administration, while passive targeted accumulation of a nonspecific probe 
is the main event over a longer time period. This study gives an insight into how OI can be used 







Figure 1.43. Structural representation of the functionalised nanoparticle 55 and its constituents: Gadolinium 
diethylenetriaminepentaacetate-di(stearylamide) (Gd-DTPA-DSA, yellow dot) as MRI contrast agent, 1,1’-
dioctadecyl-3,3,3’,3’-tetramethylindotricarbocyanine iodide (DiR, green dot) as NIR dye and the cyclic RGD-
containing pentapeptide (c(RGDf(S-acetylthioacetyl)K) (RGD) as specific targeting agent. 
The possibility to exploit OI for detecting alterations in the tumour environment has been 
reported by Kim et al. in 2011121 by assessing the accumulation of a hydrocyanine-labelled 
nanoparticle (Hydrocyanine-NC) in subcutaneous mice xenografts. The principle behind this 
study is that tumours are often involved in inflammatory and immune responses that are 
characterised by an increase of reactive oxygen species (ROS). In the presence of such an 
oxidative environment, the hydrocyanine moiety undergoes an oxidation reaction that produces 
a fluorescent cyanine dye (see Figure 1.44). Strong fluorescence intensity could be developed 
from hydrocyanine NC in a dose-dependent manner with ROS, and the nanoparticles showed 
strong intracellular fluorescence after treatment of macrophage cells (RAW 264.7) with the 
cytotoxic agent lipopolysaccharide (LPS), whereas in non-treated cells no fluorescence image 







Figure 1.44. The oxidation of a hydrocyanine to a fluorescent derivative due to the presence of intracellular ROS.
 
 
Figure 1.45. Confocal microscopy images of cellular uptake of Hydrocyanine-NC in RAW 264.7 macrophage 







1.3. Hypoxia and cancer 
Hypoxia is a microenvironment condition characterised by decreased oxygen content at the 
cellular level. This particular condition is present in the microenvironment of many tumours, 
due to an imbalance between the quantity of oxygen available and its enhanced consumption 
rate by cancer cells.122 Another cause is due to the physiological characteristics of the tumour 
microvasculature which is often undeveloped, thus limiting oxygen diffusion in deep tissues. 
Prolonged hypoxic states in tumour cells produce a marked decrease in protein synthesis, which 
results in a reduced cell proliferation and cell death: these phenomena are generally considered 
a way for the tumour to reduce its overall energy consumption.123 The inhibition of protein 
translation is achieved through two distinct pathways: 
I) Unfolded protein response (UPR) that leads to the inhibition of mRNA translation in 
the endoplasmic reticulum; 
II) Disruption of the mRNA capping complex (EIF4F) that causes the loss of recruitment 
of translatable mRNA.124 
Another important consequence of tumour hypoxia is the increase in expression of the hypoxia-
inducible factor-1 (HIF-1), an important element in tumour progression and resistance to radio- 
and chemotherapy.125 HIF-1 is a transcription factor composed of two subunits: a hypoxia-
regulated α subunit and an oxygen-dependent β subunit, the latter binding to DNA through 
hypoxia-response elements (HREs) responsible for controlled target gene transcription. The 
hypoxia-sensitive subunit α is mainly regulated through a degradation pathway that involves 
various members of the prolyl hydroxylase family of enzymes. These enzymes mediate the 
hydroxylation of proline residues in the oxygen-dependent degradation domain (ODD) of HIF-
1α. This modification is then recognised by the von Hippel-Lindau complex that ensures HIF-
1α degradation via proteosomal activity. Thus, under normoxia conditions HIF-1α levels are 
kept low. However, deficiencies of oxygen lead to prolyl hydroxylase malfunction, producing 
a decrease of proteosomal degradation and a consequent increase of HIF-1α levels. HIF-1α 
accumulation leads to the formation of the HIF-1 heterodimer by binding to the β subunit: the 
resulting enzyme is then able to upregulate several genes to promote survival in low-oxygen 







Figure 1.46. HIF-1α inhibition pathway in normoxic conditions (A) and response to hypoxic condition (B).126 
HIF-1 activation plays an important role in sustaining cell growth by stimulating energy 
production in cancer cells via aerobic glycolysis. This phenomenon, known as the Warburg 
effect, is largely dependent on HIF-1 and induces the expression of various enzymes and 
transporters responsible for internalisation and degradation of extracellular glucose. HIF-1 
promotes the activation of pyruvate dehydrogenase kinase 1 (PDK1) and MAX-interactor 1 
(MXI1), causing a steady reduction of oxidative phosphorylation in mitochondria. Both effects 
ultimately lead to a reduction of oxygen consumption in cancer cells.127 HIF-1 also promotes 
the expression of vascular endothelial growth factor (VEGF) and erythropoietin (EPO), 







1.3.1. Imaging cellular hypoxia in cancer 
The capacity to determine the extent of tumour hypoxia in solid cancers is vital for the 
evaluation of an anti-tumour therapy, since cellular hypoxia plays a pivotal role in resistance to 
therapy, increased aggressiveness and metastaticity.129-131  
Cellular hypoxia cannot be predicted from biopsies or by conventional imaging methods. Direct 
measurements of hypoxia tend to be invasive procedures (often undertaken at the time of 
surgery) and are subject to sampling errors. Instead, non-invasive methods such as PET may 
offer a better solution while using hypoxia-specific tracers.132 
An imaging method for in vivo measurement of hypoxia was developed by radiolabelling 
various nitroimidazoles. These compounds are known to undergo chemical reduction at low 
oxygen levels,133 and the most extensively studied nitroimidazole for in vivo PET imaging is 
[18F]fluoromisonidazole (18F-FMISO).134, 135 The main advantage of 18F-FMISO is due to the 
fact that its reduction is directly affected by tumour oxygenation, however, 18F-FMISO imaging 
is limited by the relatively low tissue uptake of the compound in vivo. Furthermore, the slow 
cellular washout of this tracer results in low-count-rate studies and images of limited quality.136 
The development of suitable alternatives to 18F-FMISO has brought copper(II)-diacetyl-bis(N4-
methylthiosemicarbazone), or Cu-ATSM, a metal complex that is able to overcome many of 
the limitations of 18F-FMISO. Cu-ATSM shows rapid delineation of tumour hypoxia (< 1 hour) 
and high tumour-to-background tissue ratios, greatly improving the imaging quality that can be 
achieved.137 
 
Figure 1.47. Structural representation of Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone), or Cu-ATSM. 
The anti-tumour properties of dithiosemicarbazones were first identified in the 1960s, followed 
by the discovery of an enhancement of this capability by complexation with copper(II).138 
Compared to other established radionuclides, the use of copper presents several advantages: 
copper chemistry is restricted to two main oxidation states (I and II) and its redox properties 






availability of positron-emitting isotopes of copper (60Cu, 61Cu, 62Cu and 64Cu) makes this 
element an attractive option on which to base new imaging agents. 
The first report of the hypoxia selectivity of Cu-ATSM was in an isolated rat heart model of 
ischemia in 1997. The proposed mechanism of action of Cu-ATSM as a hypoxia tracer relied 
on its behaviour as a copper transporter in cells: the complex crosses the membrane due to its 
high lipophilicity. Once inside, the hypoxic condition favours the reduction of Cu(II) to Cu(I), 
thus determining its intracellular accumulation.139 
Cu-ATSM was first used in clinical trials in 2000,140 and further clinical studies have provided 
useful information in patients with lung,140, 141 cervical142, 143 and rectal144 cancers. Since then, 
several derived bis(thiosemicarbazonato) complexes, designed with the purpose of serving as 
multimodal imaging agents, have been used in pre-clinical research for PET, SPECT and 
confocal microscopy.145-147 Furthermore, given the interest that theranostics are currently 
generating in the scientific community, bis(thiosemicarbazonato) metal complexes will keep 








1.4. Prostate Cancer 
With more than 47,600 estimated new cases in the UK in 2016, Prostate Cancer (PCa) is one 
of the most commonly diagnosed types of cancer in men, and the second most common cancer 
overall. In 2016, around 11,600 men died from prostate cancer in the UK, which means 31 
people die every day from this common form of cancer.148 If detected in its first stages, the 
localised disease can be effectively cured by radical surgery or radiation therapy (stages 1-2 in 
Figure 1.48). On the other hand, locally advanced and metastatic forms (stages 3-4, Figure 1.48) 
can be treated with Androgen Suppression Therapy (AST). AST is capable of inducing tumour 
regression for a period of two years, but unfortunately this approach is not sufficient to prolong 
the survival rate.149 PCa gradually progresses to a castration-resistant state, which presently 
remains incurable. Thus, the lack of treatments for this type of cancer have to be addressed with 
novel targeted therapies.150 
 
Figure 1.48. Anatomy of the prostate and different stages of PCa. Stages 1-2 correspond to early stages of PCa in 
which the malignancy is localised only within the prostate gland. Stage 3 represents an advanced form that is 
beginning to spread outside the prostate gland. The final, stage 4, is generally incurable due to the presence of 
metastasis, spreading into the lymph nodes.151 
The development of new therapies follows an increased understanding of the molecular 
mechanisms that drive the development of PCa, its progression, and resistance to the different 
therapies.152 Given the molecular and clinical heterogeneity displayed by castration-resistant 
PCa among patients, suitable therapeutic approaches are likely to require personalised therapy 






various evidence that molecular therapeutics developed in the last few years (for example 
antiangiogenic agents, proteasome and growth factor receptor inhibitors) may selectively hinder 
certain biochemical pathways activated in tumours as compared to conventional 
chemotherapeutic agents. It is crucial to consider also pharmacokinetic issues, such as poor 
distribution through the circulatory system, rapid clearance, scarce accessibility to the tumour 
area and excessive toxicity.150 
The recent emerging branch of nanomedicine, based on the use of tumour-targeted 
nanotherapeutics, which are drugs of a size comparable to one hundred thousandth of a human 
hair, may represent a promising approach to overcome such challenges.156 The main 
characteristic of tumour-specific nanotherapeutics is to be capable to deliver the active drug 
molecules preferably to the tumour site rather than to the normal tissues, thus assuring improved 
antitumoral activity and reduced toxicity towards healthy tissues.157 The targeted delivery of a 
bioactive molecule to the tumour site is possible through either active or passive targeting.156 
Passive targeting is based on the principle of the enhanced permeation and retention (EPR) 
effect and makes use of both the locally increased vascular permeability in the tumour area and 
the reduced lymphatic drainage directed to the tumour tissue, thus accumulating the drugs in 
the desired site. Active targeting bases its actions on ligands bound to delivery systems that act 
as homing agents and which interact with specific surface receptors widely expressed on the 
target cells, thus ensuring uptake (via receptor-mediated endocytosis) and achieving the specific 
delivery of the therapeutic agent. 
For optimum drug delivery, the choice of specific targeting ligand is crucial to achieve 
successful therapy. Simple moieties like growth factors and cytokines are usually advantageous 
in terms of production, handling and availability. An example is the widely used folate system 
that targets the related folate receptor, overexpressed in a wide range of tumours.158 
Alternatively, antibodies are attractive targeting systems due to their specificity and stability 
towards biological systems.159 Another class of ligands suitable for targeting are peptides: these 
molecules are characterised by their relatively small size, low immunogenicity and high 







1.4.1. Targeting Prostate Cancer 
Following an increased understanding of the molecular pathways responsible for tumorigenesis 
in PCa, a variety of suitable targets (e.g. receptors, antigens) are emerging. These targets are 
generally overexpressed on the outer membrane of PCa cells (Figure 1.49) and could be used 
to improve the delivery of the treatment. A brief description of these targets is presented in 
Table 1.2 below. 
 







Table 1.2. A summary of possible targets for targeted delivery of therapeutics in PCa. 





Transferrin Receptor (TfR) iron uptake, cell growth prostate, breast, pancreas 
Six-Transmembrane 
Epithelial Antigen of the 
Prostate (STEAP) 
iron homeostasis 
prostate, bladder, lung, colon, 
ovary, Ewing's sarcoma 
Prostate Specific G-Protein 
Coupled Receptor (PSGR) 





cell growth prostate, breast, lung 
Human Epidermal Growth 
Factor Receptor 2 (Her-2) 
cell growth, survival, 
adhesion, migration, cell 
differentiation 
prostate, breast, pancreas, 
gastric 
Heat Shock Proteins (HSPs) 
cell cytoprotection, 
survival 
prostate, breast, colon, lung, 
ovary, pancreas 
 
Prostate Specific Membrane Antigen (PSMA)  
The Prostate Specific Membrane Antigen is a type II integral membrane glycoprotein (a 
transmembrane protein that displays its N-terminal residue towards the cytosol) which is 
currently used as a marker for PCa cells and therapy progression. PSMA overexpression is 
correlated with all types of prostate tumours, especially metastatic and castration-resistant 
forms.161 This characteristic, coupled with its high internalisation rate, makes PSMA an 






A paper published by Banerjee and co-workers in 2014 reported the synthesis and application 
of a series of 64Cu-labelled inhibitors for PSMA, based on a lysine-glutamate urea scaffold and 
a variety of  macrocyclic chelators.166 Their most potent ligand comprised the CB-TE2A 
chelator for complexation of 64Cu (compound 56, Figure 1.50), which demonstrated improved 
biodistribution with rapid clearance from healthy tissues, resulting in significantly improved 
image contrast.167 
 
Figure 1.50. Structural representation of the urea-based, 64Cu-labelled, PSMA-targeted radiotracer 56. 
 
Transferrin Receptor (TfR) 
The transferrin receptor (TfR) is a membrane transport glycoprotein that regulates iron 
homeostasis and is widely expressed in rapidly proliferating cells.168, 169 As a target for 
therapies, TfR shows two important characteristics: 
I) TfR is overexpressed (2 to 10-fold) in PCa cells, 
II) The clathrin-mediated endocytosis, responsible for the internalization of this 
receptor, may be exploited for selective delivery of transferrin-conjugated 
systems.170 
An example of how TfR could be exploited in the context of molecular imaging comes from 
the work of Zhao et al published in 2015.171 The group successfully synthesised transferrin (Tf) 
stabilised gold nanoclusters (Tf-Au NCs, Figure 1.51) by adapting a procedure previously 
outlined by Yan and co-workers.172, 173 The obtained Tf-Au NCs were successfully applied in 
the near-infrared (NIR) targeted fluorescence imaging of PCa-overexpressing Tf receptors in 








Figure 1.51. (A) Pictorial representation of a Tf-Au NC prepared by Zhao et al. (B) In vivo NIR fluorescence 
imaging of PC3 tumour xenograft mice after 2 hours from the injection of Tf-Au NCs (8 µg Au per mouse).171 
 
Six-Transmembrane Epithelial Antigen of the Prostate (STEAP) 
The six-transmembrane epithelial antigen of the prostate (STEAP) is a metalloreductase 
significantly expressed in various tumours.174, 175 Challita-Eid and co-workers observed that 
STEAP is particularly overexpressed in prostate metastases to bone and lymph node. In vitro 
data from the same group also suggested that STEAP may be involved in intercellular 
communication between cancer cells.176 Thus, STEAP could represent a useful tool for 
targeting advanced PCa. 
In a study published in 2015, Doran and co-workers developed a formulation designated 
MSTP2109A (Figure 1.52), which consists of an antibody-89Zr radiotracer conjugate that 
recognizes STEAP1 extracellular epitopes.177 The radiolabelled complex exhibited a significant 
percentage of immunoreactivity for human STEAP1 and it was also capable of accumulating at 
the tumour site and accurately detecting metastatic PCa cells.178 
 







Prostate Specific G-Protein Coupled Receptor (PSGR) 
The prostate-specific G-protein coupled receptor (PSGR) is a 7-transmembrane domain 
receptor, specific for prostate tissue, part of the bigger family of G protein odorant receptors.179 
Its overexpression has been observed in prostate intraepithelial neoplasia (PIN) and in prostate 
cancer, implying that PSGR may be crucial for the development and progression of the 
tumour.180-182 
 
Heat Shock Proteins (HSPs) 
The heat shock proteins (HSPs) are a large family of highly conserved proteins whose 
expression is triggered by a wide range of physiological and environmental insults.183 HSPs are 
crucial for cell cytroprotection and survival: these proteins I) act as catalysts for proper protein 
folding, avoiding protein aggregation and proteosomal activation; II) interfere with the 
apoptotic machinery by inactivation of the caspase pathway. These two characteristics are also 
exploited by cancer cell for their survival: high levels of expression of HSP90, HSP70, GRP78 
and HSP27 are found in cancer cells resistant to chemotherapy.184 Numerous therapeutic 
approaches involving the targeting of HSPs have been explored,184-186 including the possibility 
to develop vaccines: HSPs have been found expressed on the cell surface of tumour cells, where 
they act as modulators of the immune system.187, 188 
 
Human Epidermal Growth Factor Receptor 2 (Her-2) 
The human epidermal growth factor receptor 2 (Her-2) is a transmembrane tyrosine kinase 
receptor, part of the HerB family, which is found to be overexpressed in numerous 
malignancies.189, 190 It positively regulates cell growth, survival, adhesion, migration and cell 
differentiation.150 The Her-2 signalling pathway stimulates the activation of the androgen 
receptor (AR) pathway, thus influencing the progression of aggressive prostate cancer.191 
Clinical attempts to exploit Her-2 as a target have led to the development of the Her-2 
monoclonal antibody, trastuzumab, for the treatment of breast cancer.192, 193 Therapeutic 
approaches for the treatment of hormone-refractory prostate cancer have shown that targeting 
HerB kinases indeed has beneficial effects. However, a study conducted by Lara and co-






thus hindering the clinical applications.194 An example of how the targeting of Her-2 could be 
exploited in therapy was published by Lin and co-workers in 2013.195 The group made use of a 
188Re labelled chelator SOCTA (succinimidyl 3,6-diaza-5-oxo-3-[2-
(triphenylmethyl)thioethyl]-8-[(triphenylmethyl)thio]octanoate) that was conjugated to 
trastuzumab (compound 57, Figure 1.53). As noted above, trastuzumab is a humanized anti-
Her2 monoclonal antibody widely used for the treatment of patients with Her2-overexpressing 
breast cancer.196 Treatment of DU145 (an androgen receptor-negative prostate cancer cell line) 
with 57 resulted in a reduction in proliferation of DU145 cells in a dose- and time-dependent 
manner. These promising results suggest that combined radio- and immuno-therapy could 
prove beneficial to treat patients with advanced tumours. 
 
Figure 1.53. Pictorial representation of the 188Re-SOCTA – Trastuzumab conjugated compound 57. 
 
Gastrin-Releasing Peptide Receptor (GRPR) 
The gastrin-releasing peptide receptor (GRPR) is another 7-transmembrane G-protein coupled 
receptor whose main ligands are the gastrin-releasing peptide (GRP) and bombesin (Figure 
1.54). While negative in normal conditions, high levels of GRPR expression are found in PCa, 
as well as in breast cancer and small-cell lung carcinoma.197-199  
 
Figure 1.54. Structural representation of the naturally occurring peptide, bombesin. 
Bombesin is a 14-amino acid peptide, originally isolated from the skin of the European fire-






in Gly-His-Leu-Met-NH2. Therefore, the two peptides present similar biological activities. 
There is a growing consensus among the scientific community that GRP and bombesin (and 
other bombesin-like peptides) may operate as growth factors in these types of cancer.202 Thanks 
to these characteristics, various labelled bombesin-based molecules have been synthesised for 
therapy and imaging applications.203-205  
The first GRP receptor targeting compound used for molecular imaging was the 64Cu DOTA-
Aoc-BBN(7-14) complex 58 (Figure 1.55), developed by Rogers et al.206 This work 
demonstrated for the first time that it was possible to incorporate the PET imaging isotope 64Cu 
into a bombesin derivative with high efficiency. Furthermore, compound 58 demonstrated a 
rapid internalisation rate into PC3 cells and good tumour localisation. 
 
Figure 1.55. Structural representation of the 64Cu radiolabelled GRP receptor targeting compound 58. 
An innovative way to combine target selectivity, therapeutic and imaging applications in a 
single scaffold has been reported in 2011 by Santos and co-workers.207 The group developed a 
novel multifunctional agent (compound 59-Re and 59-99mTc, Figure 1.56) comprising: 
(1) a pyrazolyl-diamine framework bearing a set of donor atoms, to stabilise the [M(CO)3]+ (M 
= Re, 99mTc) metal centre;  
(2) a DNA intercalating moiety based upon acridine orange (AO), to ensure close proximity of 
the radionuclide to DNA and to allow the internalization of the compound to be followed by 
confocal fluorescence microscopy;  
(3) a bombesin analogue as targeting unit, so as to provide prostate cancer cell-selectivity. 
Compound 59-99mTc demonstrated high cellular internalization and nuclear uptake in GRPr-
positive PC3 human prostate tumour cells, while the congener 59-Re showed a considerable 
accumulation of fluorescence in the nucleus and high kinetic stability, which makes these 







Figure 1.56. Structural representation of the targeted multifunctional tricarbonyl complexes 59-Re and 59-99mTc. 
In summary, in the last few years, many possible targets against prostate cancer have been 
studied and various practicable pathways have been discovered. However, given the complexity 
and the high degree of heterogeneity displayed by prostate cancer, multiple therapeutic 
approaches are needed. Effective methodologies, such as personalised medicine and rapidly 
evolving imaging techniques, will require more effort to accomplish the ultimate aim of 






1.5. Aim and objectives 
This project involves the design, synthesis and study of highly kinetically stable molecular 
systems ready for cellular uptake, so as to be of relevance to prostate cancer diagnosis using 
cellular imaging techniques.  
Such systems can also be incorporated into the synthetic scaffold of future therapeutics through: 
• incorporation of transition metals that demonstrate anticancer properties; 
• controlled carbon monoxide (CO) releasing properties, so to create a CO-releasing 
molecule (CORM) able to deliver a defined and therapeutic quantity of CO in a selective 
way. 
The molecular systems described in this work are based upon a tripodal organic core that can 
be functionalised with a wide range of functionalities (e.g. linkers, fluorophores, targeting 
groups). These systems will be tested for their suitability to act as ligands for a variety of 
transition metals possessing biomedical applications, so as to develop potential theranostic 
agents. 
In summary, the specific objectives of this work are: 
1. the development of nitrogen and thiosemicarbazone-based tripodal systems with 
potential biomedical applications; 
2. the synthesis and characterisation of N-heterocyclic carbene-based tripodal systems 
potentially able to bind transition metal ions; 
3. to explore the possibility to synthesise a tridentate system with unsymmetrical 
substituents in order to develop ligands capable of binding metals as well as attaching 
other functionalities; 
4. to test the possibility to develop novel metal complexes containing metal centres of 
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2. Novel developments into the synthesis, 
characterisation and cellular interactions of 
nitrogen and thiosemicarbazone-based tripodal 
ligands 
 
2.1 Tripodal scaffolds as host-guest compounds and 
supramolecular systems 
The last three decades have seen a noticeable increase in the development of tripodal ligands, 
which can be defined as tri-dentate ligands characterised by C3 symmetry. These systems were 
found to be particularly useful in a variety of supramolecular assemblies, particularly in the 
context of ion sensing.1-4 As many of such host molecules make use of non-covalent interactions 
(such as hydrogen bonds),  their preorganisation plays a pivotal role in the activity of the sensor. 
In 1997, Anslyn and co-workers introduced a series of guanidinium-based hosts able to bind 
tricarboxylate ions.5 Preorganisation is achieved by incorporating these guanidinium-based 
recognition groups into a trisubstituted 1,3,5-triethylbenzene core, generating a cone shaped 
cavity due to the steric bulk around the benzene core. Following Anslyn’s work, several 
research groups developed an array of hosts based upon the preorganised hexasubstituted 
benzene core.6 
 
Figure 2.1. An example of a guanidinium-based host developed by Anslyin and co-workers. 
Metal complexes have also been successfully used as anion binding sites for the development 
of chemosensors that also display optical properties.7, 8 Cabell and co-workers developed a 
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tripodal receptor consisting of Cu(II) bound by a 1,10-phenanthroline ligand, which in turn is 
attached to a bis(aminoimidazolium) receptor (Figure 2.2).9 The receptor is able to interact with 
the citrate anion through its positively charged moieties and the copper(II) centre, which in turn 
determine an increase of the phenanthroline-based fluorescence when the anion interacts with 
the metal. 
 
Figure 2.2. Structural representation of the Cu(II)-based chemosensor prepared by Cabell et al. 
The ability of tripodal systems to bind anions could be also exploited for therapeutic purposes. 
For example, two research groups, led by Gale10 and Davis,11 explored the possibility of 
influencing cellular homeostasis by increasing intracellular chloride anion levels using 
thiourea-based tripodal anion transporters (Figure 2.3). The tripodal host A developed by Gale 
and co-workers was found to be able to strongly bind several ions and permeate the cellular 
membrane due to its increased lipophilicity. Moreover, subsequent cytotoxicity studies revealed 
that compound A was active towards several cancer cell lines. The group ascribed the 
cytotoxicity of A to the alteration of intracellular pH caused by the molecule. 
 
Figure 2.3. Structural representations of the thiourea-based tripodal receptors developed by Gale (compound A) 
and Davis (compound B) 
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The usage of a hexasubstituted benzene scaffold by Davis et al allowed this research group to 
easily develop a more accessible tripodal receptor. Compound B was found to be among the 
most effective anion carriers reported in literature.11, 12 Interestingly, characterisation by X-ray 
crystallography revealed that compound B existed as a dimer, forming a cage surrounding a 
cyclic (Cl···H2O)2 dianionic cluster (Figure 2.4). 
 
Figure 2.4. Structure of the compound B forming a dimeric cage around the dianionic cluster (Cl···H2O)2. Adapted 
from ref.11 with permission from The Royal Society of Chemistry. 
Many more tripodal systems based upon the hexasubstituted benzene scaffold were extensively 
studied in the search for effective ion sensors.3, 13, 14 However, very little emphasis has been 
placed on their biological activity and their potential as ligands for biologically relevant 
transition metals. The aim of this chapter is to provide an insight into how such molecules could 
be employed for biomedical applications. 
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2.2 Synthesis of the tripodal core  
The first part of this project involved the synthesis of a library of multidentate systems suitable 
for the accommodation of the metal centre. To achieve this, the “pinwheel” hosts 
tris(bromomethyl)-trialkylbenzene derivatives were chosen as a starting point, as these an 
extensively explored synthetic tools for the construction of 1,3,5-trisubstituted cationic tripodal 
ligands. The rationale behind using hexasubstituted benzene scaffolds is to ensure a small, rigid 
backbone able to maintain a predetermined conformation upon insertion of the metal. 
The synthesis of the hexasubstituted scaffolds including alternating Me/-CH2Br and Et/-CH2Br 
units were performed following the procedures outlined by van der Made for compound 60,15 
and Anslyn for compound 61 (Scheme 2.1).16 
 
Scheme 2.1 Synthetic pathways for 1,3,5-tris(bromomethyl)mesitylene (compound 60) and 1,3,5-
tris(bromomethyl)-2,4,6-triethylbenzene (compound 61). 
Both products were characterised by 1H NMR spectroscopy. For compound 60, the 1H NMR 
spectrum showed two series of signals, one singlet at 4.58 ppm, with an integration of 6H, 
corresponds to the three pairs of CH2Br groups. The other peak, placed at 2.47 ppm, is a sharp 
singlet integrating for 9 protons, which represents the three methyl groups of the mesityl core 
(for the full 1H NMR spectrum of 60 see Appendix A). 1H NMR spectrum of compound 61, 
reported in Figure 2.5, shows three sets of 1H resonances, where the sharp singlet at 4.58 again 
corresponds at the six protons of the three CH2Br as for compound 60. The other two signals 
are a quartet placed at 2.94 ppm, with an integration of 6H, and at 1.34 ppm a triplet of intensity 
9H, belonging respectively to the CH2 and CH3 of the three ethyl arms around the benzene core. 
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Figure 2.5. 1H NMR (300 MHz, CDCl3, 298 K) spectrum of compound 61. For clarity, magnetically equivalent 
nuclei within the same NMR spin system are labelled once. 
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2.3 Tripodal nitrogen-based systems 
2.2.1 DABCO-based tripodal systems 
With the aim of developing a simple tripodal system which includes characteristics such as 
predetermined conformation and solubility in aqueous solvents, a series of lipophilic cations of 
diazabicyclooctane (compounds 62 and 63, Scheme 2.2) were investigated, and it was 
envisaged that these would be capable of forming metal complexes through host-guest 
interactions. 
The reactions were carried out by reacting the two tribromo-substituted trialkylbenzene 
derivatives 60 and 61 with an excess of diazabicyclo[2.2.2]octane (DABCO). The two reactants 
were heated in refluxing acetonitrile for up to 36 hours until the formation of a cloudy 
suspension was observed. For both reactions, the precipitated products were filtered and 
carefully washed with aliquots of acetonitrile and diethyl ether in order to obtain a white water-
soluble powder. 
 
Scheme 2.2. Synthetic pathway for compounds 62 and 63. 
Both compounds were subsequently characterised by 1H and 13C NMR spectroscopy (see 
Figure 2.6 and Figure 2.7). The proton spectrum of compound 62 showed four main peaks 
corresponding to the four different groups of protons. The peak at 4.79 corresponds to the CH2 
that separates the hexasubstituted benzene and the quaternary amine of the bonded DABCO. 
The two intense peaks respectively at 3.51 and 2.97 ppm confirmed the presence of the DABCO 
substituents. Furthermore, the integration of these two peaks confirmed the presence of three 
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DABCO residues attached to the central core. Finally, the singlet at 2.59 indicates the presence 
of a methyl moiety attached to the benzene core. 
 
Figure 2.6. 1H NMR (300 MHz, DMSO-d6, 298 K) spectrum of compound 62. For clarity, magnetically equivalent 
nuclei within the same NMR spin system are labelled once. * CD3SOCD2H. 
The proton spectrum of the compound 63, displayed below in Figure 2.7, shows comparable 
chemical shifts to the spectrum of the compound 62, with an additional peak at 0.82 ppm of 
intensity 9H that indicates the presence of the three CH3 resonances, assignable to the ethylene 
“arms”. 
 
Figure 2.7. 1H NMR (300 MHz, DMSO-d6, 298 K) spectrum of compound 63. For clarity, magnetically equivalent 
nuclei within the same NMR spin system are labelled once. 
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The 13C NMR spectrum for compound 63 is reported in Figure 2.8 below, and shows the 
presence of 7 signals, which were assigned as following: two low-fields signals, respectively at 
154.90 and 122.70 ppm correspond to the two sets of quaternary carbons of the aromatic core; 
another two intense signals at 50.35 and 45.14 ppm were assigned to the methylene groups of 
the DABCO arms. Signals corresponding to the methylene groups are at 59.79 ppm for the CH2 
bridging the aromatic core to the quaternary nitrogen of the DABCO arms, and 25.60 ppm for 
the CH2 groups of the ethylene arms. Finally, one up-field signal at 18.25 ppm was assigned to 
the CH3 groups belonging to the ethylene arms. 
 
Figure 2.8. 13C NMR (75 MHz, DMSO-d6, 298 K) spectrum of compound 63. § refers to aromatic C within phenyl 
ring. For clarity, magnetically equivalent nuclei within the same NMR spin system are labelled once. 
From the mass spectrometry analysis carried out on compound 63 (reported below in Figure 
2.9) it was possible to identify two ion species: the base peak of m/z = 697.3017 belonging to 
the singly charged species [M+279Br]+, and the doubly charged ion fragment [M+79Br]2+ at m/z 
= 309.1903. This result may suggest that compound 63 possesses strong affinity for its 
counterion. 
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Figure 2.9. (A) Mass spectrum of compound 63. (B) Ion species [M+79Br]2+ at m/z = 309.1903. (C) ion species 
[M+279Br]+ at m/z = 697.3017. 
In order to gain some preliminary evaluations on the activity of the synthesised tripodal systems 
in the cellular environment, cell viability assays were performed. In this work, cell viability was 
tested with the 2-(4,5-dimethyl-2-thiazolyl)-3,5-diphenyl-2H-tetrazolium bromide (MTT) 
assay, a widely accepted method to measure cell viability.17, 18 
In this assay, the tetrazolium salt (MTT), a yellow-coloured dye, is taken by viable cells and 
may be reduced to Formazan (purple-coloured) by NADH/NADPH-dependant reductases in 
the cytoplasm and mitochondria (Scheme 2.3). A solvent (usually dimethyl sulfoxide) is then 
added to dissolve the insoluble purple formazan product and the absorbance of this coloured 
solution is measured. This can then be correlated with the number of metabolically active (thus 
viable) cells.19 
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Scheme 2.3. Reduction of MTT into formazan by cellular reductases. 
Cellular viability assays were carried out in PC3 cells in 96 well plates incubated with 
compounds 62 and 63 in serum medium (1% DMSO) at different concentrations and times (30 
minutes, 24, 48 and 72 hours) at 37°C. MTT was then added and the treated cells incubated for 
2 hours before recording the absorbance with a plate reader. The MTT assays showed herein 
were carried out by Dr Haobo Ge at the University of Bath. 
Treatment of PC3 cells with 62 did not significantly perturb the cell viability at any 
concentration tested. Moreover, cell viability recovered to pre-treatment levels after 48 hours. 
Treatment with compound 63 produced a small loss in viability at the highest concentrations 
studied after 24 hours, with recovery of viability being observed after 72 hours. 
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Figure 2.10. Cell viability studies of PC3 cells incubated at 37°C with compounds 62 (left) and 63 (right) for 30 
minutes, 24, 48 and 72 hours. (The data were collected from six repeated measurements on the same day, N = 1). 
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2.2.2 Bipyridine-based tripodal systems 
With the aim of increasing the cavity size as well as introducing valuable spectroscopic 
properties (such as luminescence), we attempted the synthesis of more flexible ligands by 
varying the “arms” attached to the trialkylbenzene unit. Tripodal ligands such as 1,3,5-tris(3-
pyridylmethoxyl)benzene, 1,3,5-tris(2-pyridylmethoxyl)benzene, and 1,3,5-tris(4-
pyridylmethoxyl)benzene have been successfully used previously to generate metalorganic 
cages in the presence of metal halides emitting between 400 and 550 nm.20  
We, therefore, opted for 4,4’-bipyridine as a binding moiety in order to obtain a series of 
tripodal ligands characterised by an enhanced flexibility with the potential to generate 
luminescent supramolecular assemblies with a bigger cavity (see Scheme 2.4). Furthermore, 
the highly delocalised positive charge of the three bipyridinium arms was expected to make 
these compounds potential delocalised lipophilic cations (DLC).21-24 
 
Scheme 2.4. Synthetic pathway for compounds 64 and 65. 
The two compounds (64 and 65) were synthesised following an adapted procedure outlined by 
Steed et al.25, by reacting the bromomethyl benzene compounds 60 and 61 with a 10-fold excess 
of 4,4’-bipyridine in refluxing dichloromethane for 24 hours. The resulting precipitates were 
collected by filtration and washed thoroughly with dichloromethane to give in both cases a 
hygroscopic yellow powder. For compound 65, 1H and 13C NMR showed chemical shifts 
comparable to literature values25, and its mass spectrum, acquired with a Nano-ESI instrument 
at the EPRSC UK National Mass Spectrometry Facility in Swansea, showed a base peak at 
223.1230 m/z corresponding to the triply-charged molecular ion [M]3+ (see appendix A). 
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For the newly synthesised compound 64, the 1H NMR spectrum (reported in Figure 2.11) shows 
four series of multiplets between 8 and 9 ppm belonging to the 4,4’-bipyridinium arms, a singlet 
at 6.17 ppm corresponding to the six protons of the methylene linkers connecting the 4,4’-
bipyridyl arms to the mesitylene core and an intense singlet at 2.40 ppm belonging to the three 
mesityl CH3 resonances. 
 
Figure 2.11. 1H NMR (300 MHz, DMSO-d6, 298 K) spectrum of compound 64. For clarity, magnetically 
equivalent nuclei within the same NMR spin system are labelled once. * residual solvents and impurities traces. 
UV-Visible and fluorescence spectroscopy were subsequently carried out to investigate the 
emissive properties of 64 in DMSO solution. The UV-visible spectrum (blue curve in Figure 
2.12) showed an absorption maximum of 267 nm, while the fluorescence emission spectrum 
(red curve in Figure 2.12) presented a minimal Stokes shift, with an intensity maximum at 280 
nm. 
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Figure 2.12. Normalised UV-Visible (blue line) and fluorescence emission (red line) spectra of compound 64 in 
DMSO (25 µM). 
Mass spectrometry analysis for compound 64, reported in Figure 2.13, showed the presence of 
a peculiar peak at 353.1202 m/z belonging to the dicationic species [M+79Br]2+ in which the 
third positive charge appears to be quenched by the presence of a bromide ion tightly interacting 
with compound 64.  
 
Figure 2.13. Mass spectrum of compound 64 (A) and its simulated isotopic pattern (B). 
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Interestingly, Steed and co-workers reported a comparable example of such interaction in a 
solvent-free crystal structure of compound 65, shown in Figure 2.14. This acts as a first sphere 
ligand for bromide by interacting with the anion with CH···Br- hydrogen bonds.25 
 
Figure 2.14. Solvent free [65⊂Br]2+ incorporating CH · Br interactions 2.660–2.977 Å. Adapted from Ref.25 with 
permission from The Royal Society of Chemistry. 
It was possible to obtain single crystals suitable for X-ray analysis of compound 64 upon slow 
diffusion of acetonitrile into a concentrated aqueous solution of 64. Compound 64 crystallises 
in a P-1 space group and, as for its analogue compound 65, adopts a C3 symmetry. From the 
structure reported in Figure 2.15 it is possible to appreciate the presence of a bromide ion 
interacting with the ligand via CH···Br- hydrogen bonds, found at an average distance between 
2.8 and 2.9 Å. 
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Figure 2.15. Content of the asymmetric unit of compound 64. Thermal ellipsoids represented at 50% probability.  
Interestingly, two molecules of compound 64 were found to form a cage surrounding two 
bromide ions and two solvent water molecules (Figure 2.16). Such a cage-like structure is 
similar to the previously reported receptor B (Figure 2.4) prepared by Davis and co-workers.11 
 
Figure 2.16. Structure of the dimeric cage formed by compound 64 encapsulating two bromide ions and two water 
molecules. 
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As for the previous tripodal receptors discussed in this work, the two bipyridine-based 
compounds 64 and 65 were tested in cell viability assays. In this case, it was of particular 
interest to assess whether or not the compounds might be taken up by cancer cells, given their 
lipophilic cationic nature. While compound 65 was found to be nontoxic at all the 
concentrations studied, PC3 cells incubated with 64 at a concentration of 100 and 250 µM for 
30 minutes showed a moderate loss of cell viability. Cell viability only recovered to values 
above 50% after 72 hours from the initial treatment, suggesting that compound 64 does inhibit 
cell viability at higher concentrations. 
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Figure 2.17. Cell viability studies of PC3 cells incubated at 37°C with compounds 64 (left) and 65 (right) for 30 
minutes, 24, 48 and 72 hours. (The data were collected from six repeated measurements on the same day, N = 1). 
In order to investigate the cellular uptake of the bipyridine-based tripodal ligands and their 
fluorescence properties within a cellular environment, single-photon laser-scanning confocal 
microscopy (SLSCM) analysis was performed. PC3 cells were grown following standard 
culturing methods further described in Chapter 7.  
Figure 2.18 shows images taken in the confocal mode of PC3 cells upon 20 min incubation with 
compound 64. The images show moderate emission across all the visible wavelengths when the 
probe was excited at 405 nm (a1-5), while only green-red (b1-5) and red (c1-5) emissions are 
visible using 488 nm and 561 nm lasers respectively. Compound 64 appears to be taken up in 
PC3 cells and localise throughout the cytoplasm. Furthermore, there is no emission from the 







Figure 2.18. Single-photon laser-scanning confocal microscopy images of PC3 cells incubated with compound 64 (10 µg/mL 1% : 99% DMSO : DMEM) at 37 ºC 
for 20 minutes; λex = 405 nm (a1-a5), λex = 488 nm (b1-b5) and λex = 561 nm (c1-c5). DIC channel (a1, b1, c1), blue channel, λem = 420-480 nm (a2, b2, c2), green channel, 
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2.4 Tripodal anthracene-thiosemicarbazone based ligands  
In this section we describe the syntheses and characterisation of two novel tripodal anthracene-
thiosemicarbazone systems bearing the hexasubstituted cores 60 and 61 and anthracene-based 
arms connected to the core through a thiosemicarbazone linker. The rationale behind those 
experiments was to develop tripodal ligands characterised by enhanced flexibility and superior 
emissive properties compared to the bipyridine-based compound 64 and 65. The tripodal 
nitrogen-based systems discussed before were promising in terms of cellular interaction, but 
were weakly or non-fluorescent and also missing some essential cell recognition features such 
as thiosemicarbazone motif.26 Furthermore, the novel systems should be theoretically capable 
of accommodating larger transition metals complexes of relevance to molecular imaging, such 
as ruthenium or rhenium. 
Anthracene is a polycyclic aromatic hydrocarbon (PAH) characterised by intense fluorescence 
(e.g. its quantum yield in acetonitrile is 0.36).27 Absorption spectra of Anthracene and its 
derivatives typically show three well-defined bands between 340 and 390 nm, while the 
emission spectrum is composed of distinct bands around 415 nm.28 Such interesting 
luminescent properties, coupled with the commercial availability of many derivatives, make 
anthracene-based compounds an interesting area of exploration. 
The preparation of compound 66 involved an acid-catalysed imine condensation between 9-
anthracenecarboxaldehyde and thiosemicarbazide, following a procedure elucidated by 
Beckford and co-workers.29 The two reactants were dissolved in anhydrous absolute ethanol, 
followed by the addition of one or two drops of glacial acetic acid. The reaction mixture was 
stirred under reflux for four hours and upon cooling a precipitate was formed, which was 
collected by filtration and washed thoroughly with ethanol and diethyl ether to give compound 
66 as a yellow powder. Recrystallization in hot tetrahydrofuran afforded the product as orange 
crystals in high yield (90%). A detailed mechanism for the reaction is shown in Scheme 2.5 
below. 
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Scheme 2.5. Proposed reaction mechanism of the acid-catalysed imine condensation leading to compound 66. 
1H NMR analysis of compound 66 was performed and the resulting spectrum is reported in 
Figure 2.19. This shows a resonance at 11.68 ppm assignable to the hydrazinic proton H1. Such 
a downshifted resonance is due to the tautomerism of thiosemicarbazones in solution and was 
reported in a previous study.30 
 
Scheme 2.6. Thione-thiol tautomerism in compound 66. 
Two more resonances, observed at 8.36 and 7.75 ppm, could be attributed to the geminal N-H2 
protons (labelled H5 and H5’ in the spectrum shown in Figure 2.19). Such a shift to downfield 
resonances appears to be an indication of the hindered rotation due to the SC-NH2 bond 
containing a partial double bond character.29 
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Figure 2.19. 1H NMR (300 MHz, DMSO-d6, 298 K) spectrum of compound 66. Green dotted box: 1H-1H COSY 
NMR (300 MHz, DMSO-d6, 298 K) spectrum expansion highlighting anthracene protons couplings. For clarity, 
magnetically equivalent nuclei within the same NMR spin system are labelled once. 
The syntheses of two tripodal-anthracene-thiosemicarbazone ligands (referred as compounds 
67 and 68 throughout this work) was achieved by a nucleophilic substitution on the 
hexasubstituted cores 60 or 61 with the anthracene-thiosemicarbazone (compound 66). The 
reactants were dissolved in dry acetonitrile, and the resulting mixture was refluxed overnight to 
obtain a yellow precipitate. After cooling to room temperature, in both cases the precipitate was 
filtered, thoroughly washed with fresh acetonitrile and dried.  
Neutralisation of the thiosemicarbazone units was subsequently performed by treating a 
methanolic solution of the products above with an excess of triethylamine. Upon addition of 
the base, a bright yellow precipitate immediately formed. The slurry was kept stirring at room 
temperature for further 24 hours. After that time, the precipitates were filtered, washed 
extensively with methanol and dried to give the products 67 and 68 in very good yields (94% 
and 92% respectively). 
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Scheme 2.7. Synthetic pathway for compounds 67 and 68. 
The 1H NMR spectrum of 67, reported in Figure 2.20, shows a series of eight peaks. A 
resonance found at 9.62 ppm (integrating for 3H) was attributed to the hydrogen in position 10 
of the anthracene ring (entry H1 in Figure 2.20). The following doublet at 8.68 ppm of intensity 
6H was correlated to the anthracene protons in the positions 4 and 5, while the other doublet at 
8.03 ppm corresponds to the protons in positions 1 and 8 respectively. To complete the 
assignment of the signals related to the anthracene, a multiplet positioned between 7.55 and 
7.48 ppm was assigned to the four sets of protons in the positions 2,3 and 6,7 respectively. A 
last significant signal in the aromatic region of the spectrum of 67 is a singlet at 8.49 ppm, 
integrating for 3H, which was assigned to the H3-C=N connecting the anthracene tags to the 
thiosemicarbazone linkers. 
Outside the aromatic region, a broad resonance at 5.55 ppm was assigned to the hydrazinic 
proton (entry H6, Figure 2.20) while the resonance at 4.65 ppm was assigned to the protons of 
the methylene linker connecting the anthracene-thiosemicarbazone arms to the aromatic core. 
Finally, a signal at 2.70 ppm and integrating for 9 protons was assigned to the three mesityl 
CH3 resonances. 
NMR spectroscopy analysis of compound 68, with the 1H NMR spectrum reported in Figure 
2.21, shows 9 sets of resonances, suggesting that the compound is C3 symmetric. The spectrum 
is comparable to the one of the previously synthesised compound 67 with the exception of the 
two upfield signals (labelled H8 and H9 in Figure 2.21), which have been assigned to the two 
sets of alkyl protons of the three ethyl groups bonded to the central aromatic core. 
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Figure 2.20. 1H NMR (500 MHz, CDCl3, 298 K) spectrum of compound 67 and a detail of the 1H-1H COSY 
spectrum highlighting the aromatic region. For clarity, magnetically equivalent nuclei within the same NMR spin 
system are labelled once. * residual solvents and impurities traces. 
 
 
Figure 2.21. 1H NMR (500 MHz, CDCl3, 298 K) spectrum of compound 68. Blue dotted box: detail of the the 
aromatic region. For clarity, magnetically equivalent nuclei within the same NMR spin system are labelled once. 
* residual solvents and impurities traces. 
2. Nitrogen and thiosemicarbazone-based 





Mass spectrometry analysis performed on compound 67, acquired at the EPRSC UK National 
Mass Spectrometry Facility in Swansea, showed a base peak at 994.3497 m/z corresponding to 
the protonated molecular ion [M+H]+. The mass spectrum 67, with details of the molecular ion 
species and assignments are given below, in Figure 2.22. 
 
Figure 2.22. Mass spectrum of compound 67. Blue dotted box: details of the molecular ion (A) and its simulated 
isotopic pattern (B). 
Analysis of the mass spectrum acquired for compound 68, reported in Figure 2.23, indicates the 
presence of a protonated molecular ion [M+H]+ at 1036.4016 m/z, as well as the sodium adduct 
assignable to [M+Na]+, of m/z = 1058.3903. 
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Figure 2.23. Mass spectrum of compound 68. Blue dotted square: Ion species [M+H]+ at 1036.4016 m/z. Green 
dotted square: ion species [M+Na]+ at 1058.3903 m/z. 
UV-Visible and fluorescence emission spectroscopies were employed to evaluate compounds 
67 and 68 as potential imaging agents. Both compounds presented an absorption wavelength 
maximum at around 400 nm. The absorption spectrum of compound 68 clearly shows the three 
characteristic bands of the anthracene moiety at 350, 370 and 390 nm. The emission 
wavelengths for both compounds are in the visible region at around 440 nm (Figure 2.24).  
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Figure 2.24. (A) Normalised UV-Visible (blue line) and fluorescence emission (red line) spectra of a 12.5 µM 
THF solution of compound 67. (B) Normalised UV-Visible (blue line) and fluorescence emission (red line) spectra 
of a 12.5 µM THF solution of compound 68. 
The contour maps of fluorescence emission – excitation were generated to visualise the optical 
behaviour of the two synthesised compounds across the full excited emission ranges available. 
This experiment was conducted to gain a preliminary understanding of how such system might 
respond in cells visualised through confocal microscopy, using the laser wavelengths employed 
by common microscopes (e.g. 305 nm, 488 nm and 561 nm as excitation intensities). If the 
compounds mimic the autofluorescence of living cells, monitoring their activity would prove 
to be difficult, therefore it is vital that the two compounds fluoresce in a different region to that 
of the cells. An emission range of 300-500 nm would be particularly useful.  
The fluorescence excitation-emission matrices are shown below in Figure 2.25 for compound 
67, and in Figure 2.26 for compound 68. The two compounds display emissive properties 
between 400-500 nm, compound 68 exhibiting a stronger emission compared to 67, possibly 
due to a reduced C=N isomerisation in the excited state.  
(A) (B) 
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Figure 2.25. 2D fluorescence contour map for compound 67 in THF (25 µM). 
 
 
Figure 2.26. 2D fluorescence contour map for compound 68 in THF (25 µM). 
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2.5 Summary of Chapter 2 
In this chapter, three types of tripodal ligands were successfully synthesised and characterised. 
The products were obtained through nucleophilic substitution of the bromomethyl substituents 
of the hexasubstituted cores 60 and 61 previously developed with DABCO and 4,4’-bipyridine 
to achieve compounds 62, 63, 64 and 65 in good yields and acceptable purity with minimal 
work up. Such compounds were characterised spectroscopically, and their biocompatibility 
probed via MTT assay on PC3 prostate cancer cells. While most of the compounds appear to 
be nontoxic at the highest concentrations recorded, a concentration of 250 µM of compound 64 
caused a loss of more than 50% in cell viability. Such inhibition persisted even after 72 hours 
from the treatment. Further tests will be necessary to determine the factors that promote the loss 
of cell viability triggered by 64. 
Furthermore, two novel anthracene thiosemicarbazone-based tripodal systems were 
successfully synthesised in a two-step reaction, beginning with the synthesis of the anthracene 
thiosemicarbazone, reacting 9-anthraldehyde with thiosemicarbazide, to give compound 66 in 
excellent yield and high purity  
The two tripodal systems were obtained by heating the two tripodal cores 60 and 61 at reflux 
with an excess of compound 66 in acetonitrile, followed by treatment with triethylamine to give 
compound 67 and 68 in very high yields. Characterisation of the compounds 67 and 68 revealed 
that the anthracene thiosemicarbazone “arms” bind to the central aromatic core via an 
unconventional S-alkylation of the bromomethyl moieties of 60 and 61. The two ligands possess 
acceptable fluorescent properties with large emission bands around 440 nm, and could therefore 
be suitable for imaging applications. 
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3. Synthesis, spectroscopic characterisation and X-
ray crystallography of novel tripodal pro-carbene 
derivatives 
A new family of tripodal ligands, suitable for the development of novel transition metal 
complexes, are the tripodal N-heterocyclic carbenes (NHCs). Tripodal N-heterocyclic ligands 
commonly consist of a central atom or group which acts as an anchor for the three pendant arms 
bearing the three NHC groups. Several tripodal NHC ligands have been developed with central 
anchors consisting of boron,1 carbon,2 nitrogen,3 and arene groups.4 The arms of the tripodal 
NHC ligand are usually separated from the central anchor by linkers, which generally are small 
alkyl groups. By alternating these groups, the topological properties of the ligand, such as steric 
hindrance, bite angle, chirality and fluxional behaviour can be finely tuned.  
A tripodal NHC containing a central mesityl group (compound 60), 1,3,5-[tris(3-tert-
butylimidazole-2-ylidene)methyl]-2,4,6-trimethylbenzene (timtmbtBu) was first reported in 
1994 by Dias and co-workers.4 As the central arene anchor group de facto restricts the extent 
to which a single metal ion can be accommodated between the three carbene arms, the group 
was able to bind only the very large thallium atom (Figure 3.1). 
 
Figure 3.1. the Tl(I)-timtmbtBu complex prepared by Dias and co-workers. 
A different approach to the coordination chemistry of such tripodal ligands was reported by 
Hahn and co-workers in 2010, in which a tripodal NHC bearing a central phenyl group with no 
linker groups was coordinated to the group 11 transition metals Ag and Au.5 In these complexes, 
each NHC arm binds to the metal ion in a monodentate manner, so that each carbene is 
coordinated to a separate metal centre, leading to a self-assembled bis-tripodal NHC complex 
of structure [M3(NHC)2](PF6)3, with M = Ag, Au, as shown in Figure 3.2. 






Figure 3.2. Representation of the bis-tripodal carbene complex [M3(NHC)2](PF6)3 prepared by Hahn et al. 
Inspired by Hahn’s work, Pascu, Whittlesey and co-workers developed a series of tripodal 
timtebtBu and timtebdipp complexes of palladium(II), whose structures are shown in Figure 3.3.6 
X-Ray analysis showed that the compounds adopt an idealised C3-symmetrical arrangement 
with the three Pd-(ICy)I2 fragments pointing out on the opposite side of the central arene ring 
to the three ethyl substituents. 
 
Figure 3.3. Representation of the tripodal timtebtBu and timtebdipp complexes of palladium(II) prepared by Pascu, 
Whittlesey and co-workers.6 
In order to gain further understanding of the coordination chemistry of these ligands, the same 
group attempted the complexation between the timtebR tripodal ligands and a copper(I) 
precursor [Cu(MeCN)4]PF6 via a one-pot reaction, by deprotonation of the ligand precursor in 
THF solution at room temperature using sodium tert-butoxide. The reactions gave rise to 
unexpected tris-copper(I) μ3-oxo complexes [(timtebR)Cu3(μ3-O)]X (R = tBu, dipp; X = PF6, 
BF4), both adopting pseudo C3 geometries with an axis directed through the oxygen cap and the 
centroids of the copper plane and the arene ring (Figure 3.4). 






Figure 3.4. Structural representation of the [(timtebR)Cu3(μ3-O)]X complexes prepared by Pascu, Whittlesey and 
co-workers. 
With the aim of further expanding the library of tripodal NHC pro-ligands potentially able to 
bind transition metal ions, we decided to make further use of the 1,3,5-tris(bromomethyl)-2,4,6-
trimethyl benzene anchor 60 and the more rigid scaffold 1,3,5-tris(bromomethyl)-2,4,6-triethyl 
benzene (compound 61) with a series of monosubstituted imidazole as arms. A general scheme 
of the reactions involved is presented below (see Scheme 3.1). 
 
Scheme 3.1. General outline of the synthetic protocols leading to the tripodal imidazolium pro-ligands described 
in this section. 
  





3.1. Methylimidazole-based tripodal systems 
The first tripodal NHC-based pro-ligand, namely compound 69, was synthesised following a 
modified procedure from Kumbhar et al.7 by reacting 1,3,5-tri(bromomethyl)-2,4,6-
trimethylbenzene (compound 60) and 3.1 equivalents of the commercially available 1-methyl-
H-imidazole in refluxing dry acetonitrile for 24 hours (Scheme 3.2). A cream coloured 
precipitate was formed, and after recrystallisation of the crude material from a mixture of 
methanol/diethyl ether, NMR analysis was performed to assess the quality of the product. 
 
Scheme 3.2. Synthesis of the compound 69. 
The 1H NMR spectrum of compound 69 is shown in Figure 3.5. The spectrum shows two low-
field peaks, at 7.73 and 7.62 ppm respectively, corresponding to the imidazolium protons H2 
and H3. A sharp singlet at 5.61 ppm was assigned to the CH2 bridging the three imidazolium 
arms to the mesityl core. The remaining two peaks were assigned to the two sets of CH3, where 
the intense signal at 3.96 ppm corresponds to the three methyl units bound to the imidazolium 
nitrogen, and the sharp singlet at 2.38 ppm was assigned to the 9 protons of the mesitylene core. 
The absence of the imidazolium C2-H signal (entry 1 in Figure 3.5), expected between 9-10 
ppm, may indicate the occurrence of a hydrogen/deuterium exchange between H1 and O-D of 
the deuterated solvent. 






Figure 3.5. 1H NMR (300 MHz, CD3OD-d4, 298 K) spectrum of compound 69. For clarity, magnetically 
equivalent nuclei within the same NMR spin system are labelled once. * solvent peaks. 
The same reaction protocol was carried out using 1,3,5-tri(bromomethyl)-2,4,6-triethylbenzene 
(compound 61) as core instead, aiming to obtain a similar compound but with a more rigid 
conformation. The resulting reaction mixture was refluxed in dry acetonitrile for 24 hours, 
during which time no precipitate could be observed. After removal of the solvent, a deliquescent 
grey powder was obtained. The crude mixture was washed thoroughly with diethyl ether and 
subsequently recrystallised from ethyl acetate. NMR analysis was carried out, revealing an 
impure product in which the imidazole starting material was still abundant. 
A second attempt was carried out by using dry tetrahydrofuran as solvent. After refluxing the 
mixture overnight, a creamy precipitate was formed. The resulting solid was collected by 
filtration and washed several times, to give a hygroscopic white powder. Anion metathesis was 
carried out by treating the product with a saturated solution of potassium hexafluorophosphate 
(KPF6) to afford compound 70 in moderate yield (50%). An outline of the synthesis is shown 
in Scheme 3.3. 






Scheme 3.3. Reaction pathway for compound 70. 
The newly synthesised compound 70 was fully characterised by NMR and mass spectrometry. 
The 1H NMR spectrum shown, in Figure 3.6, shows a series of 7 signals. A singlet observed at 
8.85 ppm, which was assigned to the C2-H of the imidazolium arms (entry H1 in Figure 3.6), 
whilst two triplets at 7.74 and 7.61 ppm respectively correspond to the other two protons of the 
heterocycle (H2 and H3 in Figure 3.6).  
The deshielded protons of the methylene linker between the central aromatic core and the 
imidazolium arms appear in the spectrum as a sharp singlet at 5.61 ppm, a comparable value to 
that of the CH2 linkers of compound 69. Another sharp singlet at 3.82 ppm was assigned to the 
three magnetically equivalent CH3 of the methylimidazolium arms. Finally, a quartet 
integrating to 6H at 2.62 ppm and a triplet integrating to 9H at 0.84 ppm correspond to the three 
ethylene arms around the central aromatic core. 
 
Figure 3.6. 1H NMR (500 MHz, DMSO-d6, 298 K) spectrum of compound 70. For clarity, magnetically equivalent 
nuclei within the same NMR spin system are labelled once. * residual solvents and impurities traces. 





The proton resonances of compound 70 were assigned also with the help of 1H-1H 
bidimensional correlation spectroscopy (1H-1H COSY). The COSY NMR spectrum for 70 
(Figure 3.7), shows the coupling between the imidazolium protons as well as a weak interaction 
with the methyl group within the imidazolium arm (H1-H2-H3), and the protons in the ethyl 
arms (H6-H7). 
 
Figure 3.7. 1H-1H COSY NMR (500 MHz, DMSO-d6, 298 K) spectrum of compound 70. 
Mass spectrometry analysis performed on compound 70, reported below in Figure 3.8, showed 
the presence of yet another peculiar molecular ion [M+2(PF6)]+ at 737.2493 m/z, possibly 
suggesting the presence of robust interactions between the tripodal system and its counterion. 






Figure 3.8. Mass spectrum recorded for the compound 70. 
It was possible to develop suitable crystals of compound 70 for X-ray crystallography by slow 
evaporation of a concentrated solution of 70 in acetonitrile. Compound 70 crystallises in a 
trigonal P3 space group. From the ORTEP representation shown in Figure 3.9 it is possible to 
appreciate the presence of the three hexafluorophosphate counterions, one of which appears to 
be located into the molecule’s cavity. Hydrogens bonded to C8 interact with fluorine F3 (see 
corresponding labelling in Figure 3.9) of the sitting counterion at 2.310 Å, slightly shorter than 
the H-F “out-of-socket” interactions at an average of 2.5 Å. A representation of the crystal 
structure of 70, highlighting the short contact interactions between the imidazolium arms and 
fluorines from the hexafluorophosphate counterion is shown in Figure 3.10. The imidazolium-
bearing arm C1-C3-N4 angle has a value of 113.18°, almost identical to the C2-C10-C11 of the 
ethylene arm (113.10°). A selection of bonds and angles for compound 70 are presented in 
Table 3.1 below. 






Figure 3.9. Content of the asymmetric unit of compound 70 (ORTEP representation). Thermal ellipsoids 
represented at 50% probability. Hydrogen atoms have been omitted for clarity. 
 
Figure 3.10. Crystal structure of compound 70 highlighting the interactions between the imidazolium arms and 
fluorines from the hexafluorophosphate counterion. 
 
 





Table 3.1. Selected bond angles and distances for compound 70. 
Atoms involved Angle (°) / Distance (Å) 
C1-C3-N4 113.18(2)°  
C3-N4-C8 127.86(2)°  
N4-C5-N6 109.12(2)°  
C5-N6-C7 108.37(2)°  
N6-C7-C8 107.48(2)°  
C7-C8-N4 106.77(2)°  
C7-N6-C9 126.31(2)°  
C1-C3 1.513(4) Å  
C3-N4 1.485(3) Å  
C5-N4 1.323(3) Å  
C7-C8 1.344(3) Å  
 
The packing unit of compound 70 shows alternate layers, with the molecules of 70 oriented in 
opposite directions (Figure 3.12). Additionally, multiple interactions between the methylene 
hydrogens of the linkers and fluorines from the hexafluorophosphate counterions result in 
polymeric association of the tripodal systems bridged by the counterions (Figure 3.13). 
 
Figure 3.11. Packing units of compound 70. View along the b axis, highlighting the alternate layers. 






Figure 3.12. Packing units of compound 70. View along the c axis, highlighting the intermolecular associations 
between the molecules of 70 and the hexafluorophosphate counterions. 
  





3.2. Tert-butylimidazole-based tripodal systems 
A second series of tripodal NHC-based ligands, bearing a bulkier tert-butyl substituent on the 
imidazole nitrogen N6, was also successfully synthesised and is reported below. The first step 
consisted of the synthesis of the monosubstituted 1-(tert-butyl)-1H-imidazole, compound 71, 
following a preparation outlined by Cassani and co-workers.8 This consists of a modification 
of a Debus-Radziszewski imidazole synthesis in which one equivalent of ammonia is replaced 
with tert-butylamine. An outline of the synthesis is shown in Scheme 3.4. Pure product was 
afforded after extraction in dichloromethane and subsequent vacuum distillation, to give 71 as 
a pale-yellow liquid. 
 
Scheme 3.4. Synthesis of 1-(tert-butyl)-1H-imidazole precursor (compound 71). 
The 1H NMR spectrum of compound 71 (Figure 3.13), showed three signals. The two low-field 
signals at 7.51 and 6.95 ppm could be assigned to the three protons of the heterocyclic ring, 
while the intense singlet at 1.46 ppm represents the nine magnetically equivalent protons of the 
tert-butyl substituent (entry H3 in Figure 3.13). Such values are in agreement with the 
literature.8 
 
Figure 3.13. 1H NMR (300 MHz, CDCl3, 298 K) spectrum of compound 71. For clarity, magnetically equivalent 
nuclei within the same NMR spin system (H2) are labelled once. 





The subsequent step led to the synthesis of two tripodal receptors, compounds 72 and 73, having 
as core two hexasubstituted benzene rings (derived from compounds 60 and 61) and 
monosubstituted imidazole arms, derived from 71. An outline of this step is shown in Scheme 
3.5. Both syntheses were carried out under anhydrous conditions, using dry acetonitrile as 
solvent. The reaction mixture was heated at reflux, and the reaction was followed by thin-layer 
chromatography (TLC) until completion, which occurred in around 48 hours for each 
compound. After removal of the solvents and recrystallisation, both products were afforded in 
good yield (84% and 78% respectively) and NMR-level purity, which enabled future reactions 
to be carried out. 
 
Scheme 3.5. Synthetic pathway leading to compounds 72 and 73. 
The 1H NMR spectrum of compound 72 (Figure 3.14) shows 6 signals. The signal at 9.53 ppm, 
integrating for 3H, was assigned to the C2-H (H1) of the imidazolium unit that comprises the 
three arms of 72. The other two signals between 7 and 8 ppm correspond to the other two sets 
of protons of the heterocycle (H2 and H3). The singlet integrating to 6H at 5.59 ppm (H4) was 
assigned to the CH2 connecting the tert-butyl imidazolium arms to the mesityl core. Another 
resonance at 2.30 ppm integrating for 9H was assigned to the three magnetically equivalent 
mesityl CH3 groups (H5), and the intense signal at 1.59 ppm was finally assigned to the 27 
protons of the three tert-butyl substituents of the imidazolium arms (H6). All values are 
consistent with the literature.4 






Figure 3.14. 1H NMR (300 MHz, DMSO-d6, 298 K) spectrum of compound 72. For clarity, magnetically 
equivalent nuclei within the same NMR spin system are labelled once. * residual solvents and impurities traces. 
The 1H NMR spectrum of compound 73 (Figure 3.15) shows seven signals that may be assigned 
in similar fashion to 72. The three peaks between 7.5 and 9.5 ppm belong to the three C2-H of 
the imidazolium heterocycle. The singlet at 5.50 ppm, integrating for a total of 6 protons, was 
assigned to the CH2 linking the arms to the triethylbenzene core. The quartet at 2.70 ppm was 
assigned to the CH2 of the ethylene arms. The downfield value for these protons is due to their 
proximity to the aromatic ring. The intense singlet at 1.60 ppm integrates for 27H and was 
assigned to the tert-butyl groups, in concordance with the values reported for compound 72. 
Finally, a triplet of integration 9H placed upfield at 0.74 ppm was correlated to the methyl 
groups of the three ethylene arms (entry H7 in Figure 3.15).  






Figure 3.15. 1H NMR (300 MHz, DMSO-d6, 298 K) spectrum of compound 73. For clarity, magnetically 
equivalent nuclei within the same NMR spin system are labelled once. * residual solvents and impurities traces. 
Prior to mass spectrometry analysis, 73 was subjected to anion metathesis aiming to exchange 
the bromide counterion to the less coordinating hexafluorophosphate (PF6-). Compound 73 was 
thus treated with a saturated solution of ammonium hexafluorophosphate (NH4PF6) in distilled 
water in open air. The resulting suspension was stirred for a further 2 hours, then filtered and 
the filter cake was washed thoroughly with aliquots of distilled water. The product (73·3PF6) 
was obtained as a white powder by freeze-drying overnight, and it was fully characterised. 
 
Scheme 3.6. Counterion metathesis for compound 73 to give 73·3PF6. 
Electrospray ionisation mass spectrometry (ESI-MS) carried out for compound 73·3PF6 
(Figure 3.16), clearly shows the presence of an intense signal at m/z = 863.3967, corresponding 
to the ion [M+2PF6]+. Such singly charged species has also been observed in the mass spectrum 
recorded for compound 70. A second peak at m/z = 359.2157 was assigned to the doubly 





charged ion [M+PF6]2+. The presence of such a species seems to indicate that tripodal receptors 
bearing imidazolium arms possess strong affinity for their counterions, effectively acting as 
chelators for the anions. 
 
Figure 3.16. Positive-mode ESI-MS for compound 73·3PF6. (A) ion species [M+2PF6]+ at 863.3967 m/z and 
below its predicted pattern. (B) ion species [M+PF6]2+ at 359.2157 m/z and its predicted pattern. 
 





Suitable single crystals for X-ray diffraction analysis for compound 72 were obtained by slow 
evaporation of a concentrated solution of 72 in methanol. Compound 72 crystallised in the 
monoclinic P21/c space group. Three molecules of water of crystallisation are present in the 
structure which interact with the bromide counterions and the imidazolium hydrogens. An 
ORTEP representation of compound 72 is shown in Figure 3.17. 
 
Figure 3.17. X-Ray crystal structure of compound 72 (ORTEP representation). Thermal ellipsoids represented at 
50% probability. Some of the hydrogen atoms of 72 have been omitted for clarity. 
A summary of the bond lengths is reported below in Table 3.2. Bond lengths and angles for 72 
are similar to the related compound 70 and the values are typical of sp2/sp3 hybridised carbons. 
In the X-ray crystal structure of 72 depicted in Figure 3.18 it is possible to appreciate the 
presence of a molecule of water interacting with the imidazolium hydrogens within the pocket 
formed by the syn conformation adopted by the three tert-butylimidazolium arms at a distance 
of approximately 2.5 Å.  
The encapsulated water molecules have also strong hydrogen bonding interactions with the 
bromide anions that interact with two or more molecules of 72. Hydrogen bonding interactions 
were also observed between the methyl substituents of the hexasubstituted aromatic core of two 
molecules of 72. This network of interactions appears to be responsible for the formation of a 
tetrameric assembly observed in the structure of compound 72 (Figure 3.19) 






Figure 3.18. Structure of compound 72 highlighting the short contact interactions.  
 
Figure 3.19. Representation of the packing unit of compound 72 highlighting the network of short contact 
interactions between compound 72, bromide anions and water molecules. 
 
 





Table 3.2. Selected bond angles and distances for compound 72. 
Atoms involved Angle (°) / Distance (Å) 
C3-C4-N1 111.7(2)°  
N1-C5N2 109.3(2)°  
C5-N2-C7 108.2(2)°  
N2-C7-C6 107.1(3)°  
C7-C6-N1 107.1(3)°  
C6-N1-C5 108.3(2)°  
C7-N2-C8 125.1(2)°  
C1-C2 1.515(4) Å  
C4-N1 1.488(4) Å  
N1-C5 1.325(3) Å  
C6-C7 1.352(4) Å  
N1-C6 1.376(4) Å  
N2-C8 1.509(4) Å  
H6-O2 2.666(5) Å 
 
  





3.3. Mesitylimidazole-based tripodal systems 
With the aim of developing a series of NHC-based receptors containing bulkier steric groups, 
thus helping the stabilisation of low oxidation state metal centres, a further two new tripodal 
systems were successfully synthesised and characterised. The pro-ligands described in this 
section are based upon the previously synthesised hexasubstituted benzene cores 60 and 61, and 
the monosubstituted 1-mesityl-1H-imidazole as arms. 
The synthesis of the monosubstituted imidazole, compound 74, consisted of a two-step 1-
arylimidazole synthesis performed following a modified procedure from Liu et al, which 
afforded 74 as colourless needles after recrystallisation. 1H NMR spectroscopy analysis 
performed on the reaction pro duct (Figure 3.20), indicated that the reaction was successful, 
and the product was obtained with good purity. The spectrum obtained was in agreement with 
literature data.9 
 
Figure 3.20. 1H NMR (400 MHz, CDCl3, 298 K) spectrum of compound 74. For clarity, magnetically equivalent 
nuclei within the same NMR spin system are labelled once. * CDCl3. 
The synthesis of two tripodal receptors bearing the monosubstituted imidazole 74 as arms was 
carried out under similar conditions as for compounds 72 and 73, exploiting Schlenk techniques 
and by using dry acetonitrile as solvent (Scheme 3.7). The reaction mixture containing one 
equivalent of hexasubstituted benzene and an excess of imidazole 74 was stirred under reflux 
for 48 hours. After cooling down to room temperature, the solvent was removed under vacuum 
and the crude product was recrystallised from a mixture of tetrahydrofuran/pentane to give 75, 





and a mixture of acetonitrile/diethyl ether to give 76. Both compounds were obtained with good 
yields (66-70%).  
 
Scheme 3.7. Synthetic pathway leading to compounds 75 and 76. 
The novel ligands were characterised by routine spectroscopic techniques. 1H NMR spectra of 
compounds 75 and 76 (see Figure 3.21) were comparable to the previously synthesised 
imidazolium-based tripodal systems. The mesitylimidazolium arms showed 4 downfield 
resonances, between 7–10 ppm, which were assigned to the aromatic protons. Two further 
resonances at 2.3 and 1.9 ppm were correlated to the para- and ortho- methyl groups of the 
mesityl substituent respectively.  
The mass spectra of compounds 75 and 76 are shown in Appendix B. From the mass spectrum 
of 75 it was possible to identify a peak at m/z = 239.1537 corresponding to the triply-charged 
molecular ion [M]3+. The mass spectrum of compound 76 showed a peak at m/z = 919.3514 
which was assigned to the ion species [M+279Br]+, a further example of how tripodal 
imidazolium-based systems strongly interact with anions. 






Figure 3.21. 1H NMR (300 MHz, DMSO-d6, 298 K) spectra of mesitylimidazolium-based tripodal ligands. (A) 
Compound 75, (B) compound 76. * residual solvents and impurities traces. 
Using the same reaction protocol as for compound 73, anion metathesis was performed on both 
compounds 75 and 76. The two compounds, 75·3PF6 and 76·3PF6, were obtained in 
quantitative yields and the purity was deemed acceptable by NMR spectroscopy, so to enable 
further reactions to be carried out. 
Suitable crystals for X-ray analysis for compound 75·3PF6 were obtained by vapour diffusion 
using acetonitrile and diethyl ether. Compound 75·3PF6 crystallises in the monoclinic P21/c 
space group and, differently from the previously described tripodal systems, assumes a 
conformation that has arms in a “two-up one-down” arrangement (Figure 3.22), thus without 
forming a cage-like structure. The crystal structure shown in Figure 3.23 shows multiple H···F 
interactions between the fluorines of the counterions and the hydrogens of the 
mesitylimidazolium moieties at an average distance of 2.5 Å. These interactions are responsible 
for the polymeric association of molecules of 75·3PF6 along the packing unit (Figure 3.24). A 
similar type of assembly was observed for the crystal structure of compound 70. 






Figure 3.22. X-Ray crystal structure (ORTEP representation) of compound 75·3PF6. Thermal ellipsoids 
represented at 50% probability. Hydrogen atoms have been omitted for clarity. 
 
 
Figure 3.23. Structure of compound 75·3PF6 highlighting the short contact interactions. 






Figure 3.24. Molecular structure of compound 75·3PF6 showing the packing diagram in a fragment of the unit 
cell. 
The angles and bond distances measured for 75·3PF6, a selection of which are reported in Table 
3.3, are comparable to the previously discussed tripodal ligands (e.g. compound 70). 
Table 3.3. Selected bond angles and distances for compound 75·3PF6. 
Atoms involved Angle (°) / Distance (Å) 
C3-C4-N1 110.53(2)°  
N1-C5-N2 108.70(2)°  
C5-N2-C7 108.25(2)°  
N2-C7-C6 106.97(2)°  
C7-N2-C8 126.07(2)°  
C1-C2 1.517(3) Å  
C3-C4 1.512(3) Å  
C4-N1 1.483(3) Å  
N1-C5 1.322(3) Å  
C6-C7 1.345(3) Å  





Suitable single crystals of compound 76·3PF6 for X-ray diffraction were obtained analogously 
to compound 75·3PF6. An ORTEP representation of 76·3PF6 is showed in Figure 3.25. 
Compound 76·3PF6 crystallises in the orthorhombic Pnma space group. The crystal structure 
includes solvent molecules filling the intermolecular space, one of which appears to be 
accommodated in the cavity of 76·3PF6. Furthermore, N7 of the acetonitrile solvent interacts 
with the imidazolium hydrogens bonded to the two C6 of the imidazolium heteroatoms facing 
each other (see Figure 3.25 B). It is possible that such interactions are responsible for this cage-
like conformation. 
 
Figure 3.25. X-Ray crystal structure of compound 76·3PF6. (A) ORTEP representation of 76. Thermal ellipsoids 
represented at 50% probability. Hydrogen atoms have been omitted for clarity. (B) Structure of compound 76 
highlighting the short contact interactions between the mesityl imidazolium arms of 76 and one acetonitrile 
molecule. 
Analysis of the unit cell of compound 76·3PF6, an example of which is shown in Figure 3.26, 
revealed a closely packed cell unit due to a network of interactions between molecules of 76, 
the solvent and the hexafluorophosphate counterion. Particularly crucial to this type of 
conformation is the presence of the counterion deeply embedded within the pocket of 
compound 76·3PF6. A summary of the bond lengths is reported below in Table 3.4. 






Figure 3.26. Representation of the unit cell of compound 76·3PF6. (A) View along the a-axis, and (B) view along 
the b-axis. 
 
Table 3.4. Selected bond angles and distances for compound 76·3PF6. 
Atoms involved Angle (°) / Distance (Å) 
C1-C2-C3 112.41(2)°  
C4-C5-N2 112.56(2)°  
C6-N1-C9 125.73(2)°  
C23-N4-C26 123.13° 
C1-C2 1.527(3) Å  
C4-C5 1.509(3) Å  
C5-N2 1.489(3) Å  
H6-N7 (acetonitrile) 2.592(5) Å 
H24-N7 (acetonitrile) 2.397(5) Å 
 
A second batch of crystals of compound 76·3PF6 was obtained by slow evaporation of a 
concentrated solution of 76·3PF6 in acetonitrile. Compound 76·3PF6 crystallises in the triclinic 
P-1 space group. The structure, reported in Figure 3.27, is comparable to compound 75 where 
the molecule assumes an “open” configuration, with the three arms pointing in separate 
directions. To minimise the steric hindrance, the three ethyl arms adopt a “two-up one-down” 





configuration. However, the presence of molecular disorder along one of those arms suggests 
that such a configuration is a dynamic equilibrium in which the arms of the tripodal system 
76·3PF6 can “flip” above and below the plane of the central benzene ring. The packing unit of 
shows further interactions between the mesityl moieties of two molecules of 76·3PF6 (Figure 
3.28), which may be responsible for the “open” conformation adopted by the molecule. 
 
Figure 3.27. X-Ray crystal structure (ORTEP representation) of compound 76·3PF6 in “open configuration”. 
Thermal ellipsoids represented at 50% probability.  
 
Figure 3.28. Representation of a packing unit of compound 76·3PF6 in “open” configuration. Hydrogen atoms 
have been omitted for clarity. 





From the packing visualisation of the unit cell (Figure 3.29) it was possible to appreciate the 
presence of short contact interactions, at an average distance of 2.5 Å, between the imidazolium 
moieties and the hexafluorophosphate anions. Moreover, the “open” configuration assumed by 
compound 76·3PF6 appear to be due to further interactions between the counterion and the 
mesitylene groups. 
 
Figure 3.29. Unit cell of compound 76·3PF6 in “open” configuration, highlighting the H···F interaction between 
the imidazolium and mesityl moieties of 76·3PF6 and the hexafluorophosphate anions. 
  





3.4. Summary of Chapter 3 
This chapter described the syntheses of 9 tripodal receptors which are based upon the two 
hexasubstituted aromatic core 60 and 61 and unsymmetrical imidazole arms with different 
methyl, tert-butyl and mesityl moieties. Initially, we performed the syntheses of two 
symmetrical tripodal ligands bearing three methylimidazole arms. It was possible to obtain a 
single crystal suitable for X-ray diffraction analysis for the novel compound 70, which allowed 
us to visualise how the three imidazole arms are accommodated towards the same side to form 
a pocket, which in turn closely interacts with the molecule’s counterions. Moreover, these 
interactions are responsible to the formation of polymeric assemblies. 
Furthermore, 4 tripodal ligands based on the bulkier tert-butyl and mesityl imidazole were 
obtained in good yields and purity. Crystal structures were also obtained for the novel 
compounds 75 and 76, which have allowed us to gain some understanding of how those systems 
present a dynamic equilibrium between “open arms” or a “closed arms” configuration and the 
influence of the counterion in the assembly of these systems. 
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4. Synthesis, characterisation and cellular 
interactions of novel bis-NHC-based tripodal 
systems with multifunctional capabilities 
The possibility to synthesise a tridentate system with unsymmetrical substituents was also 
investigated in this work, in order to develop ligands capable of binding metals as well as 
attaching other functionalities (e.g. fluorophores, linkers, targeting peptides). A pictorial 
representation of a conceptual bis-NHC-based tripodal system is shown below in Figure 4.1. 
 
Figure 4.1. Pictorial representation of a conceptual compound based upon a bis-NHC – based tripodal system. 
In this chapter, three novel bis-NHC-based tripodal receptors bearing different substituents 
around the hexasubstituted central core were synthesised and characterised. The unsymmetrical 
bis-NHC-based tripodal systems described in this chapter were obtained by replacing one of 
the imidazolium-based arms of the tripodal ligand 76 (whose synthesis is described in Chapter 
3) either with a carboxylic acid-based linker or with an anthracene-thiosemicarbazone moiety. 
A summary of the functionalities described in this chapter is shown in Scheme 4.1. 
 
Scheme 4.1. General representation of the unsymmetrical bis-NHC-based tripodal ligands described in this 
section. 
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4.1. Bifunctional NHC-based systems bearing a carboxylic linker 
The first series of reactions described in this section had the purpose of mono-functionalising 
the tripodal core (compound 61). To do so, it was decided to employ linkers bearing carboxylic 
acids, which are capable of reacting with one of the bromomethyl substituents of the tripodal 
core via a base-catalysed nucleophilic substitution.  
 
Scheme 4.2. General mechanism of a nucleophilic substitution. 
First, compound 61 was treated with the commercially available 4-(tert-butoxy)-4-oxobutanoic 
acid in presence of potassium carbonate (K2CO3) as base, following a procedure previously 
developed by our group.1 The reaction was carried out by dissolving compound 61 and the 
carboxylic acid in acetonitrile, followed by addition of an excess of K2CO3. The reaction 
mixture was stirred under reflux overnight (for a total of 16 hours) before the solvent was 
removed under vacuum. Following work up, TLC of the organic extract revealed the presence 
of unreacted starting materials, and thus the product was purified by silica gel chromatography 
which gave compound 77 as white solid in 29% yield. 
 
Scheme 4.3. Synthetic pathway leading to compound 77. 
The 1H NMR spectrum recorded for compound 77 (Figure 4.2), showed the presence of nine 
sets of signals. Two singlets at 5.25 and 4.65 ppm were correlated to the methylene units 
bridging the 4-(tert-butoxy)-4-oxobutanoate linker (H1) and the two bromomethyl groups 
respectively (H2). Similarly, the two quartets at 2.99-2.93 and 2.87-2.81 ppm were assigned to 
the CH2 of the three ethylene arms around the aromatic core (labelled as H3 and H4 in Figure 
4.2). 
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The presence of two sets of signals indicates a magnetically inequivalence between the ethyl 
arms positioned para- and ortho- relatively to the linker. Furthermore, the CH3 protons 
belonging to the ethyl arms are subject to the same chemical inequivalence, exhibiting two 
triplets at 1.40 and 1.31 ppm, assigned to the para- and ortho- positions respectively (see peaks 
labelled H8 and H9 in Figure 4.2). Finally, the two multiplets H5 and H6 were assigned to the 
CH2 groups connecting the two carbonyl units of the linker, and the intense singlet H7 at 1.48 
ppm was attributed to the nine magnetically equivalent protons of the linker’s tert-butyl 
substituent. 
 
Figure 4.2. 1H NMR (400 MHz, CDCl3, 298 K) spectrum of compound 77. For clarity, magnetically equivalent 
nuclei within the same NMR spin system are labelled once. * residual solvents and impurities traces. 
Following the purification of compound 77 by silica chromatography, the synthesis of the bis-
imidazolium salt proceeded by reacting 77 with a slight excess of 1-mesityl-1H-imidazole 
(compound 74) in dry acetonitrile under reflux conditions. The reaction mixture was monitored 
by TLC until all of compound 77 was consumed. Finally, recrystallisation from 
dichloromethane gave rise to compound 78 as a white solid in 83% yield.  
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Scheme 4.4. Synthetic pathway leading to compound 78. 
The 1H NMR spectrum of compound 78 (Figure 4.3), shows the characteristic peaks of the 
bonded imidazolium arms in the downfield part of the spectrum (labelled H1, H2 and H3) and 
the four aromatic protons of the mesitylene bulky group appear as a singlet at 7.10 ppm (entry 
H7 in Figure 4.3). Two more singlets were assigned to the six methyl units of the mesityl groups 
at 2.29 ppm for the position para- (H9), and 1.95 for the position ortho- (H10) relative to the 
bonded nitrogen.  
 
Figure 4.3. 1H NMR (500 MHz, DMSO-d6, 298 K) spectrum of compound 78. For clarity, magnetically equivalent 
nuclei within the same NMR spin system are labelled once. * residual solvents and impurities traces. 
The assignment of the 1H NMR spectrum of 78 was carried out using a bidimensional 1H-1H 
COSY spectrum (Figure 4.4), which displays the correlations among vicinal protons. In this 
spectrum, three sets of correlating protons were observed: a first set can be identified as the 
three hydrogens of the imidazolium heterocycle (H1-2-3); the second set is correlated the 
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aromatic protons of the mesitylene group with the protons of the methyl substituents situated 
in the ortho- positions (H9 and H10, compared to the aromatic protons labelled H4 in both figures 
4.3 and 4.4). Finally, the third correlation can be observed between the CH2 and CH3 protons 
of the ethyl arms of the tripodal core (H7 and H12). 
 
Figure 4.4. 1H-1H COSY NMR (500 MHz, DMSO-d6, 298 K) spectrum of compound 78. 
Mass spectrometry analysis performed on compound 78 (Figure 4.5), shows a peak at m/z = 
375.2469, indicating the presence of a dicationic molecular ion [M]2+, thus strengthening the 
hypothesis that compound 78 is a bis-imidazolium salt. 
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Figure 4.5. Mass spectrum of the compound 78. A) Ion species [M]2+ at m/z = 375.2469, and B) its predicted 
pattern. 
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4.2. Bifunctional NHC-based systems bearing a terminal azido 
linker 
A second monofunctionalised tripodal core was obtained by reacting compound 61 with the 
linker 6-azidohexanoic acid (referred in this work as compound 79) in refluxing acetonitrile 
and with potassium carbonate as base. The linker 79 was also synthesised from 6-
bromohexanoic acid and sodium azide following an adapted preparation outlined by Travelli 
and co-workers.2 A summary of the overall synthesis is reported below in Scheme 4.5. 
 
Scheme 4.5. Synthetic pathway leading to the monofunctionalised compound 80. 
As for the previous asymmetric tripodal receptor, compound 80 was treated with a slight excess 
of mesityl imidazole (compound 74) in refluxing acetonitrile, affording the dicarbene 
compound 81 as a white powder in good yield.  
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Scheme 4.6. Synthesis of compound 81. 
The 1H NMR spectrum of 81 (Figure 4.6), shows four signals characteristic of the imidazolium 
arms, between 8.0 and 9.5 ppm. The presence of two singlets at 9.44 and 9.22, assigned to the 
C2-H (labelled H1 in Figure 4.6), may indicate a conformational asymmetry for the two mesityl 
imidazolium arms or impurity traces in the NMR sample. Resonances assigned to the mesityl 
substituents were also comparable to the previously synthesised mesityl imidazolium 
derivatives. Chemical shifts characteristic of the 6-azidohexanoyl linker were also assigned: an 
expansion of the upfield region is reported in the blue box in Figure 4.6. Such values are in 
agreement with literature values found for compound 79.2 
 
Figure 4.6. 1H NMR (500 MHz, DMSO-d6, 298 K) spectrum of compound 81. For clarity, magnetically equivalent 
nuclei within the same NMR spin system are labelled once. * residual solvents and impurities traces. 
Mass spectrometry analysis performed on compound 81 confirmed the predicted chemical 
formula. Positive-mode ESI mass spectrum of 81, reported in Figure 4.7, shows the presence 
of a fragment at m/z = 364.7366, indicative of the presence of a doubly-charged molecular ion. 
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A second fragment with m/z = 810.3881, belonging to a singly-charged species, was attributed 
to the bromide adduct [M+79Br]+. The base peak of the spectrum of compound 81, with m/z = 
624.2776, appears to be a bromide adduct of the fragmented molecule, where one of the mesityl 
imidazolium arms is removed (Figure 4.7 C). 
 
Figure 4.7. Mass spectrum of compound 81. (A) ion species [M]2+ of m/z = 364.7360. (B) ion species [M+79Br]+ 
of m/z = 810.3881. 
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4.3. Synthesis, characterisation and in vitro confocal imaging of a 
bis-NHC-based system bearing an anthracene-
thiosemicarbazone “arm” 
The final part of this chapter describes the development of a new unsymmetrical bis-NHC-
based tripodal system, designed with the aim of producing a potential ligand that possesses 
intrinsic fluorescent properties. To achieve this, it was decided to exploit the well-known 
photophysical properties of anthracene, previously described in Chapter 2.  
A second feature of choice was the nature of the linker to be placed between the tripodal core 
and the fluorophore. We selected thiosemicarbazide, an inexpensive thiourea derivative that is 
attracting considerable pharmacological interest due to the successful use of the metal complex 
derivative copper(II)-diacetyl-bis(N(4)-methylthiosemicarbazone (Cu-ATSM) as a hypoxia 
imaging agent in PET studies.3 Furthermore, condensation reaction between thiosemicarbazide 
and aldehydes or ketones gives thiosemicarbazone derivatives which have recently been studied 
for their anti-tumour properties.4  
The synthesis was designed to minimise the number of steps so to have the highest overall yield, 
to use sparingly the reactants and to prevent secondary reactions. The following retrosynthetic 
analysis (Scheme 4.7) represents the shortest pathway to obtain the final compound 83. 
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Scheme 4.7. Retrosynthetic analysis leading to compound 83. 
The first disconnection of the tripodal ligand 83 corresponds to a substitution of the two 
bromide groups of 82 with 1-mesityl-1H-imidazole (compound 74), which gives the dicationic 
tripodal ligand. The monosubstituted compound 82 is also product of a substitution of one 
bromide of compound 61 with anthracene-thiosemicarbazone (compound 66), whose synthesis 
is reported in Chapter 2. 
The synthesis of the monosubstituted tripodal system 82 was attempted by reacting the core 61 
and the linker/fluorophore 66. The two compounds were dissolved under vigorous stirring in 
acetonitrile and heated at reflux for 16 hours, leading to the formation of an orange precipitate. 
After filtering off the orange residue, the mother liquor was concentrated to 1-2 mL and the 
product was precipitated with diethyl ether to give a bright yellow powder, which was washed 
copiously to give compound 82 without further purification being required. 
The 1H NMR spectrum of 82 (Figure 4.8) shows the triethylbenzene resonances between 1.0 
and 3.0 ppm and what appears to be two merged singlets at 4.75 ppm, which we assigned to the 
six protons of the three methylene groups that connect the two bromo groups and the 
linker/fluorophore to the core (entry H6 in Figure 4.8). A second set of resonances, placed 
between 7.5 and 9.5 ppm, were assigned to the aromatic protons belonging to the anthracene 
substituent.  
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Figure 4.8. 1H NMR (400 MHz, DMSO-d6, 298 K) spectrum of compound 82. For clarity, magnetically equivalent 
nuclei within the same NMR spin system are labelled once. * residual solvents and impurities traces. 
Mass spectrometry analysis was also performed. Electrospray Ionisation in positive mode for 
compound 82 (Figure 4.9), shows clearly the presence of two main fragments. The intense peak 
at m/z = 640.0807 represents the protonated molecular ion [M+H]+, while the less intense signal 
at m/z = 662.0625 corresponds to the sodium adduct. 
 
Figure 4.9. Positive-mode ESI-MS for compound 82. Blue dotted square: Ion species [M+H]+ at m/z = 640.0807. 
Green dotted square: Ion species [M+Na]+ at m/z = 662.0625. 
UV-Visible and fluorescence spectroscopy were also carried out to define the emissive 
properties of compounds 66 and 82. Both compounds exhibited broad absorption band in the 
region 320–460 nm, with structural bands located at 350, 370, and 390 nm, which is typical for 
transitions between the π-electronic energy levels of the anthracene moiety.5 Fluorescence 
emission spectra of both compounds are broad and the resulting Stokes shifts are large, with 
107 and 110nm for compounds 66 and 82 respectively (see Figure 4.10).  
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Figure 4.10. A: Normalised UV-Visible (red line) and fluorescence emission (blue line) spectra of compound 66 
in CH2Cl2 (12.5 µM). B: Normalised UV-Visible (violet line) and fluorescence emission (green line) spectra of 
compound 82 in CH2Cl2 (12.5 µM). 
To further elucidate the structure of compound 82, infrared spectroscopy analysis was carried 
out. The results are shown in Figure 4.11 B, along with the FTIR spectrum of the starting 
material 66 (Figure 4.11 A). The spectrum of 66 shows a unique medium-intense band a 3439 
cm-1 that we assigned to the N-H stretching of the germinal NH2. The intense band at 1600 cm-
1 was attributed to the C=N stretching and the strong signal at 1279 cm-1 was correlated to the 
C=S stretching. 
In the spectrum of compound 82 (Figure 4.11 B) a broad absorption was observed in the higher 
frequency part of the spectrum, with a strong peak at 2965 cm-1, indicative of the various C-H 
stretchings from the hexasubstituted benzene core. Two strong signals at 1635 cm-1 and 1586 
cm-1 were correlated to the C=N stretchings of the newly synthesised compound. Coupled with 
the absence of the C=S stretching previously observed, the IR spectrum of 82 strengthens the 
hypothesis of the S-alkylation of compound 61 by the thiosemicarbazone 66, thus reinforcing 
the case for the proposed structure. A list of the main FT-IR band assignments is for the two 
compounds is shown in Table 4.1 
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Figure 4.11. Solid state FT-IR spectra of compound 66 (A) and compound 82 (B). 
 
Table 4.1. Band assignments for the FT-IR spectra of compounds 66 and 82 (Figure 4.10). 
Compound Wavenumber (cm-1) Vibrational mode 
66 
3439 
N-H st 3213 
3155 









632 C-S st 
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The last part of the synthesis consisted of the reaction between the newly synthesised compound 
82 and mesityl imidazole (compound 74) by employing the procedure already exploited for the 
previously synthesised imidazolium-based receptors. An outline of the synthesis is reported in 
Scheme 4.8. After standard work up and recrystallisation in chloroform a yellow powder was 
obtained in a very good yield (87%). 
 
Scheme 4.8. Synthesis of compound 83. 
The 1H NMR spectrum of the reaction product (Figure 4.12), displays resonances comparable 
to compound 82 as well as the resonances of the bonded imidazolium (signals labelled H2, 
H7and H8). Interestingly, the spectrum of 83 showed a splitting of the resonances attributed to 
the ortho-methyl moieties of the mesityl substituents (labelled H13 and H13’ in Figure 4.12). As 
the resonance labelled H13’ is partially overlapping with a residual acetone signal, a two-
dimensional 1H-1H COSY NMR spectrum was recorded (for the full 1H-1H COSY spectrum of 
compound 83 see appendix C). As for the previously analysed mesityl imidazolium-based 
systems, the ortho-methyl moieties of the mesityl groups of 83 couple with the aryl C-H protons 
of the mesityl ring (labelled H10 in Figure 4.12). In the spectrum of 83, both resonances labelled 
H13 and H13’ couple with H10. 
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Figure 4.12. 1H NMR (400 MHz, DMSO-d6, 298 K) spectrum of compound (83). Blue dotted box: expansion of 
the aromatic region. For clarity, magnetically equivalent nuclei within the same NMR spin system are labelled 
once. 
Further confirmation of the molecular formula came from mass spectrometry analysis. The ESI 
mass spectrum of compound 83 (Figure 4.13), shows a fragment at m/z = 425.7384, which we 
assigned to the dicationic molecular ion [M]2+. 
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Figure 4.13. Positive-mode ESI-MS spectrum of compound 83. Blue dotted square: fragment [M]2+ at m/z = 
425.7384 (A), and its simulated pattern (B). 
UV-Visible spectroscopy performed on a DCM solution of compound 83 produced a similar 
spectrum compared to its starting material. Compared to 82, the fluorescence emission spectrum 
of compound 83 presented a smaller Stokes shift and the presence of three emission bands at 
435, 464 and 500 nm. The normalised UV-Vis and fluorescence spectra of 83 are shown in 
Figure 4.14. 
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Figure 4.14. Normalised UV-Visible (blue line) and fluorescence emission (red line) spectra of a 12.5 µM solution 
of compound 83 in CH2Cl2. 
The optical properties of compounds 82 and 83 were also evaluated using 2D fluorescence 
contour maps generated by scanning solutions of the two compounds across the full excited 
emission ranges available (Figure 4.15 and Figure 4.16 respectively). Both compounds display 
emissions between 450-550 nm, which are particularly intense in the case of compound 83 
where the emissive window is blue-shifted towards lower values of 400 nm. 
 
Figure 4.15. 2D fluorescence contour map of compound 82 (12.5 µM in CH2Cl2). 
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Figure 4.16. 2D fluorescence contour map of compound 83 (12.5 µM in CH2Cl2). 
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4.3.1. Single-photon laser-scanning microscopy investigation of ATSC-
based probes in PC3 cancer cells 
For the newly synthesised ATSC-based compounds 82 and 83 single-photon laser-scanning 
confocal microscopy (SLSCM) analysis was performed. PC3 cells were grown according to 
standard culturing methods, placed onto glass-bottomed dishes and allowed to grow to a 
suitable confluence. 
Figure 4.17 shows the images of PC3 cells incubated for 20 min with compound 82 taken in 
the confocal mode. The images show broad emission across blue and green channels when the 
probe is excited at 405 nm (a1-5), while there seems to be no emission using 488 nm and 561 
nm lasers respectively. Compound ss appear to be taken up in PC3 cells and localises 
throughout the cytoplasm, whereas no emission appears to originate from the nuclei. 
SLSCM analysis of compound 83, shown in Figure 4.18, revealed broad emissions in all the 
visible wavelengths when the probe is excited at 405 nm, while only green-red emissions are 
visible using the 488 nm laser. Interestingly, irradiation of the sample at 561 nm showed a 
noticeable emission in all three channels. Further tests will be needed to explain such emission 
at the highest excitation wavelength tested. Compound 83 appeared to localise evenly 






































Figure 4.17. Single-photon laser-scanning confocal microscopy images of PC3 cells incubated with compound 82 (10 µg/mL 1% : 99% DMSO : DMEM) 
at 37 ºC for 20 minutes; λex = 405 nm (a1-a5), λex = 488 nm (b1-b5) and λex = 561 nm (c1-c5). DIC channel (a1, b1, c1), blue channel, λem = 420-480 nm (a2, 
b2, c2), green channel, λem = 516-530 nm (a3, b3, c3), red channel λem = 615-650 nm (a4, b4, c4), and overlapping of the DIC, blue, green and red channels 








































Figure 4.18. Single-photon laser-scanning confocal microscopy images of PC3 cells incubated with compound 83 (10 µg/mL 1% : 99% DMSO : DMEM) 
at 37 ºC for 20 minutes; λex = 405 nm (a1-a5), λex = 488 nm (b1-b5) and λex = 561 nm (c1-c5). DIC channel (a1, b1, c1), blue channel, λem = 420-480 nm (a2, 
b2, c2), green channel, λem = 516-530 nm (a3, b3, c3), red channel λem = 615-650 nm (a4, b4, c4), and overlapping of the DIC, blue, green and red channels 
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4.4. Summary of Chapter 4 
This chapter describes the syntheses of three NHC-based tripodal systems in which one of the 
three arms has been modified with two carboxylic acid-based linkers (compounds 78 and 81), 
as well as with the introduction of an anthracene-thiosemicarbazone derivative as fluorophore 
(compound 83).  
Compound 83 was obtained in a two-step reaction, firstly by preforming a nucleophilic 
substitution of one bromomethyl arm of the core 61 with 66, to give compound 82 after a simple 
workup. Spectrophotometric analyses of 82 revealed that the preferential mode of substitution 
of the bromide is through sulphur as for the previously reported compounds 67 and 68, thus 
suggesting that thiosemicarbazone compounds are able to S-alkylate the hexasubstituted 
aromatic cores.  
Finally, reaction between mesityl imidazole derivative compound 74 and compound 82 has 
been performed. The unsymmetrical tripodal system 83 was obtained in acceptable purity and 
good yield and its fluorescent properties were evaluated by fluorescence spectroscopy. The new 
compound shows absorption peaks characteristic of the anthracene moiety and a larger 
fluorescence emission curve between 450-550 nm, which is suitable for cellular imaging 
applications.  
Lastly, single-photon laser-scanning confocal microscopy experiments carried out on PC3 
prostate cancer cells incubated with compound 83 revealed that the compound was able to cross 
the cellular membrane and localise throughout the cytoplasm, where it displayed intense 
fluorescence when irradiated at 405, 488 and 561 nm. 
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5. Incorporation of metallic units onto tripodal 
synthetic scaffolds 
Following the successful syntheses of several tripodal systems, we began to test the possibility 
of developing novel metal complexes containing metal centres of relevance to imaging and/or 
therapy. The following chapter reports the complexation attempts between a series of transition 
metals and few selected tripodal ligands previously discussed.  
 
5.1. Tripodal ATSC-based metal complexes 
The focus of this section is the synthesis and evaluation of organometallic complexes composed 
from the newly synthesised tripodal anthracene-thiosemicarbazone (ATSC) ligands 67 and 68, 
previously described in Chapter 2, with a variety of transition metal precursors. 
Preliminary radiolabelling experiments with the positron-emitter radiotracer zirconium-89 
revealed that 67 was able to coordinate the radionuclide with a very high radio-incorporation 
factor (see Appendix D). However, subsequent attempts to synthesise the “cold” complex were 
unsuccessful. Therefore, we opted to make use of other transition metals that act as softer Lewis 
acids, such as ruthenium and rhenium, to develop a series of coordination compounds with the 
two tripodal ATSC-based ligands. Given the structural complexity of such tripodal systems, a 
prediction of the coordination modes between the metal centre and these ligands cannot be 
made unequivocally. Nonetheless, there are several literature examples that can help to 
speculate the coordination modalities involving these transition metals and thiosemicarbazone-
based ligands.1-7 A summary of the possible binding modalities between the ATSC-based 
ligands and the metal centre is shown in Figure 5.1. 
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Figure 5.1. Proposed binding modes between the ATSC-based ligands 67 (R = Me), 68 (R = Et) and the transition 
metal centre (M = Re, Ru). 
 
5.1.1. Rhenium complexes 
Rhenium(I) tricarbonyl complexes (of the general formula fac-[Re(CO)3L] where “L” is a 
tridentate ligand) have been demonstrated to exhibit interesting luminescent properties,8 arising 
from its octahedral d6 low-spin configuration. This allows precise detection by confocal 
microscopy in cells, but also presents some weaknesses such as very low luminescence quantum 
yield in aqueous medium9.  
5. Incorporation of metallic units onto 




Rhenium tricarbonyl complexes are usually obtained by refluxing a mixture of the ligand with 
the metal precursor in an appropriate solvent for several hours. In this work, a microwave-
assisted methodology was investigated in order to obtain the desired products in much shorter 
times. Equimolar quantities of ligand and the metal precursor halogen-pentacarbonylrhenium(I) 
(Re(CO)5X, with X = Br or Cl), were dissolved in dry toluene, and placed into a microwave 
vial and purged with argon. The reaction mixture was heated at 150 ºC for 30 minutes under 
microwave irradiation, during which time an orange precipitate was formed. The precipitates 
were filtered and washed several times with fresh toluene and diethyl ether, the products were 
obtained as orange solids in moderate yields. A general reaction scheme, along with the 
proposed product structures, is shown below in Scheme 5.1.  
 
Scheme 5.1. Synthetic pathway leading to rhenium complexes 84 and 85. 
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The newly synthesised compounds were analysed with standard spectroscopic techniques. 1H 
NMR spectra of both metal complexes show little variations in the chemical shifts compared to 
their ligands. The 1H NMR spectrum of compound 85 is shown in Figure 5.2. 
 
Figure 5.2. 1H NMR (500 MHz, CDCl3, 298 K) spectrum of compound 85. For clarity, magnetically equivalent 
nuclei within the same NMR spin system are labelled once. * residual solvents and impurities traces. 
Positive-mode ESI mass spectrum of a 1µg/ml solution of compound 84 in methanol was 
subsequently acquired, revealing the presence of a bi-protonated molecular ion ([M+2H+Cl], 
with M = C63H51N9O3S3Re, corresponding to the proposed structure for compound 84), along 
with a chlorine adduct. However, given the complexity of the recorded mass spectrum, as well 
as the presence of potential alternative rhenium-ligand coordinations (such as the fragment with 
m/z = 564.2638), it was not possible to unequivocally define the molecular formula of 
compound 84. The full spectrum acquired for compound 84 is shown below in Figure 5.3.  
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Figure 5.3. Positive-mode ESI-MS for compound 84. Blue box: Ion species [M+2H+Cl]+ at 1301.3227 m/z. 
The presence of chlorine in the ion species with m/z = 1301.3227 in the mass spectrum recorded 
for compound 84 might be a suggestion of an alternative complexation mode, leading to a Re-
arene half-sandwich compound. Previous literature reports have demonstrated the possibility 
of preparing various half-sandwich compounds of rhenium (Figure 5.4 A),10, 11 while Hogarth 
and co-workers successfully synthesised a tripodal-based complex of molecular formula 
Cr(CO)3(η6-arene) in which the metal centre interacts with the hexasubstituted core of 
compound 64 (Figure 5.4 B).12 
5. Incorporation of metallic units onto 





Figure 5.4. Examples of half-sandwich complexes. Adapted from ref.10 (A) and ref.12 (B). 
We thus propose an alternative structure for compound 84 of molecular formula Re(CO)3(η2-
67). This structure could help rationalise the broad peaks observed in the up-field region of the 
NMR spectrum (the full 1H NMR spectrum recorded for 84 is shown in appendix D). 
 
Scheme 5.2. Alternative reaction scheme proposed for compound 84. 
The mass spectrum of compound 85 recorded in positive-mode ESI was acquired at the EPRSC 
UK National Mass Spectrometry Facility in Swansea. The spectrum, reported in Figure 5.5, 
shows a peak at 1306.3282 m/z corresponding to the molecular ion [M]+ (where M = 
C66H57N9O3S3Re, corresponding to the proposed structure for compound 85). 
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Figure 5.5. Mass spectrum of compound 85. Blue dotted box: details of the molecular ion [M]+ and its simulated 
isotopic pattern. 
FT-IR analysis was also used to confirm the presence of carbonyl ligands bonded to the metal 
centre for 84 and 85. From the spectra shown in Figure 5.7 it is possible to distinguish the 
presence of three intense bands at 2017, 1907 and 1883 cm-1 for the metal complex 84 (Figure 
5.7, purple line) and at 2020, 1907 and 1887 cm-1 for the analogue 85 (Figure 5.7, green line). 
The broad bands observed at lower wavenumbers are due to the overlapping E, Eˈ modes (see 
Figure 5.6 for their composition).13 These values are in agreement with typical C-O stretching 
vibrations of carbon monoxide units of a fac-[M(CO)3] metal complex. Furthermore, such lower 
frequencies suggest the presence of strong π-backbonding between the CO ligand and the Re(I) 
centre.14 
 
Figure 5.6. A1, E, and E’ vibrational modes in C3v symmetry for complexes 84 and 85. L = tripodal ligand 67 or 
68. 
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Figure 5.7. Solid-state FT-IR spectra of metal complexes 84 (B) and 85 (D) and their ligand precursors 67 (A) 
and 68 (C).  
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UV-Visible and fluorescence emission measurements were carried out for both complexes. 
Normalised spectra for compounds 84 and 85 are shown below in Figure 5.8. The two metal 
complexes exhibit absorption patterns characteristic of the anthracene moiety, with three 
distinct bands at 350, 370 and 390 nm. Fluorescence spectra for both metal complexes show 
large Stokes shifts, with intensity maxima of 441 nm and 475 nm for compound 84 and 85 
respectively. Compared to the fluorescence spectra of the starting ligands, reported in this work 
in Chapter 2, the redshift observed in the spectrum of compound 85 could be due to the presence 
of metal-to-ligand charge-transfer (MLCT).15 
 
Figure 5.8. Left: normalised UV-visible (purple line) and fluorescence emission (pink line) spectra of compound 
84 in THF (12.5 µM). Right: normalised UV-visible (blue line) and fluorescence emission (red line) spectra of 
compound 85 in THF (12.5 µM). 
Analogously for the ligands 67 and 68, fluorescence contour maps were generated to visualise 
the optical behaviour of the complexes 84 and 85 across the full excited emission ranges 
available. Both complexes display emissive properties between 390 to 500-550 nm, which 
makes them suitable dyes for confocal microscopy of cells. 2D contour maps of the two 
complexes are shown below in Figure 5.9 for compound 84 and in Figure 5.10 for compound 
85. 
Compared to the 2D maps generated for the ligands precursors 67 and 68 shown in Chapter 2, 
the rhenium complexes 84 and 85 exhibited stronger fluorescence emissions from 370 to 500 
nm. The emission intensity is particularly enhanced upon metallation of the ligand precursor 67 
(Figure 5.9). 
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Figure 5.9. 2D fluorescence contour map for compound 84 (5 µM in THF). 
 
Figure 5.10. 2D fluorescence contour map for compound 85 (5 µM in THF). 
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5.1.2. Ruthenium complexes 
Ruthenium anticancer drugs have attracted increasing interest in the last couple of decades, with 
two of them (NAMI-A and KP1019) currently undergoing clinical trials in Europe.16, 17 
Compared to cisplatin and congeners, ruthenium complexes often display lower toxicity and 
are capable of overcoming the resistance induced by platinum drugs in cancer cells.18 
In this section we report the complexation attempts between tripodal ATSC-based ligands and 
a ruthenium(II) precursor, so to test the capacity of these new tripodal systems to accept other 
transition metals with biomedical applications. As for the previous complexation attempts (see 
section 5.1.1.), we opted to perform the syntheses by exploiting microwave technology to 
considerably shorten the reaction times.  
In an argon-purged microwave vial, equimolar quantities of compound 68 and triruthenium 
dodecacarbonyl (Ru3(CO)12) were heated in toluene at 150°C for 30 minutes under microwave 
irradiation. A cloudy, deep red solution was obtained. After removal of the solvent, a red 
powder was obtained. TLC examination clearly showed the presence of two spots, one of which 
belonging to the tripodal starting material 68. Silica gel flash chromatography was performed, 
and the crude product was eluted with a mixture of chloroform/hexane (60:40) to give the final 
product as a red solid in moderate yield (44%). A general outline of the synthesis is shown in 
Scheme 5.3. 
 
Scheme 5.3. Synthesis of compound 86. 
1H NMR analysis performed on the newly synthesised compound 86 revealed the presence of 
8 signals (Figure 5.11). Due to the poor resolution of the multiplets, the assignment of each 
resonance of the aromatic region (between 7 – 9 ppm) proved to be difficult. However, the 
assignment of the resonances found in the aliphatic region (1 – 3 ppm) was facilitated by a 1H-
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1H COSY analysis which revealed a noticeable shift upfield of the signals belonging to the 
methylene units 1 and 2, which is probably due to the complexation of the ligand with the metal 
centre. 
 
Figure 5.11. 1H NMR (400 MHz, CDCl3, 298 K) spectrum of compound 86 and a detail of the 1H-1H COSY 
spectrum highlighting the aliphatic region (green dotted box). For clarity, magnetically equivalent nuclei within 
the same NMR spin system are labelled once. * residual solvents and impurities traces. 
Accurate mass spectrometry analysis of compound 86 was carried out and the results shown in 
Figure 5.12 and in Figure 5.13. The spectrum of 86 revealed the presence of a monometallic 
ion fragment at m/z = 1194.2958, corresponding to the protonated molecular ion with the loss 
of one molecule of carbon monoxide [M+H-CO]+ (where M = C66H57N9O3S3Ru, corresponding 
to the initially proposed structure for compound 85 with three CO ligands bound to the 
ruthenium centre). 
5. Incorporation of metallic units onto 





Figure 5.12. Mass spectrum of compound 86. 
 
 
Figure 5.13. Detail of the fragment [M+H-CO]+, along with its predicted isotopic pattern. 
The FT-IR spectrum of compound 86, along with its pro-ligand compound 68, is shown in 
Figure 5.14. The IR spectrum of the metal complex clearly shows the presence of strong bands 
at 2041 cm-1 and 1972 cm-1 which are indicative of CO stretching vibrations of carbon 
monoxide units bound to a metal centre.19 A summary of the band assignments for 86 and the 
metal precursor Ru3(CO)12 is shown in Table 5.1. We also noted a shift in the C=N bands, 
positioned at 1586-1526 cm-1 in the free ligand, to lower values of 1579-1494 cm-1 in the 
complex. This shift may suggest that the azomethine nitrogens coordinate to the metal.20  
5. Incorporation of metallic units onto 




Figure 5.14. Normalised FT-IR spectra of compound 86 (red curve) and its ligand precursor 68 (blue curve). 
 
Table 5.1. Band assignments for the FT-IR spectra of the metal precursor Ru3(CO)12 and 86 (Figure 5.13). 















The strong, broad bands assigned to the CO stretching in the IR spectrum of compound 86 
might also be an indication of the presence of ruthenium clusters. Previous unpublished results 
from our group involving the reactivity of tripodal NHC ligands with the cluster Fe3(CO)12 led 
to a compound of formula [(timtebtBuH3)2][{Fe2(CO)8}3] in which the diiron cluster acts as 
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Figure 5.15. Representation of the crystal structure of half a unit cell containing [(timtebtBuH3)2][{Fe2(CO)8}3]. 
The results from the 1H NMR analysis of 86 (previously reported in Figure 5.11) led us to 
consider the possibility of having again obtained an alternative complexation structure that 
involves a metal-arene interaction. The presence of such broad signals in the low field part of 
the 1H NMR spectrum of 86 might suggest that the ruthenium centre interacts with the aromatic 
rings of the anthracene arms, therefore generating an Ru-anthracene “half sandwich compound” 
(Figure 5.16). 
 
Figure 5.16. Alternative structure proposed for compound 86 involving the arene coordination with the metal 
centre. 
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Reports on metal-arene coordination arrangements between ruthenium-carbonyl moieties and 
aromatic systems (Figure 5.17) have been published by Kraupp,22 Lin,23 Casey24 and Yildirim.25  
 
Figure 5.17. Literature examples of Ruthenium “half sandwich” compounds from Lin (A), Casey (B) and Yildirim 
(C). 
The UV-visible and fluorescence spectra of compound 86 are shown in Figure 5.18 A. The UV-
Vis spectrum (blue curve) shows the characteristic absorption bands of the anthracene moiety 
at 350, 370 and 390 nm. The fluorescence spectrum (red curve) shows a relatively narrow 
emission band with an intensity maximum at 441 nm. A fluorescence 2D map was also 
generated and is in Figure 5.18 B. Compound 86 appears to exhibit higher fluorescence 
emission compared to its ligand precursor 68, whose spectra is reported in Chapter 2. 
 
Figure 5.18. (A) Normalised UV-Visible (blue line) and fluorescence emission (red line) spectra of compound 86 
(5 µM in THF). (B) 2D fluorescence contour map (5 µM in THF). 
  
(A) (B) 
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5.2. Metal complexes of tripodal NHC-based ligands 
N-Heterocyclic carbenes represent one of the most important classes of ligands in 
organometallic chemistry. NHCs are good σ-donors and π-acceptors, which makes them able 
to form strong metal–carbene bonds, thus giving complexes that are stable in biological 
media.26 
The aim of this work was to test the ability of few selected tripodal NHC-based ligands to bind 
transition metals with demonstrated antiproliferative capabilities such as silver,27 gold,28 
copper29 and ruthenium.30 
 
5.2.1. Silver(I) complexes 
Silver and its salts have been exploited as antimicrobial agents and have proved to exhibit low 
toxicity for humans. Thus, most of the biomedical studies on silver complexes have been 
conducted on their antimicrobial properties.31 Youngs and co-workers were the first to report 
the anticancer activity of Ag(I)-NHC compounds.32 Since then, several groups have been 
developing new Ag(I)-NHC complexes which have displayed remarkable activity towards 
several cancer cell lines.27, 33 
In this section, we describe various attempts to develop new metal complexes of silver(I) with 
a few selected ligands synthesised in Chapter 3. In order to synthesise such complexes, we 
decided to use a method involving the in situ deprotonation of the carbene, by simply mixing 
the ligand precursor with silver(I) oxide (Ag2O) in an appropriate solvent.34 This methodology 
presented several advantages compared to the typical deprotonation-metallation of NHCs, as it 
did not require solvent pre-treatments (such as solvent drying), anhydrous conditions, and 
strong bases to deprotonate the C2 carbon. 
After performing a literature review regarding multidentate Ag-NHC complexes, it was decided 
to attempt the metalation of some selected tripodal systems previously obtained. This would 
probe whether it would be possible to synthesise trimetallic complexes in which each 
imidazolium “arm” of the tripodal ligand was bound to a silver atom. A representation of the 
proposed reaction is shown in Scheme 5.4. 
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Scheme 5.4. Proposed synthesis of tripodal NHC-Ag3 complexes. 
The first reaction was attempted by mixing a suspension of the ligand precursor compound 76 
and a 3-fold excess of Ag2O in acetonitrile. The reaction vessel was wrapped with tinfoil to 
prevent photodecomposition, then the slurry was stirred at room temperature and followed via 
TLC. After 48 hours the mixture was filtered through a Celite® pad to remove all the unreacted 
Ag2O and the solvent was removed under vacuum to give an off-white powder. However, upon 
redissolution the crude product quickly turned grey, possibly due to photosensitivity. 
Nonetheless, a 1H NMR spectrum of the crude product, shown below in Figure 5.19, revealed 
a small peak at 8.60 ppm, which we attributed to the C2-H proton, indicating an incomplete 
deprotonation of all three NHC sites.  
 
Figure 5.19. 1H NMR (300 MHz, MeCN-d3, 298 K) spectrum of the reaction product formed between compound 
76 and Ag2O. 
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Mass spectrometry analysis of the reaction product was carried out. The resulting spectrum 
(Figure 5.20) shows no traces of a trimetallic pattern. A bimetallic pattern was instead identified 
with an ion species of m/z = 998.3050, attributable to the formation of a bimetallic complex of 
formula 76·Ag2Br. The last assignable peak in the spectrum in Figure 5.20 belongs to the 
monometallic ion species with m/z = 865.3919, which is presumably indicative of a potential 
Ag1-NHC species. Unfortunately, attempts to repeat the preparation of this bimetallic 
compound were unsuccessful. 
 
Figure 5.20. Mass spectrum recorded for the product between compound 76 and Ag2O. 
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Following the unsuccessful initial attempt to obtain a trimetallic complex, we performed 
subsequent experiments with different equivalents of metal precursor (1, 2, 3.3 and large 
excess), times (up to 5 days) and solvents. Higher equivalents of Ag2O appeared to trigger 
photodecomposition of the samples with a monometallic species formed as by-product, while 
ratios of 1:1 – 1:2 ligand precursor – Ag2O seemed to favour the formation of a monometallic 
species. A paper from Willans and co-workers reported the development of a small 
tris(imidazolium) cage that reacts with Ag2O to give an Ag(I) carbene complex, in which one 
of the imidazolium moieties remains protonated (Figure 5.21).35 
 
Figure 5.21. Structural representation of the tris(imidazolium) cage complex of Ag(I) prepared by Willans et al. 
Based on this precedent and our results above, we therefore decided to further explore the path 
leading to monometallic species and their properties. The synthesis of the Ag1-NHC complex, 
named compound 87 in this work, thus involved mixing the ligand precursor 76·3PF6 and a 
small excess of Ag2O in acetonitrile. After stirring for 48 hours at room temperature, the 
mixture was filtered through a Celite® pad and the solvent removed via rotary evaporator. The 
residue was purified by silica gel chromatography, eluting with dichloromethane, to give an 
off-white powder in moderate yield (53%). 
 
Scheme 5.5. Synthesis of compound 87. 
5. Incorporation of metallic units onto 




The 1H NMR spectrum of 87 (Figure 5.22) shows 15 sets of signals. The signal at 9.22 ppm, 
integrating for 1H, was assigned to the imidazolium C2-H proton (entry H1 in Figure 5.22). The 
two signals at 8.01 and 7.91 ppm, both integrating for 2H, were assigned to the N(CH)2N of the 
imidazol-2-ylidene groups (entries H2 and H3 in Figure 5.22). A up-field shift of the N(CH)2N 
signals (entries H6 and H7, Figure 5.22) of the uncoordinated imidazolium moiety was also 
observed This shielding effect could be due to the endo position of the two imidazolium 
hydrogens,36 and as suggested by the “close” configuration assumed by the crystal structure of 
the ligand 76·3PF6, reported in Chapter 3 (section 3.3), figure 3.25. 
Two resonances at 7.38 and 7.12 ppm, integrating for 2H and 4H respectively, were assigned 
to the aromatic C-H of the mesityl moieties (H4 and H5 in Figure 5.22). Two more signals at 
5.63 (H8), integrating for 2H, and 5.56 ppm (H9), integrating for 4H, were correlated to the CH2 
connecting the mesitylimidazolium arms and the hexasubstituted aromatic core. Compared to 
the 1H NMR spectrum of the starting material (compound 76·3PF6, reported in Chapter 3, 
section 3.3), the splitting of the CH2 linkers may be indicating the presence of an asymmetric 
complex. Additional signal splittings, indicative of such asymmetry, are evident in the shifts of 
the proton signals of the ethylene arms (entries H10, H11 and H14, H15 in Figure 5.22). 
 
Figure 5.22. 1H NMR (400 MHz, DMSO-d6, 298 K) spectrum of compound 87. For clarity, magnetically 
equivalent nuclei within the same NMR spin system are labelled once. * residual solvents and impurities traces. 
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Electrospray ionisation mass spectrometry performed on compound 87 further strengthened the 
hypothesis that 87 is a di-cationic, monometallic Ag1-NHC species. In the spectrum of 87, 
shown below in Figure 5.23, two main peaks can be identified. The base peak at m/z = 
1011.3786 corresponds to the singly charged adduct [M+PF6]+, while the next most intense 
peak at m/z = 433.2100 may be assigned to the doubly charged molecular ion, [M]2+. 
 
Figure 5.23. Mass spectrum of compound 87. Green dotted box: ion species [M]2+ at 433.2100 m/z. Blue dotted 
box: ion species [M+PF6]+ at 1011.3786 m/z. 
The UV-visible and fluorescence spectra of compound 87 are shown in Figure 5.24. The UV 
spectrum (red line) shows an absorption maximum at 280 nm, which is due to the presence of 
the aromatic units. The fluorescence emission spectrum is broad, with a Stokes shift of several 
hundred nm and an emission intensity maximum at 431 nm. 
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Figure 5.24. Normalised UV-Visible (red line) and fluorescence emission (blue line) spectra of compound 87 (25 
µM in CH2Cl2). 
In order to shorten the reaction time for the preparation of 87, we considered employing 
microwave methodology. The use of microwave heating for the synthesis of NHC-based 
complexes of coinage metals (such as Ag) has been shown to allow for a drastic reduction of 
the reaction times compared to conventional heating, while affording comparable or better 
yields of the desired products.37 
The microwave-assisted synthesis of compound 87 was achieved by dissolving the ligand 
precursor compound 76·3PF6 in appropriate amount of anhydrous dichloroethane (DCE), 
followed by a slight excess of Ag2O. The vial containing the reaction mixture was sealed, 
purged with argon and heated at 150 °C under microwave irradiation for 42 minutes. After work 
up and chromatography, the product was obtained as a white solid.  
The 1H NMR spectrum of the product of the microwave-assisted reaction is shown in Figure 
5.25, along with its 1H-1H COSY spectrum (Figure 5.26). As for the spectrum of the complex 
obtained by the conventional heating method (Figure 5.22), the same magnetic inequivalence 
between the aliphatic protons may be observed (entries H6, H7, H8, H10 and H11 in the 1H NMR 
spectra reported in Figure 5.25). The methylene groups linking the imidazolium arms and the 
aromatic core also display such inequivalence: compared to the ligand precursor, with the 
resonance at around 5.50 ppm being split upon complexation into two signals at 5.52 and 5.29 
ppm (labelled as H4 and H5 respectively). However, an important difference in the resonance 
shown by the spectrum of compound 87 (Figure 5.22) and that of the product of the microwave 
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reaction (Figure 5.25) can be observed in the downfield region: the spectrum of compound 87 
clearly shows the presence of the undeprotonated imidazolium proton (H1 in Figure 5.22), as 
well as splitting of the signals generated by the remaining protons of the chemically diverse 
heteroatoms. In the 1H NMR spectrum of the compound obtained through the microwave 
reaction (Figure 5.25), such splittings are not observed, and the pro-carbenic proton signal 
observed for 87 is missing.  
Given the obvious differences between the 1H NMR spectra shown in Figure 5.22 and 5.25, it 
is possible to conclude that the product of the microwave reaction is not compound 87. 
Moreover, the lack of signal attributable to the pro-carbenic proton suggests that the 
complexation of the metal centre involved all three NHC arms. Several groups reported the 
synthesis of tri-coordinate complexes of Ag(I) with monodentate tertiary phosphines and 
multidentate nitrogen donors able to enforce such coordination over the metal centre.38-42 The 
proposed structure of the newly synthesised Ag(I) complex, further referred as compound 88, 
is shown in Figure 5.25. 
 
Figure 5.25. 1H NMR (400 MHz, CDCl3, 298 K) spectrum of compound 88 synthesised via the microwave 
method. For clarity, magnetically equivalent nuclei within the same NMR spin system are labelled once. * residual 
solvents and impurities traces. 
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Figure 5.26. 1H-1H COSY (400 MHz, CDCl3, 298 K) spectrum of compound 88. On the right: detail of the 
spectrum highlighting the aliphatic region. For clarity, magnetically equivalent nuclei within the same NMR spin 
system are labelled once. 
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The mass spectrum of compound 88, shown in Figure 5.27, clearly shows an intense peak at 
m/z = 865.3957, corresponding to the molecular ion [M]+ of the mono-metallic complex. 
 
Figure 5.27. Mass spectrum of compound 88. 
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The microwave-assisted methodology was employed again to react the tripodal NHC-based 
compound 75 with the silver precursor Ag2O. The reaction was carried out by mixing in a 
microwave vial a dichloroethane solution of ligand precursor 75 and a slight excess of powdered 
Ag2O (1.2 equivalents). The reaction vessel was sealed, and the mixture heated at 150°C for 40 
minutes. The product was obtained as a pale-yellow powder after recrystallisation from 
dichloromethane. 
 
Scheme 5.6. Microwave-assisted synthesis of compound 89. 
The new metal complex, named compound 89, was characterised with NMR spectroscopy. The 
1H NMR spectrum of compound 89 is shown in Figure 5.28. The resonances in the spectrum of 
89 were comparable to the ones observed for the ligand precursor 75, with the sole exception 
of the pro-carbenic proton signal (C2-H), which is usually deshielded to values around 9.5-10.5 
ppm. There was also an upfield shift in the signals belonging to the N(CH)2N of the imidazol-
2-ylidene groups of ca. 0.5 ppm, possibly due to complexation. 
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Figure 5.28. 1H NMR (300 MHz, MeCN-d3, 298 K) spectrum of compound 89 and a detail of the 1H-1H COSY 
spectrum highlighting the aromatic region. For clarity, magnetically equivalent nuclei within the same NMR spin 
system are labelled once. * residual solvents and impurities traces. 
The mass spectrum of compound 89 (Figure 5.29) displays a peak at m/z = 412.1783, which 
can be attributed to the protonated, doubly charged molecular ion ([M+H]2+, with M = 
C48H54N6Ag as molecular formula corresponding to the proposed structure for compound 89). 
A second species, with m/z = 823.3513, was correlated with the molecular ion [M]+ of the 
proposed formula for compound 89. The presence of such a species coupled with the 1H NMR 
results indicating that the complexation have occurred in all three “arms” of the ligand precursor 
compound 75, could be an indication of an alternative coordination modality between the metal 
centre and compound 75, which sees the silver ion coordinating the three NHC arms of 75 in a 
similar fashion as for the previously obtained compound 88. 
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Figure 5.29. Mass spectrum of compound 89. Green dotted box: ion species [M+H]2+ at m/z = 412.1783. Blue 
dotted box: ion species [M]+ at m/z = 823.3513. 
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Another metalation attempt, using Ag2O as metal precursor and microwave heating, involved 
the use of the tripodal tert-butylimidazolium-based compound 73, whose synthesis is reported 
in Chapter 3, section 3.2. The reaction was carried out by dissolving compound 73 in DCE, 
followed by addition of a slight excess of finely powdered Ag2O. The mixture was heated under 
MW irradiation at 150 °C for 32 minutes, and the product was obtained as a pale orange powder 
in fair yield (61%). 
 
Scheme 5.7. Synthesis of compound 90. 
The results of 1H NMR spectroscopy analysis performed on compound 90 are shown in Figure 
5.30. The spectrum of 90 shows 9 resonances. Two signals in the aromatic region, at 7.57 and 
7.28 ppm respectively, were assigned to the hydrogens of the imidazole-ylidene arms 
coordinated to the silver centre (H1 and H2). The signal at 5.43 ppm was assigned to the three 
methylene groups linking the aromatic core and the arms (H3). Finally, the sharp singlet at 1.62 
ppm was assigned to the protons of the three tert-butyl moieties (H5) and the signal at 0.74 ppm 
was assigned to the 15 protons of the three ethylic arms (labelled H4 and H6 in Figure 5.30). 
The remaining three signals identifiable in the 1H NMR spectrum of 90 were correlated to 
unreacted ligand 73: at 9.36 ppm was assigned to the C2-H protons of the un-coordinated tert-
butyl imidazolium, while the two signals at 7.61 and 7.38 were assigned to the remaining 
protons of the uncoordinated imidazolium arms (labelled with * in Figure 5.30). 
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Figure 5.30. 1H NMR (300 MHz, DMSO-d6, 298 K) spectrum of compound 90. For clarity, magnetically 
equivalent nuclei within the same NMR spin system are labelled once. * residual solvents and impurities traces. 
Mass spectrometry analysis carried out on compound 90 (Figure 5.31) revealed the presence of 
three species: the first, with m/z = 677.3499 was correlated to the molecular ion [M]+, of the 
proposed structure, where M corresponds to the molecular formula for compound 90 
(C36H54N6Ag). The second ion species found, with m/z = 715.3280, presented unexpectedly the 
chlorine isotopic pattern and was correlated with the species [M+Cl]+.  
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Figure 5.31. Mass spectrum of compound 90. Blue dotted box: ion species [M]+ at m/z = 677.3499. Green dotted 
box: ion species [M+Cl]+ at m/z = 715.3280. 
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5.2.2. Synthesis of a novel gold(I)-carbene complex 
Following the discovery of the gold(I) complex auranofin as an antirheumatic reagent in 1985,43 
the usage of gold complexes in medicine has been increasingly explored. More recently, a series 
of binuclear NHC-based gold(I) complexes displaying attractive anticancer activity was 
developed by Barnard and co-workers.44 Carbene ligands have some similarities to phosphines, 
but metal-carbene complexes are often more stable than similar metal-phosphine complexes.45 
In addition, NHCs are often easier to synthesise than phosphines and their 
lipophilic/hydrophilic properties can be readily fine-tuned by the incorporation of appropriate 
functional groups. 
It was decided to investigate the possibility to develop a gold(I)-NHC complex from the 
previously obtained Ag(I)-NHC complex 87. Silver complexes are known to be effective 
carbene-transfer agents, often without loss of structure.34 
The reaction was performed by dissolving the previously synthesised metal complex 87 in dried 
dichloromethane, followed by the gold(I) precursor chloro(dimethylsulfide)gold(I). The 
resulting mixture was placed into a Schlenk tube, wrapped in tinfoil to avoid 
photodecomposition and stirred at room temperature overnight. After work-up by filtration, the 
product was obtained as an off-white solid. 
 
Scheme 5.8. Synthesis of compound 91. 
The newly obtained compound 91 was analysed by 1H NMR, but due to the poor resolution of 
the multiplets it was not possible to assign all the signals found in the 1H NMR spectrum. 
Subsequent mass spectrometry analysis revealed the presence of two ion signals that were 
assigned to the presence of the predicted metal complex: a doubly charge species [M]2+ at m/z 
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= 477.1082 and the base peak at m/z = 1098.8146, which was assigned to the singly-charged 
[M+PF6]+. The mass spectrum of compound 91 is shown in Figure 5.32. 
 
Figure 5.32. Mass spectrum recorded for compound 91. Green dotted box: ion fragment [M]2+ at m/z = 477.1082. 
Blue dotted box: ion signal [M+PF6]+ at m/z = 1098.8146. 
However, the acquired spectroscopic data are not sufficient to clearly determine the proposed 
structure. The presence of the hexafluorophosphate counterion in the singly-charged ion species 
recorded in the mass spectrum of compound 91 might suggest that the counterion is closely 
interacting with the positive charge of the tripodal ligand. Moreover, the presence of the 
chloride adduct of the ion species [M+PF6] of m/z = 1134.3948 might suggest an alternative 
complexation mode where the metal halide Au(I)Cl is bound to only one NHC arm of the 
tripodal ligand (see Figure 5.33). 
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Figure 5.33. Alterative structure proposed for compound 91. 
The UV-visible and fluorescence spectra of compound 91 are shown in Figure 5.34. The UV 
spectrum (blue line) shows an absorption maximum at 280 nm. The fluorescence emission 
spectrum, similarly to the silver complex (and precursor) 87 is broad, with an intensity 
maximum at 419 nm. 
 
Figure 5.34. Normalised UV-visible (blue line) and fluorescence emission (red line) spectra of compound 91 (25 
µM in CH2Cl2). 
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5.2.3. Synthesis of a novel copper(I)-carbene complex 
Copper is found in all living organisms and is a crucial trace element in redox chemistry, growth 
and development.46 Copper toxicity derives from its ability to produce reactive oxygen species 
(ROS), displace other metal ions, peroxidise lipids, and directly cleave DNA and RNA.47  
Most of the reports regarding copper complexes as anti-cancer agents have focused on 
copper(II), while very few examples of copper(I) species have been examined. Even few reports 
of Cu(I)-NHC complexes are focused around its capability to act as anticancer compound,48, 49 
thus we decided to investigate the possibility to develop a novel Cu(I)-NHC complex from the 
silver(I) complex 87.  
The synthesis of the copper(I) complex, named 92 in this work, followed the transmetallation 
synthetic route between the silver complex 87 and the copper(I) precursor 
copper(I)tetrakis(acetonitrile)hexafluorophosphate (molecular formula = 
[(CH3CN)4Cu(I)][PF6]). The reaction was carried out by stirring the two reactants in anhydrous 
DCM at room temperature under an inert atmosphere for 16 hours, until a cloudy solution was 
formed. The copper(I) complex 92 was isolated as a white solid upon filtration and 
precipitation. 
 
Scheme 5.9. Synthesis of compound 92. 
The 1H NMR spectrum of compound 92 (Figure 5.35) shows 16 signals. The signal at 8.82 
ppm, integrating for 1H, was assigned to the imidazolium C2-H proton (labelled H1 in Figure 
5.35). There are two poorly resolved signals between 7.50 and 7.29 ppm, the first assigned to 
the N+(CH)2N protons (labelled H2and H3) of the uncoordinated imidazolium arm, the second 
to the N(CH)2N protons belonging to the coordinated imidazol-2-ylidene groups (labelled H4 
and H5). The signal at 7.00 ppm (H6) was assigned to the four aromatic C-H of the mesityl 
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moieties linked to the coordinated ylidene arms, while the signal at 6.72 ppm, labelled H7 in 
Figure 5.35, was correlated to the mesityl C-H of the uncoordinated arm. 
Two signals at 5.81 ppm and 5.53 ppm were correlated to the methylene moieties linking the 
coordinated NHC arms and the hexasubstituted aromatic core (labelled H8 and H9 in Figure 
5.35). Further splittings, which may indicate the presence of an asymmetric system, are evident 
in the signals assigned to the methyl groups of the mesityl substituents (labelled H11 and H12 
for the p-CH3, and H13 and H14 for the o-CH3); as well as for the proton resonances of the 
ethylene arms (labelled H15 and H16 in Figure 5.35). 
 
Figure 5.35. 1H NMR (400 MHz, CDCl3, 298 K) spectrum of compound 92. For clarity, magnetically equivalent 
nuclei within the same NMR spin system are labelled once. * residual solvents and impurities traces. 
Mass spectrometry analysis performed on compound 92 revealed the presence of two well 
defined peaks at m/z = 410.2170 and m/z = 965.3866, which could be attributed to the doubly 
charged ion species [M]2+ and the singly-charged hexafluorophosphate adduct [M+PF6]+ 
respectively. The positive mode mass spectrum of 92 is shown below in Figure 5.36. 
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Figure 5.36. Mass spectrum recorded for compound 92. Green dotted box: the doubly-charged ion species [M]2+ 
at m/z = 410.2170. Blue dotted box: ion species [M+PF6]+ at m/z = 965.3866. 
The normalised UV-visible and fluorescence spectra of compound 92 are reported in Figure 
5.38. The UV spectrum (red line) shows an absorption maximum at 280 nm, which is again due 
to the presence of the aromatic units. As for the previously synthesised metal-NHC complexes 
87 and 91, the fluorescence emission spectrum of compound 92 is broad (see Figure 5.38). 
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Figure 5.38. Normalised UV-Visible (red line) and fluorescence emission (blue line) spectra of a 25 µM solution 
of compound 92 in CH2Cl2. 
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5.2.4. Ruthenium complexes 
The last series of reactions involving tripodal NHC-based ligands and transition metals 
discussed in this chapter aimed to develop a trimetallic species by exploiting the ability of the 
ruthenium cluster Ru3(CO)12 to generate interesting metal complexes with a wide array of N-
heterocyclic carbenes.50-52 
Unpublished work within our group has shown that compound 73 will react with Fe3(CO)12 to 
form 73[Fe(CO)4]3 (Figure 5.39),53 although no spectroscopic characterisation was obtained to 
support the X-ray structure. Further attempt to reproduce those results proved unsuccessful, 
thus it was decided to explore the reactivity of the tripodal ligands with its ruthenium analogue 
Ru3(CO)12 as more robust metal carbonyl cluster. 
 
Figure 5.39. Crystal structure of half a unit cell containing 73[Fe(CO)4]3. Hydrogen atoms are removed for clarity. 
The synthesis of the ruthenium analogue of 73[Fe(CO)4]3, compound 93, was attempted as 
shown in Scheme 5.10. Treatment of Ru3(CO)12 with compound 73 and potassium tert-butoxide 
(tBuOK) in tetrahydrofuran (THF) at room temperature for two hours led to a colour change in 
the resulting suspension from orange to deep red and, after work up, the isolation of a red solid. 
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Subsequent 1H NMR analysis, using deuterated methanol as solvent, revealed the presence of 
the characteristic C2-H signal at 9.78 ppm, likely belonging to unreacted 73.  
 
Scheme 5.10. Generic synthetic pathway for the compound 93. 
Further attempts were carried out by varying the reaction times and the type of base for 
deprotonation. Among the various attempts, pre-treatment of compound 73 with potassium 
bis(trimethylsilyl) amide in THF and subsequent addition of the deprotonated ligand into a THF 
solution of Ru3(CO)12 cooled down to -78 ºC gave a bright red suspension, which turned deep 
red after warming up to room temperature in the course of 16 hours. 1H NMR analysis 
performed on the dark red product obtained is shown below in Figure 5.40. There are 6 sets of 
signals with chemical shifts and integrations comparable to the ligand precursor compound 73. 
The absence of the low field signal belonging to the C2-H is also evident from the spectrum, 
suggesting that complexation might have occurred on all three imidazolium “arms”. 
 
Figure 5.40. 1H NMR (500 MHz, MeCN-d3, 298 K) spectrum of compound 93. For clarity, magnetically 
equivalent nuclei within the same NMR spin system are labelled once. * residual solvents and impurities traces. 
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Subsequent FT-IR analysis performed on compound 93 is shown in Figure 5.41. The IR 
spectrum shows a medium, broad band with peaks at 2054, 2011, 1995 and 1979 cm-1, which 
may be attributed to the C-O stretching of the carbon monoxide ligands. However, such values 
are not typical of trigonal bipyramidal [M(CO)4(L)] complexes.50 A summary of the band 
assignments for 93 and the metal precursor Ru3(CO)12 is shown in Table 5.2. Further attempts 
to isolate a defined product proved inconclusive as the product readily decomposed into a brown 
powder, insoluble in common organic solvents such as CH2Cl2, Methanol, THF etc. 
 
Figure 5.41. Normalised FT-IR spectra of compound 93 (red curve) and its ligand precursor compound 73 (blue 
curve). 
 
Table 5.2. Band assignments for the FT-IR spectra of the metal precursor Ru3(CO)12 and 93 (Figure 5.41). 
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To shed a better light on the reactivity of such tripodal systems with the ruthenium cluster, it 
was decided to make use of the more flexible methyl-substituted ligand precursor 72. This 
experiment aimed to prove whether the rigid conformation of compound 73 was a limitation to 
its reactivity towards Ru3(CO)12 and if it was possible to generate the trimetallic complex 
72[Ru(CO)4]3 thanks to the enhanced flexibility of this ligand precursor. 
The reaction between compound 72 and Ru3(CO)12 was performed in two steps: first, 
deprotonation of the compound 72, by adopting a modified procedure by Dias and co-worker,54 
followed by work up to isolate the free carbene (further referred as compound 94 in this work) 
as a white solid in good yield (74%). 1H NMR analysis performed on the free carbene (Figure 
5.42) revealed that the deprotonation of the three tert-butyl imidazolium arms was successful 
as no signals arising from the C2-H protons were observed. Furthermore, formation of the free 
carbene was confirmed by 13C NMR analysis of 94 where the resonance of the carbene was 
found at 214.7 ppm (Appendix D). 
 
Figure 5.42. 1H NMR (500 MHz, C6D6, 298 K) spectrum of compound 94. For clarity, magnetically equivalent 
nuclei within the same NMR spin system are labelled once. * C6D6. 
The second step of the reaction involved the treatment of a THF solution of Ru3(CO)12 with the 
previously synthesised free carbene 94. The reaction mixture was kept stirring at room 
temperature until the formation of a cloudy red solution was observed. IR analysis performed 
on the THF solution of the product showed the presence of three bands at 2071, 2027 and 2006 
cm-1 (Figure 5.43). 
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Figure 5.43. FT-IR spectrum recorded form a THF solution of 94. 
Upon cooling the aforementioned solution at -30 ºC, red crystals suitable for X-ray diffraction 
were isolated. However, due to the poor quality of the crystals, only a partially ordered resolved 
structure was obtained (Figure 5.45), showing the presence of a rearranged anionic cluster in 
which compound 72 acts, in its tri-protonated state, as a counterion. There are several 
disordered solvent units in the unit cell which were only partially refined. Unfortunately, due 
to the low scale on which the reaction was performed, their high air/moisture sensitivity, and 
the rather low yield of this reaction in terms of single crystal harvested, further spectroscopic 
analysis could not be performed to confirm the full identity of the bulk with respect of the single 
crystal analysed. 
From the single crystal X-ray diffraction data and the spectroscopic evidence available, the 
current interpretation of the partially resolved structure is that a complex salt of the tris-
imidazolium salt of the N-heterocyclic carbene 94 was obtained. The salt that results from the 
5. Incorporation of metallic units onto 




combination of [H394]3+ with Ru4(CO)12 fragments and crystallises in the high symmetry space 
group R-3 and shows severe disorder. A detailed crystallographic analysis was performed with 
the assistance of Dr Gabriele Kociok Köhn and Professor Paul Raithby. A possible 
interpretation of the structure is that it consists of two triply-protonated 94 cations and two 
[Ru4(CO)12(µ3-CO)]2- anions, the charge balance being complete by the presence of two Br- 
(disordered) in the asymmetric unit. The availability of HBr (additionally to adventitious water) 
to assist the formation of this complex may well be assigned to residual impurities of the earliest 
starting material used in preparing the imidazolium salt precursor. 
The [94]3+ cations are in general positions while both the [Ru4(CO)12(µ3-CO)]2- anions sit on 
crystallographic 3-fold axes. The Ru-Ru bond lengths within the tetrahedral tetra-metal anions 
are consistent with the presence of unbridged Ru-Ru single bonds, and the [Ru4(CO)12(µ3-
CO)]2- formulation is consistent with the presence of a closo-60 electron species for this 
counterion, the correct electron count for a Ru4 tetrahedron by the Effective Atomic Number 
Rule. The formation of [Ru4(CO)12(µ3-CO)]2- anions has been observed in the reactions of 
Ru3(CO)12 with organic reagents previously55 and has apparently occurred under the reaction 
conditions used here. 
To fully confirm this hypothesis, a further stretching frequency in the IR of the complex salt at 
around 1750 cm-1 would have been expected, which would be consistent with the presence of 
the µ3-CO ligand crystallographically observed in the anion,56 but these signals are often weak 
and could not be located with certainty in the solution IR recorded hereby (Figure 5.43). Similar 
examples of such cluster rearrangement, possibly mediated by the bulky nature of the carbene 
involved and presence of adventitious deprotonated solvents (H2O, HBr), have been previously 
reported by the groups of Carty,55 Whittlesey57 and Cabeza51, and are a further indication that 
tripodal carbene chemistry leads to diversity in the products formation, which present 
challenges in their spectroscopic characterisation. 
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Figure 5.44. Alternative reaction scheme proposed for the reaction between compound 94 and Ru3(CO)12. 
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Figure 5.45. The X-ray diffraction study showing the reaction product obtained by the reaction the free carbene 
compound 94 and Ru3(CO)12 postulated to occur through a cluster rearrangement and ligand protonation. 
Hydrogen atoms are removed for clarity. (B) The content of the asymmetric unit showing the disordered solvent 
molecules present; the bromine counterions are disordered, whereas the tripodal units are well defined, as is one 
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5.3. Cell viability assays 
Cellular viability assays were obtained with the assistance of Dr Haobo Ge whom carried out 
these evaluations in PC3 cells in Pharmacy and Pharmacology Department, University of Bath. 
Standard 96 well plates were incubated with compounds 68 and 85 in serum medium (1% 
DMSO) at different concentrations and times (24, 48 and 72 hours) at 37°C. MTT was then 
added and the treated cells incubated for 2 hours before recording the absorbance with a plate 
reader.  
The results of MTT assays performed on the ATSC-based ligand precursor 68, whose synthesis 
and characterisation were previously reported in Chapter 2, is shown below in Figure 5.46. 
Treatment of PC3 cells with compound 68 showed a moderate loss in viability at the highest 
concentration (250 µM) of compound. Interestingly, treatment of PC3 cells with compound 85 
did not significantly perturb the cell viability at any concentration tested. Cell viability 
recovered to pre-treatment levels after 48 hours (see Figure 5.47). This could be due to 
differences in cellular uptake between the two compounds, with compound 68 being slightly 
more cytotoxic, possibly due to its uncoordinated thiosemicarbazone arms. 
 
Figure 5.46. Cell viability studies of compound 68 at t = 24, 48 and 72 hours. The data were collected from six 
repeated measurements on the same day, N = 1 
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Figure 5.47. Cell viability studies of compound 85 at t = 24, 48 and 72 hours. The data were collected from six 
repeated measurements on the same day, N = 1 
Cellular viability assays were performed by treating PC3 cells with the newly synthesised NHC-
based complexes 87, 91 and 92 to determine the half maximal inhibitory concentration (IC50) 
values of such complexes (Table 5.3). IC50 is a measure that indicates the capacity of a 
compound to inhibit a specific biological function and it is commonly used to evaluate the 
capability of a drug to reduce the cell viability by 50%. 
In order to calculate IC50 values, MTT assays were carried out in 96 well plates containing PC3 
cells treated with each of the NHC-based metal complexes at different concentrations for 24 
and 48 hours. MTT was then added to the cells and incubated for a further 2 hours. After 
measuring the absorbance at 570 nm as described previously (Chapter 2), the absorbance 
readings were plotted as dose-response curves and the IC50 of the complexes were calculated 
(see Table 5.3). It can be seen that the most toxic compound for PC3 cells after 24 hours of 
treatment, is the gold(I) complex 91. After 24 hours of treatment, the least cytotoxic compound 
proved to be the copper(I) complex 92. Incubation of PC3 cells with the selected compound for 
48 hours revealed that the silver(I) complex 87 displayed IC50 values comparable to its gold(I) 
analogue 91, whereas only a small change of IC50 values could be appreciated for compounds 
91 and 92.  
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Table 5.3. Summary of compounds tested in PC3 cells with MTT assays and its IC50 values calculated after 
incubation of the compound for 24 and 48 hours.  
Compound IC50 at 24 hours (mg/mL) IC50 at 48 hours (mg/mL) 
87 (9.7 ± 0.9)·10-6 (3.1 ± 0.7)·10-6 
91 (3.3 ± 0.9)·10-6 (3.8 ± 0.5)·10-6 
92 (1.3 ± 0.1)·10-5 (1.1 ± 0.1)·10-5 
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5.4. In vitro confocal fluorescence investigations of the metal 
complexes 
Epi-fluorescence and single-photon laser scanning confocal microscopy analysis were 
performed on PC3 cells, treated with selected metal complexes previously described in this 
section. PC3 cells were grown according to standard culturing methods, placed onto glass-
bottomed dishes and allowed to grow to a suitable confluence prior treatment with a DMSO 
solution (10 mM) of the compound. 
Figure 5.48 shows the images of PC3 cells incubated for 20 min with compound 84 taken in 
the confocal mode. The images show broad emission across blue and green channels when the 
probe is excited at 405 nm (a1-5), while only green-red and red emissions were observed when 
using 488 nm and 561 nm lasers respectively (b1-5 and c1-5). Compound 84 appear to be taken 
up in PC3 cells and localised throughout the cytoplasm, whereas no emission appears to 
originate from the nucleus. 
 
Figure 5.48. Single-photon laser-scanning confocal microscopy images of PC3 cells incubated with compound 84 
(10 µg/mL 1% : 99% DMSO : DMEM) at 37 ºC for 20 minutes; λex = 405 nm (a1-a5), λex = 488 nm (b1-b5) and λex 
= 561 nm (c1-c5). DIC channel (a1, b1, c1), blue channel, λem = 420-480 nm (a2, b2, c2), green channel, λem = 516-
530 nm (a3, b3, c3), red channel λem = 615-650 nm (a4, b4, c4), and overlapping of the DIC, blue, green and red 
channels (a5, b5, c5). Scale bar: 20 μm. 
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Confocal microscopy analysis of PC3 cells treated with compound 85 is shown below in Figure 
5.49. Compound 85 shows comparable emissive properties to its analogue 84, displaying broad 
emission in all channels when excited at 405 nm.   
 
Figure 5.49. Single-photon laser-scanning confocal microscopy images of PC3 cells incubated with compound 85 
(10 µg/mL 1% : 99% DMSO : DMEM) at 37 ºC for 20 minutes; λex = 405 nm (a1-a5), λex = 488 nm (b1-b5) and λex 
= 561 nm (c1-c5). DIC channel (a1, b1, c1), blue channel, λem = 420-480 nm (a2, b2, c2), green channel, λem = 516-
530 nm (a3, b3, c3), red channel λem = 615-650 nm (a4, b4, c4), and overlapping of the DIC, blue, green and red 
channels (a5, b5, c5). Scale bar: 20 μm. 
SLSCM analysis performed in PC3 cells treated with the ruthenium-based compound 86 is 
shown below in Figure 5.50. A homogeneous distribution of 86 is observed in the blue and 
green channels when the 405 nm laser is employed, while it is visible only in the green and red 
channels and only in the red, respectively, after irradiating the probe with 488 and 561 nm 
lasers. As for its rhenium(I)-based analogues discussed before, compound 86 appears to localise 
mainly in the cytoplasm, with no emission arising from the nuclear region of the cells.  
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Figure 5.50. Single-photon laser-scanning confocal microscopy images of PC3 cells incubated with compound 86 
(10 µg/mL 1% : 99% DMSO : DMEM) at 37 ºC for 20 minutes; λex = 405 nm (a1-a5), λex = 488 nm (b1-b5) and λex 
= 561 nm (c1-c5). DIC channel (a1, b1, c1), blue channel, λem = 420-480 nm (a2, b2, c2), green channel, λem = 516-
530 nm (a3, b3, c3), red channel λem = 615-650 nm (a4, b4, c4), and overlapping of the DIC, blue, green and red 
channels (a5, b5, c5). Scale bar: 20 μm. 
SLSCM (Figure 5.51) and epi-fluorescence microscopy (Figure 5.52) images of fixed PC3 cells 
incubated with a DMSO : serum-free medium (1:99) solution of 10 mM of the gold(I) complex 
91 were acquired following the same protocol as for the previous metal complexes. Compound 
91 displayed broad emission in all the channels when the probe was excited at 405 nm, while it 
is only visible in the green and red and red only after excitation at 488 and 561 nm wavelengths 
respectively. The complex localises throughout the cytoplasm and some emission appear to 
originate from the cellular nuclei, although is unclear if such emission is due to compound 91 
being able to penetrate the nuclear membrane, whether it actually influences the cell 
morphology. 
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Figure 5.51. Single-photon laser-scanning confocal microscopy images of fixed PC3 cells incubated with 
compound 91 (10 µg/mL 1% : 99% DMSO : DMEM) at 37 ºC for 20 minutes; λex = 405 nm (a1-a5), λex = 488 nm 
(b1-b5) and λex = 561 nm (c1-c5). DIC channel (a1, b1, c1), blue channel, λem = 420-480 nm (a2, b2, c2), green channel, 
λem = 516-530 nm (a3, b3, c3), red channel λem = 615-650 nm (a4, b4, c4), and overlapping of the DIC, blue, green 
and red channels (a5, b5, c5). Scale bar: 20 μm. 
 
 
Figure 5.52. Epi-fluorescence acquisition of fixed PC3 cells incubated at 37 ºC for 20 min with compound 91 (10 
µg/mL 1% : 99% DMSO : DMEM). DIC channel (d1), blue channel, λem = 420-480 nm (d2), green channel, λem = 
516-530 nm (d3), red channel λem = 615-650 nm (d4), and overlapping of the DIC, blue, green and red channels 
(d5). Scale bar: 20 μm. 
PC3 cells were also incubated with the copper(I) complex 92, and SLSCM images were 
collected (Figure 5.53). Compound 92 strongly emits in the blue channel and more lightly in 
the green and red channels when excited with a 405 laser, while the emission is less intense and 
confined to green and red and red only, respectively, when 488 and 561 lasers were employed. 
Compound 92 is taken up by the cells and localise in the cytoplasm, whereas no emission 
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appears to originate from the nuclei. Furthermore, treatment of the cells with the complex did 
not alter the cell morphology. 
 
Figure 5.53. Single-photon laser-scanning confocal microscopy images of PC3 cells incubated with compound 92 
(10 µg/mL 1% : 99% DMSO : DMEM) at 37 ºC for 20 minutes; λex = 405 nm (a1-a5), λex = 488 nm (b1-b5) and λex 
= 561 nm (c1-c5). DIC channel (a1, b1, c1), blue channel, λem = 420-480 nm (a2, b2, c2), green channel, λem = 516-
530 nm (a3, b3, c3), red channel λem = 615-650 nm (a4, b4, c4), and overlapping of the DIC, blue, green and red 
channels (a5, b5, c5). Scale bar: 20 μm. 
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5.5. Summary of Chapter 5 
This chapter described the synthesis of several metal complexes deriving from some selected 
tripodal ligands and their testing as potential imaging agents. 
The two tripodal-ATSC ligands 67 and 68 were successfully metallated by exploiting 
microwave technology to obtain complexes of rhenium(I) (compounds 84 and 85) and 
ruthenium(II) (compound 86). Their emissive properties were evaluated and were found to be 
suitable for in-vitro cellular imaging applications. 
Attempts to develop a trimetallic silver(I) complex from the tripodal ligand precursor 76 
resulted instead in the formation of the monometallic, NHC-based complex 87, in which two 
arms of the tripodal system are bound to the metal centre, while the third arm remains in its 
protonated state. Attempts made to obtain the same compound via a novel microwave-assisted 
synthesis resulted instead in a new, tri-coordinated Ag(I) compound (88), in which the silver 
centre is coordinated to all the three NHC arms of 76. The same reaction protocol was employed 
for the ligand precursors 73 and 75. Spectroscopic analyses carried out on the reaction products 
pointed to the formation of tri-coordinated complexes of Ag(I) (compounds 89 and 90). 
As silver(I)-NHC complexes are usually excellent carbene-transfer agents, the possibility to 
transmetallate the silver(I) centre with other coinage metals was explored. The metal complex 
87 was successfully transmetallated with gold(I) and copper(I) precursors to give the new metal 
complexes 91 and 92 respectively. 
The last complexation attempts discussed in this chapter involved the tripodal tert-
butylimidazolium based ligands 72 and 73 and the ruthenium cluster Ru3(CO)12, aiming to 
obtain trimetallic metal complexes where each NHC “arm” binds a [Ru(CO)4] moiety. The 
various attempts to achieve such complexations proved fruitless, however these experiments 
demonstrated that tripodal systems are able to induce the rearrangement of the ruthenium 
cluster. Further experiments will be carried out to explore the fascinating nature of such 
organometallic reactions. 
Cell viability assays were carried out on a few selected metal complexes. While the tripodal 
ATSC-based rhenium(I) complex 85 was found to be essentially non-toxic towards PC3 cancer 
cells, the NHC-based complexes 87, 91 and 92 displayed remarkable toxicity towards the same 
cell line, with IC50 values comparable to the anticancer drug cisplatin.58 
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Finally, cellular imaging experiments on PC3 cells were carried out using single-photon laser 
scanning microscopy. The confocal microscopy results showed that the selected metal 
complexes are taken up by the cells and localise primarily in the cytoplasm, where they display 
interesting emissive properties. Complexes 84, 85, 86, 91 and 92 are therefore suitable for in 
vitro imaging applications. 
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Nolan, S. Díez‐González, L. Morel and A. Gautier, Chem.: Eur. J., 2009, 15, 314-318. 
49. W. Liu and R. Gust, Coord. Chem. Rev., 2016, 329, 191-213. 
50. M. I. Bruce, M. L. Cole, R. S. Fung, C. M. Forsyth, M. Hilder, P. C. Junk and K. 
Konstas, Dalton Trans., 2008, 4118-4128. 
51. J. A. Cabeza, I. del Río, D. Miguel, E. Pérez-Carreño and M. G. Sánchez-Vega, 
Organometallics, 2007, 27, 211-217. 
52. C. E. Ellul, M. F. Mahon, O. Saker and M. K. Whittlesey, Angew. Chem. Int. Ed., 2007, 
46, 6343-6345. 
53. S. I. Pascu, unpublished work. 
54. H. R. Dias and W. Jin, Tetrahedron Lett., 1994, 35, 1365-1366. 
55. A. A. Cherkas, J. F. Corrigan, S. Doherty, S. A. MacLaughlin, F. van Gastel, N. J. 
Taylor and A. J. Carty, Inorg. Chem., 1993, 32, 1662-1670. 
56. A. A. Bhattacharyya, C. C. Nagel and S. G. Shore, Organometallics, 1983, 2, 1187-
1193. 
57. C. E. Ellul, O. Saker, M. F. Mahon, D. C. Apperley and M. K. Whittlesey, 
Organometallics, 2007, 27, 100-108. 
58. S. Tardito, C. Isella, E. Medico, L. Marchio, E. Bevilacqua, M. Hatzoglou, O. Bussolati 
and R. Franchi-Gazzola, J. Biol. Chem., 2009, 284, 24306-24319. 
 
 




6. Conclusions and future work 
An increasing number of metal complexes are being investigated in a wide array of biomedical 
applications, such as molecular imaging and the development of new therapies. The focus of 
this work has been the development of tripodal molecules and their related metal complexes 
and their biomedical application. 
Chapter 2 described the syntheses and characterisation of tripodal systems based upon the 
hexasubstituted benzene scaffold, and their potential for biomedical applications was probed. 
In this chapter, three types of tripodal ligands were successfully synthesised and characterised. 
The products were obtained through nucleophilic substitution of the bromomethyl substituents 
of the hexasubstituted cores 60 and 61 with DABCO and 4,4’-bipyridine, to give compounds 
62, 63, 64 and 65 in good yields and acceptable purity with minimal work up. Such compounds 
were characterised spectroscopically, and their biocompatibility probed via MTT assay on PC3 
prostate cancer cells. While most of the compounds appear to be nontoxic at the highest 
concentrations recorded, a concentration of 250 µM of compound 64 caused a loss of more than 
50% in cell viability. Such inhibition persisted even after 72 hours from the treatment. Further 
tests will be necessary to determine the factors that promote the loss of cell viability triggered 
by 64. 
Furthermore, two novel anthracene-thiosemicarbazone-based tripodal systems were 
successfully synthesised by a two-step procedure, beginning with the synthesis of the 
anthracene-thiosemicarbazone (compound 66), by reacting 9-anthraldehyde with 
thiosemicarbazide, to give 66 in excellent yield and high purity. Characterisation of the new 
compounds 67 and 68 indicated that three molecules of 66 bind to the central aromatic core via 
an unconventional S-alkylation of the bromomethyl moieties of 60 and 61. The two compounds 
possess acceptable fluorescent properties for cellular imaging experiments, with large emission 
bands around 440 nm. 
Chapter 3 described the development of new tripodal N-heterocyclic carbene-based compounds 
with the potential to act as ligands for a variety of transition metals. This chapter described the 
syntheses of nine tripodal systems which are based upon unsymmetrical imidazole arms. 
Initially, we performed the syntheses of two symmetrical tripodal compounds bearing three 
methylimidazole arms via a nucleophilic substitution of the bromomethyl moieties of 60 and 
61 with a small excess of 1-H-methylimidazole. It was possible to obtain crystals suitable for 




X-ray diffraction analysis for the novel compound 70, which allowed us to visualise how the 
three imidazole arms can be oriented towards the same face of the aromatic core to form a cage 
around the hexafluorophosphate counterion. 
Two tripodal systems based upon the monosubstituted tert-butylimidazole were successfully 
prepared in a two-step reaction. First, the unsymmetrical 1-(tert-butyl)-1H-imidazole (referred 
as compound 71 in this work) was obtained following a modified Debus-Radziszewski 
imidazole synthesis. The monosubstituted imidazole was then reacted with the two 
hexasubstituted cores 60 and 61 to give the tripodal systems 72 and 73 respectively in good 
yields and purities. Moreover, crystals suitable for X-ray diffraction were successfully obtained 
for compound 72. The unit cell of 72 shows that the compound is able to form a cage by 
interacting with the solvent water molecules and can self-assemble via hydrogen bond 
interactions into a tetramer of formula [(72)4(H2O)12][Br]12. 
Finally, two novel mesitylimidazole-based tripodal systems have been prepared and 
characterised. The two compounds, named 75 and 76 in this thesis, were obtained by reacting 
an excess of the freshly prepared 1-H-mesitylimidazole (compound 74) with the two 
hexasubstituted cores 60 and 61. Anion metathesis was subsequently performed to give 
compounds 75·3PF6 and 76·3PF6 respectively in quantitative yields and satisfactory NMR 
purity. Furthermore, crystal structures were also obtained for the compounds 75·3PF6  and 
76·3PF6, which allowed us to gain some understanding of how those systems present a dynamic 
equilibrium between “open arms” and “closed arms” configurations, and how these tripodal 
systems are able to form polymeric associations through the network of interactions between 
the tripodal systems and their anions. 
Chapter 4 explored the possibility of developing a tridentate system with unsymmetrical 
substituents, so as to develop ligands capable of binding metals as well as other functionalities, 
thus creating a multimodal system in a single compound. This chapter describes the syntheses 
of three mesitylimidazolium-based tripodal systems in which one of the three NHC arms was 
modified with two carboxylic acid-based linkers (compounds 78 and 81), as well as with the 
introduction of an anthracene-thiosemicarbazone derivative as fluorophore (compound 83). The 
azido group of 81 could be used to bind further functionalities, such as targeting groups (e.g. 
bombesin), so as to enhance the specificity of the tripodal system towards the biological target. 
Compound 83 was obtained in a two-step reaction, firstly by preforming a nucleophilic 
substitution of one bromomethyl arm of the core 61 with the anthracene-thiosemicarbazone 66, 




to give compound 82 after a simple workup. Spectrophotometric analyses performed on 82 
suggested that the preferential mode of substitution of the bromide is through sulphur, as for 
the previously reported compounds 67 and 68, further indicating that thiosemicarbazone-based 
compounds are able to S-alkylate the hexasubstituted aromatic cores such as compound 61. 
Finally, reaction between the mesitylimidazole derivative 74 and compound 82 was performed. 
The unsymmetrical tripodal system 83 was obtained in acceptable purity and good yield and its 
fluorescent properties were evaluated by fluorescence spectroscopy. The new compound 
showed absorption peaks characteristic of the anthracene moiety and, compared to its precursor 
82, a larger fluorescence emission curve (between 450-550 nm) which is suitable for cellular 
imaging applications. Lastly, single-photon laser-scanning confocal microscopy experiments 
carried out on PC3 prostate cancer cells incubated with compound 83 revealed that the 
compound was able to cross the cellular membrane and localise throughout the cytoplasm, 
where it displayed intense fluorescence when irradiated at 405, 488 and 561 nm. Given the 
promising emission properties of 83, future experiments should involve testing the capacity of 
this compound to act as a ligand for biologically relevant transition metals 
Chapter 5 explored the possibility of developing novel tripodal-based metal complexes 
containing metal centres of relevance to imaging and/or therapy. The chapter describes the 
complexation attempts between a series of transition metals and a few selected tripodal ligands 
previously discussed. The two tripodal-ATSC ligands 67 and 68 were metallated by exploiting 
microwave technology to obtain complexes of rhenium(I) (compounds 84 and 85) and 
ruthenium(II) (compound 86). Their emissive properties were evaluated and found to be 
suitable for in vitro cellular imaging applications. 
Attempts to develop a trimetallic silver(I) complex from the tripodal ligand precursor 76 
resulted instead in the formation of the monometallic, bis NHC-based complex 87, in which 
two arms of the tripodal system are bound to the metal centre, while the third arm remains in 
its protonated state. The usage of a novel, microwave-assisted synthetic protocol to obtain the 
Ag(I) complex 87 gave instead a new, tri-coordinated Ag(I) compound (88), in which the silver 
centre is coordinated to all the three NHC arms of 76. The microwave-assisted synthesis was 
also employed for the ligand precursors 73 and 75. Spectroscopic analyses carried out on the 
reaction products pointed to the formation of tri-coordinated complexes of Ag(I) (compounds 
89 and 90). 




As silver(I)-NHC complexes are usually excellent carbene-transfer agents, the possibility to 
transmetallate the silver(I) centre with other group 11 metals was explored. The silver(I)-based 
complex 87 was successfully transmetallated with gold(I) and copper(I) precursors to give the 
new metal complexes 90 and 91 respectively. 
The last complexation attempts discussed in this chapter involved the combination of the 
tripodal tert-butylimidazole-based compounds 72 and 73 with the ruthenium cluster Ru3(CO)12, 
aiming to obtain trimetallic metal complexes where each NHC “arm” is attached to a [Ru(CO)4] 
moiety. The various attempts to achieve such complexation modes proved to be fruitless, 
however these experiments demonstrated that tripodal systems are able to induce the 
rearrangement of the ruthenium cluster into an anionic species, where the protonated tripodal 
system acts as a counterion. 
Cell viability assays were carried out on a few selected metal complexes from Chapter 5. While 
the tripodal ATSC-based rhenium(I) complex 85 was found to be essentially non-toxic towards 
PC3 cancer cells, the NHC-based complexes 87, 90 and 91 displayed remarkable toxicity 
towards the same cell line, with IC50 values comparable to the anticancer drug cisplatin on PC3 
cells. Further experiments will be necessary to elucidate how these complexes are able to elicit 
their cytotoxic effects. Finally, cellular imaging experiments on PC3 cells were carried out 
using single-photon laser scanning microscopy. The confocal microscopy results show that the 
selected metal complexes are taken up by the cells and localise in the cytoplasm. The 
anthracene-based compounds 84, 85 and 86 emit preferentially in the blue channel, whereas the 
gold(I) NHC-based compound 90 appears to be more emissive in the green channel. Further 
tests will aim to investigate the behaviour of these complexes in a variety of conditions (e.g. 
cellular hypoxia) and to confirm their sub-cellular location through co-localisation studies. 
Overall, the work presented in this thesis represents a contribution towards the development of 
novel multifunctional tripodal-based systems and their metal complexes, which are of relevance 
for biomedical applications in the context of prostate cancer in vitro imaging and therapy. 
 
 




7. Experimental section 
7.1. Materials and methods 
Reagents and solvents were obtained from Aldrich Chemical Co., Fluoro Chem and Fisher 
(Acros) and used without further purification unless otherwise stated. 
All reactions involving air- or moisture-sensitive reagents or intermediates were carried out 
under anhydrous conditions and nitrogen or argon atmosphere, using standard Schlenk 
techniques, unless otherwise stated. 
Microwave reactions were carried out in a Biotage Initiator 2.5 reactor in stirred capped vials. 
 
Chromatography 
Thin layer chromatography (TLC) was carried out on Merck silica gel 60 F254 analytical plates 
(Matrix silica gel with aluminium support and fluorescent indicator 254 nm, 0.2 mm thickness) 
and visualized by ultraviolet (UV) fluorescence (λ = 254, 366 nm). The elution conditions for 
TLC varied and are quoted for each compound. 
 
Infrared Spectroscopy 




UV-Vis spectra were acquired in 1 cm quartz cuvettes in a Perkin Elmer Lambda 650 UV-Vis 
spectrometer controlled by UV-Winlab software. 
 
Fluorescence Spectroscopy 
Fluorescence spectra were acquired in a 1 cm quartz cuvette in a Perkin Elmer LS55 
luminescence spectrometer controlled by FL-Winlab 4.0 software 
 




Nuclear Magnetic Resonance Spectroscopy 
1H NMR spectra were recorded on Bruker on a 300 MHz Bruker Avance, 400 MHz Bruker 
Avance or a 500 MHz Bruker Avance II+ spectrometers operating at 300.130, 400.130 and 
500.130 MHz respectively. 13C NMR spectra were recorded on a 500 MHz Bruker Avance II+ 
spectrometer operating at 125.758 MHz. Chemical shift assignments were made by using 
standard COSY (cosygpqf) and HMQC (hmqcgpqf) pulse sequences outlined within the Bruker 
library. Spectra are attributed to the deuterated solvent residual peak, and coupling constants 
(J) are reported in hertz (Hz) with a possible discrepancy ≥ 0.2 Hz. Chemical shifts δ are 
reported in ppm. Chemical shifts of solvent residues were identified as follows: CDCl3: 1H, δ = 
7.26, 13C, δ = 77.23; DMSO-d6: 1H, δ = 2.50; 13C, δ = 39.51; CD3OD: 1H, δ = 4.78, 3.31; 13C, δ 
= 49.15; CD3CN: δ = 1.94; 13C, δ = 118.69, 1.39; C6D6: 1H, δ = 7.16; 13C, δ = 128.39; D2O: 1H, 
δ = 4.79). Peak multiplicities are given as follows: s, singlet; d, doublet; t, triplet; q, quartet; m, 
multiplet; dd, doublet of doublets; dt, doublet of triplets; bs, broad. 
 
Mass Spectrometry 
MS (m/z) spectra were recorded on a Bruker Daltonics MicroTOF. Accurate Mass Spectrometry 
was carried out at the EPSRC National Mass Spectrometry Centre, Swansea University, U.K.. 
Different techniques were used such as MALDI, ESI and EI (Swansea) and ESI (Bath). 
 
Single Crystal X-Ray Diffraction 
X-ray crystallography data were collected at 150 K on an Agilent SuperNova Dual 
diffractometer, using monochromated Cu-Kα radiation (λ = 1.54184 Å). All structures were 
solved with SHELXT and refined by a full-matrix least-squares procedure based on F2. Single 
crystal X-ray diffraction and structure refinements were carried out by Dr. Gabrielle Kociok-
Köhn, Department of Chemistry, University of Bath. 
 
Cell culturing and cell plate preparation 
Cells were cultured at 37˚C in 5 % CO2 atmosphere and diluted once a suitable confluency had 
been obtained. PC-3 cells were cultured in RPMI 1640 containing 10 % heat activated foetal 
calf serum (FCS), 0.5 % penicillin/streptomycin (10 gmL-1) and 200 mM of L-glutamine. The 
medium contained no fluorescent indicator dyes such as phenol red and was therefore suitable 
for use in fluorescence imaging studies. Excess supernatant containing dead cell constituents 




and excess proteins and metabolites was aspirated. The viable live adherent cells were washed 
with 2 x 10 mL aliquots of PBS to remove residual media containing FCS. Cells were then re-
suspended in 10 mL PBS with an additional 2-5 mL Trypsin and incubated for a further 5 
minutes at 37°C. After trypsinisation, 5 mL of medium containing 10 % serum was added to 
inactivate the trypsin and the suspension was centrifuged for 5 minutes (1000 rpm) to remove 
residual dead cell constituents. The resulting supernatant was aspirated, and 5 mL of medium 
was added. Cells were counted using a haemocytometer and seeded as appropriate. Fresh 
DMEM (10% FCS) was added to the suspended cells to give a sufficient concentration of cells 
(ca. 300000 cells mL-1). The cells were plated in a Petri dish with a glass cover slip (MaTek) 
and left for 24 hours to adhere before fluorescence imaging measurements were made. Cell 
culturing and studies were carried out by Dr. Haobo Ge, Department of Chemistry, University 
of Bath. 
 
Laser Scanning Confocal Microscopy 
Confocal microscopy images were acquired in a Nikon Eclipse Ti instrument equipped with 
405/488/561 nm excitation lasers. The images were processed using a Nikon NIS elements-AR 
Analysis 4.30.02 software. 
 
MTT Assays 
Cell viability assays (MTT) were performed with the assistance of Dr Haobo Ge in the 
Department of Pharmacy and Pharmacology, University of Bath, by culturing cells at 37˚C in 
RPMI medium in 96 well plates (ca. 5x104 cells mL-1). The cells were incubated for 48 hours 
to adhere and then the compounds of interest were added in different concentrations in RPMI 
medium (1% DMSO). The concentrations used were 0.25, 0.1, 0.05, 0.01, 1x10-3, 0.5x10-3, 
1x10-4, 1x10-6 mM. The compounds were incubated for different times at 37˚C, to be 
subsequently washed with PBS before the MTT reagent was added. The tetrazolium compound 
was incubated for 2 hours, then the cell media was removed and DMSO was added. The 
absorbance of the generated colour was measured using a Molecular Devices Versa Max ELISA 
plate reader. Data were calculated from at least six consistent results and IC50 values were 
calculated from the fitting obtained with the software Origin 9.0. The error reported corresponds 
to the error of the mean. 
  




7.2. Experimental procedures 
7.2.1. Synthesis of compounds from Chapter 2 
1,3,5-Tris(bromomethyl)-2,4,6-trimethylbenzene (compound 60) 
 
To a stirring mixture of mesitylene (12.0 g, 0.10 mol) and paraformaldehyde (10 g, 0.33 mol) 
in 50 mL of glacial acetic acid, 70 mL of hydrogen bromide in acetic acid (33% wt) were added. 
The mixture was stirred for 4 hours at 50°C, then poured into 100 mL of distilled water to afford 
a precipitate, which was filtered, washed with aliquots of distilled water and dried in a freeze 
drier to give the product as a white powder (36.2 g, 91%). 
1H NMR (300 MHz, CDCl3, 298 K) δ 4.58 (6H, s, CH2Br), 2.47 (9H, s, CH3). 




1,3,5-Tris(bromomethyl)-2,4,6-triethylbenzene (compound 61) 
 
In a 500 mL round-bottomed flask connected to a condenser, zinc powder (5.0 g, 76.0 mmol) 
and acetic acid (glacial, 50 mL) were added in the open air. At room temperature, to the stirring 
reaction mixture, hydrogen bromide in acetic acid (33% wt, 50 mL) was added slowly over the 
course of 30 minutes. The reaction mixture was stirred until all the zinc powder had dissolved, 
leading to an orange-coloured solution. To this solution, 1,3,5-triethylbenzene (10.0 g, 8.62 mL, 




62.0 mmol), paraformaldehyde (15 g, 93.0 mmol) and hydrogen bromide in acetic acid (33% 
wt, 148 mL) were added together and the resulting slurry was heated to 90°C for 48 hours, 
resulting in a dark brown solution. The solution was cooled down to room temperature with 
continuous stirring, where upon a white precipitate was formed. The solid was filtered and 
washed with water (3 x 20 mL). The remaining solution was collected and reheated at 90°C for 
a further 24 hours, allowing the formation of a second crop of product (total recovery: 28.2 g, 
97%). 
1H NMR (300 MHz, CDCl3, 298 K) δ 4.58 (6H, s, CH2Br), 2.94 (6H, q, J = 7.6 Hz, CH2CH3), 
1.34 (9H, t, J = 7.6 Hz, CH2CH3). 




diazabicyclo[2.2.2]octan-1-ium) tribromide (compound 62) 
 
In a 250 mL two-necked round bottomed flask compound 60 (0.500 g, 1.25 mmol) and 
diazabicyclo[2.2.2]octane (DABCO, 1.41 g, 12.6 mmol) were dissolved in dry acetonitrile (100 
mL) and refluxed under anhydrous conditions (N2) for 24 hours, during which time a precipitate 
formed. The solid was collected by filtration, washed with acetonitrile, diethyl ether (3 times, 
50 mL each), and dried in order to obtain a white powder (0.785 g, 85%). 
1H NMR (300 MHz, DMSO-d6, 298 K) δ 4.79 (6H, s, CH2N), 3.51 (18H, t, J = 7.1 Hz, 
N+CH2CH2N), 2.97 (18H, t, J = 7.1 Hz, N+CH2CH2N), 2.59 (9H, s, CH3). 




13C NMR (75 MHz, DMSO-d6, 298 K) δ 146.5 (CCH2), 127.1 (CCH3), 62.5 (CH2N), 51.1 
(N+CH2CH2N), 45.5 (N+CH2CH2N), 21.6 (CH3). 




diazabicyclo[2.2.2]octan-1-ium) tribromide (compound 63) 
 
Under anhydrous conditions (N2 atmosphere), compound 60 (0.500 g, 1.13 mmol) and 1.27 g 
(11.3 mmol) of diazabicyclo[2.2.2]octane (DABCO) were refluxed in dry acetonitrile (100 mL) 
for 36 hours, during which time a precipitate occurred. The precipitate was collected by 
filtration, washed with acetonitrile, diethyl ether and dried to give the product as a hygroscopic 
white powder (0.876 g, 73%). 
1H NMR (300 MHz, DMSO-d6, 298 K) δ 4.69 (6H, s, CH2N), 3.57 (18H, t, J = 7.3 Hz, 
N+CH2CH2N), 3.19 (6H, d, J = 7.7 Hz, CH2CH3), 2.98 (18H, t, J = 7.2 Hz, N+CH2CH2N), 0.82 
(9H, t, CH2CH3). 
13C NMR (75 MHz, DMSO-d6, 298 K) δ 154.9 (CCH2CH3), 122.7 (CCH2N+), 59.9 (CH2N), 
50.5 (N+CH2CH2N), 45.1 (N+CH2CH2N), 25.6 (CH2CH3), 18.2 (CH3). 
ESI-MS calculated for C33H57N6Br2+ [M+279Br]+ 697.2988, found 697.3017. 
  





tribromide (compound 64) 
 
Under anhydrous conditions in a nitrogen atmosphere, compound 60 (0.500 g, 1.25 mmol) and 
4,4’-bipyridine (1.77 g, 11.3 mmol) were dissolved in dry dichloromethane (100 mL). The 
resulting solution was stirred at reflux for 24 hours. After that time, a yellow precipitate was 
produced and collected by filtration, washed with aliquots of dichloromethane and diethyl ether 
to afford the product as a pale-yellow powder (0.736 g, 71%). 
1H NMR (300 MHz, DMSO-d6, 298 K) δ 9.11 (6H, d, J = 6.9 Hz, N+CH2CH2N), 8.86 (6H, dd, 
J = 7.1, 2.9 Hz, N+CH2CH2N), 8.60 (6H, d, J = 6.5 Hz, CH2CH2N), 8.02 (6H, dd, J = 8.7, 4.1 
Hz, CH2CH2N), 6.19 (6H, s, CH2N), 2.39 (9H, s, CCH3). 
13C NMR (75 MHz, DMSO-d6, 298 K) δ 151.3 (C-C BiPy), 144.9 (CHN), 141.2 (N+CH), 128.8 
(C-C BiPy), 126.1 (CCHCHN), 122.3 (NCHCHC), 58.6 (N+CH2), 16.5 (CH3). 
ESI-MS calculated for C42H39N6Br2+ [M+Br]2+ 353.1204, found 353.1202. 
  





tribromide (compound 65) 
 
In a 250 mL round bottom flask, compound 61 (0.500 g, 1.13 mmol) and 4,4’-bipyridine (1.96 
g, 12.5 mmol) were dissolved in dry dichloromethane (150 mL). The resulting solution was 
stirred at reflux under anhydrous conditions for 24 hours. After that time, a pale-yellow 
precipitate was produced and subsequently collected by filtration, washed with 
dichloromethane (3 x 50 mL) and diethyl ether (3 x 50 mL) to afford the product as a yellow 
deliquescent powder (0.882 g, 76%). 
1H NMR (300 MHz, DMSO-d6, 298 K) δ 9.43 (6H, d, J = 52.2 Hz, N+CH2CH2N), 8.86-8.63 
(6H, m, N+CH2CH2N), 8.62 (6H, bs, CH2CH2N), 7.96 (6H, bs, CH2CH2N), 6.16 (6H, s, CH2N), 
2.66 (6H, bs, CH2CH3), 0.97 9H, s, CH2CH3). 
13C NMR (75 MHz, DMSO-d6, 298 K) δ 152.6 (C-C BiPy), 151.3 (CHN), 150.8 (N+CH), 149.3 
(C-C BiPy), 145.3 (CCH2CH3), 141.3 (CCH2N+), 126.0 (CCHCHN+), 122.2 (CCHCHN), 57.2 
(N+CH2), 23.9 (CH2CH3), 15.9 (CH3). 
ESI-MS calculated for C45H45N63+ [M]3+ 223.1230, found 223.1230. 
  




2-(Anthracen-9-ylmethylene)hydrazine-1-carbothioamide (compound 66) 
 
In a 100 mL round-bottomed flask, 9-anthracenecarboxaldehyde (0.500 g, 2.42 mmol), and 
thiosemicarbazide (0.221 g, 2.42 mmol) were suspended in 30 mL of anhydrous absolute 
ethanol containing 1-2 drops of acetic acid. The reaction mixture was stirred at reflux for 3.5 
hours. After cooling down to room temperature, the resulting precipitate was collected by 
filtration and washed thoroughly with ethanol, diethyl ether and dried (0.609 g, 90%). 
1H NMR (300 MHz, DMSO-d6, 298 K) δ 11.68 (1H, s, CHNNH), 9.33 (1H, s, C(10)H), 8.71 
(1H, s, CH=N), 8.58-8.55 (2H, m, C(4,5)H), 8.36 (1H, s, SCNHH), 8.16-8.13 (2H, m, C(1,8)H), 
7.75 (1H, s, SCNHH), 7.67-7.55 (4H, m, C(2,3-6,7)H). 
Analysis consistent with literature data.3 
 
  





ylmethylene)hydrazine-1-carbimidothioate) (compound 67) 
 
In a round-bottomed flask connected to a condenser a mixture of compound 66 (0.463 g, 1.66 
mmol) and compound 60 (0.200 g, 0.50 mmol) were dissolved in 100 mL of dry acetonitrile. 
The reaction mixture was stirred under reflux for 16 hours. After cooling down to room 
temperature, the resulting precipitate was filtered and washed with acetonitrile and diethyl ether 
to give an orange-yellow powder, which was re-dissolved in 100 mL of methanol. To the 
vigorously stirring solution, an excess of triethylamine was added dropwise, resulting in the 
formation of a cloudy solution. The slurry was kept stirring for further 24 hours. The solvent 
was removed via rotary evaporator, tetrahydrofuran was added, and the resulting mixture was 
filtered (to remove the insoluble triethylamine hydrobromide) and washed thoroughly with 
further THF. The final product was afforded, after evaporation of the solvent, as a bright yellow 
powder (0.463 g, 94%). 
1H NMR (500 MHz, CDCl3, 298 K) δ 9.62 (3H, bs, C(10)H), 8.71-8.67 (6H, m, C(4,5)H), 8.49 
(3H, s, C(9)-CH=NNH), 8.05-7.99 (6H, m, C(1,8)H), 7.56-7.48 (12H, m, C(2,3-6,7)H), 5.55 
(3H, bs, NNHCNHS), 4.65 (6H, s, CH2S), 2.70 (9H, s, CH3). 
13C NMR (125 MHz, CDCl3, 298 K) δ 162.4 (SCNHNH), 153.4 (C(9)CHN), 137.6 (CCH2S), 
135.7 (CCH3), 131.5 (C(4)CC(10), C(10)CC(5)), 130.5 (C(1)CC(9), C(8)CC(9)), 129.3 (C(9)), 
128.9 (C(1,8)), 126.9 (C(4,5), 125.6 (C(10)) 125.4 (C(2,3,6,7), 31.1 (CH2S), 16.7 (CH3). 
ESI-MS calculated for C60H51N9S3 [M+H]+ 994.3502, found 994.3497. 
  





ylmethylene)hydrazine-1-carbimidothioate) (compound 68) 
 
In a round-bottomed flask connected to a condenser a mixture of compound 66 (0.418 g, 1.49 
mmol) and compound 61 (0.200 g, 0.45 mmol) were dissolved in 100 mL of dry acetonitrile. 
The reaction mixture was stirred under reflux for 18 hours. After cooling down to room 
temperature, the resulting precipitate was filtered and washed with acetonitrile and diethyl ether 
to give an orange-yellow powder, which was re-dissolved in 100 mL of methanol. To the 
vigorously stirring solution, an excess of triethylamine was added dropwise, resulting in the 
formation of a precipitate. The slurry was kept stirring for further 24 hours. The precipitate was 
finally filtered, washed with methanol and dried to give the final product as a yellow powder 
(0.431 g, 92%). 
1H NMR (500 MHz, CDCl3, 298 K) δ 9.63 (3H, s, C(10)H), 8.71-8.66 (6H, m, C(4,5)H), 8.49 
(3H, s, C(9)-CH=NNH), 8.05-7.99 (6H, m, C(1,8)H), 7.54-7.49 (12H, m, C(2,3-6,7)H), 5.56 
(6H, s, SC=NH-NH), 4.67 (6H, s, CH2S), 3.08 (6H, q, J = 7.4 Hz, CH2CH3), 1.50 (9H, t, J = 
7.4 Hz, CH2CH3). 
13C NMR (125 MHz, CDCl3, 298 K) δ 162.3 (SCNHNH), 153.4 (C(9)CHN), 144.4 (CCH2S), 
143.9 (CCH2CH3), 131.5 (C(4)CC(10), C(10)CC(5)), 130.5 (C(9)), 130.3 (C(1)CC(9), 
C(8)CC(9)), 128.9 (C(1,8)), 126.6 (C(4,5), 125.6 (C(10)) 125.4 (C(2,3,6,7), 29.6 (CH2S), 23.6 
(CH2CH3), 16.5 (CH2CH3). 
ESI-MS calculated for C63H57N9S3 [M+H]+ 1036.3972, found 1036.4016. 




7.2.2. Synthesis of compounds from Chapter 3 
3,3',3''-((2,4,6-Trimethylbenzene-1,3,5-triyl)tris(methylene))tris(1-methyl-1H-imidazol-3-
ium) tribromide (compound 69) 
 
To a stirring solution of compound 60 (1.00 g, 2.51 mmol) in 250 mL of dry acetonitrile, 1-
methyl-1H-imidazole (0.650 mL, 8.27 mmol) was added. The resulting mixture was refluxed 
under an argon atmosphere for 24 hours. Following the formation of a white precipitate, the 
mixture was cooled down to room temperature, filtered and the precipitate washed with aliquots 
of acetonitrile and diethyl ether. The pure product was obtained after recrystallization form a 
methanol/diethyl ether mixture as colourless needles (1.21 g, 75%). 
1H NMR (400 MHz, CD3OD, 298 K) δ 7.73 (3H, t, J = 1.8 Hz, NCH=CHN), 7.62 (3H, t, J = 
1.8 Hz, NCH=CHN), 5.61 (6H, s, CH2N), 3.96 (s, 9 H, N-CH3), 2.38 (9H, s, Ar-CH3). 
Analysis consistent with literature data.4 
  





ium) tris(hexafluorophosphate) (compound 70) 
 
In a 250 mL two necked round bottomed flask compound 61 (1.00 g, 2.27 mmol) was dissolved 
in 100 mL of dry tetrahydrofuran under vigorous stirring. To this solution, 1-methyl-1H-
imidazole (0.636 mL, 7.48 mmol) was added. The resulting mixture was heated at reflux under 
an argon atmosphere for 18 hours, resulting in the formation of a light beige precipitate, which 
was filtered and washed with aliquots of tetrahydrofuran. The resulting hygroscopic powder 
was dissolved in 100 mL of methanol and treated with a saturated solution of potassium 
hexafluorophosphate in methanol, which gave the pure product as a white powder (1.11 g, 
50%). 
1H NMR (500 MHz, DMSO-d6 298 K) δ 8.85 (s, 3H, NCHN) 7.74 (3H, t, J = 1.8 Hz, 
NCH=CHN), 7.61 (3H, t, J = 1.8 Hz, NCH=CHN), 5.46 (6H, s, CH2N), 3.82 (s, 9 H, N-CH3), 
2.62 (6H, q, J = 7.4 Hz, CH2CH3), 0.84 (9H, t, J = 7.4 Hz, CH2CH3). 
13C NMR (125 MHz, DMSO-d6, 298 K) δ 148.0 (NCHN), 136.4 (CCH2CH3), 128.9 (CCH2N+), 
124.2 (NCH=CHN), 123.2 (NCH=CHN), 47.2 (CH2N), 36.3 (N-CH3), 23.5 (CH2CH3), 16.0 
(CH2CH3). 
ESI-MS calculated for C27H39N6P2F12+ [M+2PF6]+ 737.2514, found 737.2493. 
  




1-(tert-Butyl)-1H-imidazole (compound 71) 
 
Distilled water (50 mL) was placed in a 250 mL 3-necked flask connected to two dropping 
funnels and a condenser. One dropping funnel contained a mixture of aqueous glyoxal (11.5 
mL, 0.10 mol, 40% w/v) and aqueous formaldehyde (8.10 ml, 0.10 mol, 40% conc.); the other 
dropping funnel tert-butylamine (10.6 mL, 0.10 mol) and aqueous ammonia (6.80 mL, 0.10 
mol, 25% w/v). The water was heated to reflux and then the contents of both dropping funnels 
were added dropwise and simultaneously. The reaction mixture turned brown and after the 
addition was complete, it was subsequently stirred for 30 minutes at 100°C. The solution was 
cooled to room temperature and the solvent was removed under reduced pressure to give a 
brown oil, which was extracted into dichloromethane (150 mL) and then it was washed with a 
saturated solution of sodium chloride (3 x 150 mL). The organic layer was dried over sodium 
sulphate and the solvent removed under reduced pressure. The pure product was purified by 
Kugelröhr distillation to give a very pale-yellow oil (b.p.116°C) (5.77 g, 44%). 
1H NMR (300 MHz, CDCl3, 298 K) δ 7.52 (1H, s, NCHN), 6.95 (2H, s, NCH=CHN), 1.46 
(9H, s, tBu-CH3). 
13C NMR (75 MHz, CDCl3, 298 K) δ 134.2 (NCHN), 128.9 (NCH=CHN), 116.2 (NCH=HCN), 
54.6 (tBu-C), 30.5 (tBu-CH3). 
Analysis consistent with literature data.5 
  





imidazol-3-ium) tribromide (compound 72) 
 
In a 250 mL two necked round bottomed flask compound 60 (5.00 g, 12.6 mmol) and compound 
71 (5.16 g, 41.6 mmol) were dissolved in dry acetonitrile (100 mL) and refluxed under 
dinitrogen atmosphere for 48 hours. After removal of the solvent under vacuum, the solid was 
washed with diethyl ether and the product was recrystallized from a dichloromethane/diethyl 
ether mixture to give a white microcrystalline solid (8.13 g, 84%). 
1H NMR (300 MHz, DMSO-d6, 298 K) δ 9.50 (3H, t, J = 1.7 Hz, NCHN), 8.06 (3H, t, J = 1.9 
Hz, NCH=CHN), 7.51 (3H, t, J = 1.8 Hz, NCH=CHN), 5.57 (6H, s, CH2N), 2.28 (9H, s, Ar-
CH3), 1.58 (27H, s, C(CH3)3). 
13C NMR (125 MHz, DMSO-d6, 298 K) δ 141.4 (CCH2N), 134.9 (NCHN), 129.7 
(NCH=CHN), 122.3 (Ar-C), 120.9 (NCH=CHN), 60.2 (NC(CH3)3), 48.2 (CH2N), 29.5 
(C(CH3)3), 16.9 (CH3). 
Analysis consistent with literature data.6 
  





imidazol-3-ium) tribromide (compound 73) 
 
In a 500 mL two-necked round bottomed flask compound 61 (1.18 g, 2.67 mmol) and 
compound 71 (1 g, 8.1 mmol) were mixed in anhydrous conditions under flux of nitrogen. 250 
mL of anhydrous acetonitrile were added, the resulting reaction mixture was stirred under reflux 
for 48 hours. The reaction mixture was cooled down and a white-grey precipitate was obtained. 
The solid was filtered, washed with aliquots of acetonitrile and dried. Counterion metathesis 
was performed by treating a rapidly stirring aqueous suspension of the product with ammonium 
hexafluorophosphate. Following recrystallization from tetrahydrofuran/n-pentane, the product 
was obtained as a white powder (1.695 g, 78%). 
1H NMR (300 MHz, DMSO-d6, 298 K) δ 9.64 (3H, t, J = 1.7 Hz, NCHN), 8.05 (3H, t, J = 1.9 
Hz, NCH=CHN), 7.55 (3H, t, J = 1.9 Hz, NCH=CHN), 5.50 (6H, s, CH2N), 2.71 (6H, q, J = 
7.4 Hz, CH2CH3), 1.60 (27H, s, C(CH3)3), 0.74 (9H, t, J = 7.2 Hz, CH2CH3). 
13C NMR (75 MHz, DMSO-d6, 298 K) δ 147.7 (CCH2CH3 or CCH2N), 136.2 (NCHN), 122.3 
(CCH2CH3 or CCH2N), 128.9 (NCH=CHN), 120.8 (NCH=CHN), 60.1 (NC(CH3)3), 48.9 
(CH2N), 29.5 (C(CH3)3), 23.6 (CH2CH3), 15.2 (CH2CH3). 
  





imidazol-3-ium) tris-hexafluorophosphate (compound 73·3PF6) 
 
Compound 73·3PF6 was obtained by treating a rapidly stirring aqueous suspension of 
compound 73 (0.100 g, 0.12 mmol) with an excess ammonium hexafluorophosphate (0.053 g, 
0.33 mmol). The suspension was filtered and dried in a freeze drier to give the product as a 
white powder (0.117 g, 99%). 
1H NMR (300 MHz, DMSO-d6, 298 K) δ 9.58 (3H, t, J = 1.7 Hz, NCHN), 8.00 (3H, t, J = 1.9 
Hz, NCH=CHN), 7.51 (3H, t, J = 1.8 Hz, NCH=CHN), 5.52 (6H, s, CH2N), 2.73 (6H, q, J = 
7.3 Hz, CH2CH3), 1.62 (27H, s, C(CH3)3), 0.76 (9H, t, J = 7.2 Hz, CH2CH3). 
13C NMR (75 MHz, DMSO-d6, 298 K) δ 148.3 (CCH2CH3 or CCH2N), 137.4 (NCHN), 121.9 
(CCH2CH3 or CCH2N), 127.5 (NCH=CHN), 121.2 (NCH=CHN), 59.1 (NC(CH3)3), 48.4 
(CH2N), 29.2 (C(CH3)3), 23.1 (CH2CH3), 15.4 (CH2CH3). 
ESI-MS calculated for C36H57N6P2F12+ [M+2PF6]+ 863.3923, found 863.3967. 
 
  




1-Mesityl-1H-imidazole (compound 74) 
 
In a 1 L round-bottom flask, a solution of 2,4,6-trimethylaniline (37.7 mL, 0.10 mol) in 
methanol (50 mL) was treated with 30% aqueous glyoxal (16.2 mL, 0.10 mol) for 16 hours at 
room temperature. A pale-yellow solution was formed. Ammonium chloride (10.7 g, 0.20 mol) 
was added, followed by 37% aqueous formaldehyde (16 mL, 0.20 mol). The mixture was 
diluted with methanol (400 mL) and refluxed for 1 hour. Phosphoric acid (14 mL, 85% wt) was 
slowly added dropwise over a period of 10 minutes. The resulting mixture was stirred at reflux 
for further 8 hours. After removal of the solvent, the dark brown residue was poured onto ice 
(300 g) and neutralised with a 40% wt potassium hydroxide solution until pH 9. The resulting 
slurry was extracted with diethyl ether (5 x 150 mL). The organic phases were combined and 
washed with distilled water, brine and dried over sodium sulphate. After removal of the solvent, 
the pure compound was afforded following recrystallization from a concentrated solution of 
ethyl acetate as colourless needles (26.9 g, 71%). 
1H NMR (300 MHz, CDCl3, 298 K) δ 7.44 (1H, t, J = 1.2 Hz, NCHN), 7.23 (1H, t, J = 1.1 Hz, 
NCH=CHN), 7.00-6.94 (2H, m, Ar-CH), 6.89 (1H, t, J = 1.3 Hz, NCH=CHN), 2.34 (3H, s, p-
CH3), 1.99 (6H, s, o-CH3). 
Analysis consistent with literature data.7 
  





3-ium) tribromide (compound 75) 
 
In a 250 mL two-necked round-bottomed flask compound 60 (0.505 g, 1.27 mmol) and 
compound 74 (0.712 g, 3.82 mmol) were mixed under nitrogen. 100 mL of dry acetonitrile was 
added, and the resulting reaction mixture was stirred under reflux for 48 hours. After two days, 
the reaction mixture was cooled down and a pale-yellow precipitate was obtained. The 
precipitate was recrystallized from tetrahydrofuran/n-pentane to give the pure product as a 
white powder (0.688 g, 70%). 
1H NMR (300 MHz, CD3CN, 298 K) δ 10.13 (3H, t, J = 1.6 Hz, NCHN), 8.00 (3H, s, J = 1.8 
Hz, NCH=CHN), 7.42 (3H, t, J = 1.8 Hz, NCH=CHN), 6.97 (6H, s, m-CH), 5.64 (6H, s, CH2N), 
2.34 (9H, s, Ar-CH3), 2.31 (9H, s, p-CH3) 1.93 (18H, s, o-CH3). 
13C NMR (75 MHz, DMSO-d6, 298 K) δ 149.7 (CH2-p-Me), 140.1 (NCHN), 136.4 (CCH3), 
134.7 (CH2-o-Me), 130.6 (CCH2N) 129.7 (CH Mes), 128.2 (CN), 124.8 (NCH=CHN), 122.7 
(NCH=CHN), 21.3 (CH3), 19.9 (p-CH3), 17.3 (o-CH3). 
ESI-MS calculated for C48H57N63+ [M]3+ 239.1543, found 239.1537. 
  





ium) tribromide (compound 76) 
 
In a 250 mL Schlenk tube, compound 61 (0.362 g, 0.82 mmol) and compound 74 (0.459 g, 2.46 
mmol) were stirred in anhydrous conditions under nitrogen. 100 mL of anhydrous acetonitrile 
was added, and the reaction mixture was stirred under reflux for 48 hours. After cooling down 
to room temperature, the solution was concentrated to ~2-3 mL before layering it with diethyl 
ether. The pure product was obtained as colourless crystals (0.413 g, 66%). 
1H NMR (300 MHz, DMSO-d6, 298 K) δ 9.38 (3H, s, NCHN), 8.02 (3H, t, J = 1.8 Hz, 
NCH=CHN), 7.93 (3H, t, J = 1.8 Hz, NCH=CHN), 7.12 (6H, s, m-CH), 5.66 (6H, s, CH2N), 
2.77 (6H, q, J = 7.5 Hz, CH2CH3), 2.31 (9H, s, p-CH3) 1.96 (18H, s, o-CH3), 0.92 (9H, t, J = 
7.2 Hz, CH2CH3).  
13C NMR (75 MHz, DMSO-d6, 298 K) δ 148.2 (CH2-p-Me), 140.6 (NCHN), 137.1 
(CCH2CH3), 134.5 (CH2-o-Me), 131.5 (CCH2N) 129.6 (CH Mes), 128.9 (CN), 124.5 
(NCH=CHN), 123.5 (NCH=CHN), 20.9 (p-CH3), 17.4 (o-CH3), 16.0 (CH2CH3). 









ium) tris-hexafluorophosphate (compound 76·3PF6) 
 
Compound 76·3PF6 was obtained by treating a rapidly stirring aqueous suspension of 
compound 76 (0.100 g, 0.10 mmol) with an excess ammonium hexafluorophosphate (0.054 g, 
0.33 mmol). The suspension was filtered and dried in a freeze drier to give the product as a 
white powder (0.118 g, 99%). 
1H NMR (300 MHz, DMSO-d6, 298 K) δ 9.47 (3H, s, NCHN), 8.04 (3H, t, J = 1.8 Hz, 
NCH=CHN), 7.98 (3H, t, J = 1.8 Hz, NCH=CHN), 7.13 (6H, s, m-CH), 5.70 (6H, s, CH2N), 
2.81 (6H, q, J = 7.4 Hz, CH2CH3), 2.32 (9H, s, p-CH3) 1.99 (18H, s, o-CH3), 0.93 (9H, t, J = 
7.2 Hz, CH2CH3).  
13C NMR (75 MHz, DMSO-d6, 298 K) δ 148.8 (CH2-p-Me), 139.8 (NCHN), 136.7 
(CCH2CH3), 134.8 (CH2-o-Me), 131.8 (CCH2N) 130.1 (CH Mes), 128.5 (CN), 124.1 
(NCH=CHN), 122.9 (NCH=CHN), 21.0 (p-CH3), 17.5 (o-CH3), 16.1 (CH2CH3). 
  




7.2.3. Synthesis of compounds from Chapter 4 
3,5-Bis(bromomethyl)-2,4,6-triethylbenzyl tert-butyl succinate (compound 77) 
 
In a 100 mL round-bottomed flask connected to a condenser compound 60 (0.500 g, 1.13 mmol) 
and 4-(tert-butoxy)-4-oxobutanoic acid (0.198 g, 1.13 mmol) were dissolved in 50 mL of 
acetonitrile. To the stirring solution, potassium carbonate (0.235 g, 1.70 mmol) was added and 
the resulting mixture was refluxed for 18 hours. After cooling down to room temperature, the 
solvent was removed under vacuum and dichloromethane was added. The resulting mixture 
was washed three times with a sodium hydroxide 1M solution, the organic phase dried over 
magnesium sulphate and the solvent was removed. Pure product was afforded after purification 
via silica gel flash chromatography with a solvent system of 10% ethyl acetate/hexane (0.176 
g, 29%). 
1H NMR (400 MHz, CDCl3, 298 K) δ 5.25 (2H, s, CH2O) 4.65 (4H, s, CH2Br), 3.00 (2H, q, J 
= 7.5 Hz, p-CH2CH3), 2.89 (2H, q, J = 7.5 Hz, o-CH2CH3), 2.62-2.59 (2H, m, COCH2), 2.56-
2.53 (2H, m, CH2CO), 1.48 (9H, s, C(CH3)), 1.40 (3H, t, J = 7.6 Hz, p-CH2CH3), 1.31 (6H, t, J 
= 7.6 Hz, o-CH2CH3). 
13C NMR (125 MHz, CDCl3, 298 K) δ 173.1 (CH2OOCCH2), 171.7 (COOtBu), 144.3 (p-Ar-
CCH2CH3), 143.8 (o-Ar-CCH2CH3), 132.4 (Ar-CCH2O), 130.6 (Ar-CCH2Br), 81.4 (C(CH3)3), 
61.6 (CH2O), 30.6 (CH2COOtBu), 29.1 (CH2CH2COOtBu), 28.4 ((C(CH3)3), 23.3 (o-Ar-
CCH2CH3), 22.7 (p-Ar-CCH2CH3), 16.0 (o-CH2CH3), 15.6 (p-CH2CH3). 
ESI-MS calculated for C23H3O4Br2 [M+NH4]+ 552.1143, found 552.1128. 
  





phenylene)bis(methylene))bis(1-mesityl-1H-imidazol-3-ium) dibromide (compound 78) 
 
In a 250 mL round-bottomed flask equipped with a magnetic stirrer and a condenser, a mixture 
of compound 77 (0.730 g, 1.37 mmol) and the monosubstituted imidazole (compound 74) 
(0.534 g, 2.88 mmol) were dissolved in 100 mL of dry acetonitrile. The reaction mixture was 
refluxed under an argon atmosphere for 48 hours. After cooling down to room temperature, the 
solvent was removed under reduced pressure and the crude product was recrystallized from a 
mixture of dichloromethane/n-pentane to give the title compound as a white powder (1.04 g, 
83%). 
1H NMR (500 MHz, DMSO-d6, 298 K) δ 9.30 (2H, s, NCHN), 8.00 (4H, s, NCHCHN), 7.98 
(4H, s, NCHCHN), 7.10 (4H, s, Mes-CH), 5.64 (4H, s, CH2N), 5.17 (2H, s, CH2O), 2.72 (6H, 
q, J = 7.4 Hz, CH2CH3), 2.48-2.46 (4H, m, COCH2CH2CO), 2.29 (6H, s, Mes-p-CH3), 1.95 
(12H, s, Mes-o-CH3), 1.33 (9H, s, C(CH3)), 1.08-1.02 (9H, m, CH2CH3). 
13C NMR (125 MHz, DMSO-d6, 298 K) δ 172.0 (CH2OOCCH2), 171.1 (COOtBu), 147.6 (Mes-
p-CCH3), 146.6 (p-Ar-CCH2CH3), 140.3 (o-Ar-CCH2CH3), 136.5 (NCHN), 134.2 (Mes-o-
CCH3), 131.2 (CCH2N), 129.2 (Mes-o-CCH3), 124.2 (NCH=CHN), 123.4 (NCH=CHN), 79.9 
(C(CH3)3), 60.2 (CH2O), 47.3 (CH2N), 29.7 (CH2COOtBu), 28.8 (CH2CH2COOtBu), 27.8 
(C(CH3)3), 23.0 (p-Ar-CCH2CH3), 22.5 (o-Ar-CCH2CH3), 20.5 (Mes-p-CCH3), 17.0 (Mes-o-
CCH3), 16.8 (p-CH2CH3), 15.7 (o-CH2CH3). 
ESI-MS calculated for C47H62N4O4 [M]2+ 373.2380, found 373.2469. 
  




6-Azidohexanoic acid (compound 79) 
 
In a 250 mL round-bottomed flask 6-bromohexanoic acid (1.00 g 5.13 mmol) was dissolved in 
80 mL of dimethyl sulfoxide. To the stirring solution, sodium azide (0.500 g, 7.69 mmol) was 
added and the resulting mixture was stirred at room temperature for 16 hours. After this time, 
200 mL of distilled water was added, and the crude product was extracted with diethyl ether (5 
x 150 mL). The organic phases were combined and dried over magnesium sulphate, filtered and 
the solvent removed under reduced pressure to give the pure product as a pale-yellow oil 
(0.503g, 72%). 
1H NMR (300 MHz, CDCl3, 298 K) δ 10.76 (1H, s, COOH), 3.23 (2H, t, J = 6.9 Hz, CH2N3), 
2.31 (2H, t, J = 7.3 Hz, CH2COOH), 1.68-1.65 (2H, m, CH2CH2N3), 1.59-1.56 (2H, m, 
CH2CH2COOH), 1.46-1.42 (2H, m, N3CH2CH2CH2). 








3,5-Bis(bromomethyl)-2,4,6-triethylbenzyl 6-azidohexanoate (compound 80) 
 
In a 100 mL round-bottomed flask connected to a condenser compound 61 (0.500 g, 1.13 mmol) 
was dissolved in 50 mL of acetonitrile. To the stirring solution, potassium carbonate (0.235 g, 
1.70 mmol) and compound 79 (0.178 g, 1.13 mmol) were added and the resulting mixture was 
refluxed for 16 hours. After cooling down to room temperature, the solvent was removed under 
reduced pressure and dichloromethane was added. The resulting mixture was washed three 
times with 1M sodium hydroxide solution, the organic phase dried over magnesium sulphate, 
and the solvent removed. Pure product was afforded after purification via silica gel flash 
chromatography with a solvent system of 2-20% ethyl acetate/hexane (0.181 g, 32%). 
1H NMR (500 MHz, CDCl3, 298 K) δ 5.16 (2H, s, CH2O), 4.60 (4H, s, CH2Br), 3.21 (2H, t, J 
= 6.9 Hz, CH2N3), 2.96 (2H, q, J = 7.5 Hz, p-CH2CH3) 2.79 (2H, q, J = 7.6 Hz, o-CH2CH3) 
2.36 (2H, t, J = 7.5 Hz, COCH2), 1.70-1.63 (2H, m, COCH2CH2), 1.61-1.54 (2H, m, 
CH2CH2N3), 1.45-1.38 (2H, m, N3CH2CH2CH2), 1.35 (3H, t, J = 7.6 Hz, p-CH2CH3), 1.23 (6H, 
t, J = 7.7 Hz, o-CH2CH3). 
13C NMR (125 MHz, CDCl3, 298 K) δ 173.1 (COOCH2), 143.6 (p-Ar-CCH2CH3), 142.7 (o-
Ar-CCH2CH3), 132.5 (Ar-CCH2O), 130.7 (Ar-CCH2Br), 60.8 (CH2O), 49.5 (CH2N3), 34.2 
(OCCH2), 30.1 (CH2Br), 29.6 (CH2CH2N3), 23.4 (o-Ar-CCH2CH3), 22.0 (p-Ar-CCH2CH3), 
16.3 (o-CH2CH3), 15.7 (p-CH2CH3). 









phenylene)bis(methylene))bis(1-mesityl-1H-imidazol-3-ium) dibromide (compound 81) 
 
In a 250 mL round-bottomed flask a mixture of compound 80 (0.300 g, 0.58 mmol) and 
compound 74 (0.227 g, 1.22 mmol) were dissolved in 80 mL of dry acetonitrile. The reaction 
mixture was refluxed under anhydrous atmosphere for 48 hours. After cooling down to room 
temperature, the solvent was removed under reduced pressure and the crude product was 
recrystallized from a mixture of dichloromethane/hexane to give the compound 81 as a white 
powder (0.398 g, 77%). 
1H NMR (500 MHz, DMSO-d6, 298 K) δ 9.44 (1H, s, NCHN), 9.22 (1H, s, NCHN), 8.03-7.99 
(2H, m, NCH=CHN), 7.96-7.92 (2H, m, NCH=CHN), 7.11 (4H, s, Mes m-CH), 5.68, 5.59 (4H, 
s, CH2N), 4.56 (2H, s, CH2O), 3.28 (2H, t, J = 7.2 Hz, CH2N3), 2.81-2.76 (4H, m, o-CH2CH3), 
2.73-2.70 (2H, m, p-CH2CH3), 2.54 (2H, bs, COCH2), 2.29 (6H, s, Mes p-CH3), 1.97,1.94 (12H, 
s, Mes o-CH3), 1.56-1.53 (2H, m, COCH2CH2), 1.33-1.26 (2H, m, CH2CH2N3), 1.22-1.14 (2H, 
m, N3CH2CH2CH2) 1.07-1.03 (6H, m, o-CH2CH3), 0.93 (3H, t, J = 7.3 Hz, p-CH2CH3). 
13C NMR (125 MHz, CDCl3, 298 K) δ 173.8 (COOCH2), 147.1 (p-Ar-CCH2CH3), 146.2 (Mes-
p-CCH3), 143.9 (p-Ar-CCH2CH3), 142.3 (o-Ar-CCH2CH3), 137.5 (NCHN), 133.9 (Mes-o-
CCH3), 132.3 (Ar-CCH2O), 131.8 (CCH2N), 125.2 (NCH=CHN), 124.7 (NCH=CHN), 62.4 
(CH2O), 50.0 (CH2N3), 34.6 (OCCH2), 28.9 (CH2CH2N3), 22.8 (o-Ar-CCH2CH3), 22.3 (p-Ar-
CCH2CH3), 16.1 (o-CH2CH3), 15.8 (p-CH2CH3). 
ESI-MS calculated for C45H59N7O22+ [M]2+ 364.7360, found 364.7366. 
 
 





carbimidothioate (compound 82) 
 
In a 250 mL two-necked round-bottomed flask connected to a condenser, compound 61 (0.500 
g, 1.13 mmol) was dissolved in 100 mL of dry acetonitrile. To this solution, compound 66 
(0.158 g, 0.57 mmol) was added. The resulting suspension was heated to reflux and stirred for 
16 hours. After cooling down to room temperature, the reaction mixture was filtered, the filtrate 
concentrated to 1-2 mL and diethyl ether was added to precipitate the title compound, which 
was washed with further aliquots of diethyl ether and dried to give a bright yellow powder 
(0.142 g, 39%). 
1H NMR (400 MHz, DMSO-d6, 298 K) δ 9.81 (1H, s, C=NH), 9.68 (1H, s, C(10)H), 8.86 (1H, 
s, CHNNH), 8.60-8.58 (2H, m, C(4,5)H), 8.23-8.21 (2H, m, C(1,8)H), 7.71-7.64 (4H, m, C(2,3-
6,7)H), 4.75 (4H, s, CH2Br), 4.73 (2H, s, CH2S), 2.95-2.91 (6H, m, CH2CH3), 0.87-0.81 (9H, 
m, CH2CH3). 
13C NMR (125 MHz, DMSO-d6, 298 K) δ 164.1 (SCNHNH), 143.9 (C(9)CHN), 137.8 
(CCH2S), 136.9 (C-p-CH2CH3), 133.3 (C-o-CH2CH3), 131.1 (C(4)CC(10), C(10)CC(5)), 130.3 
(CCH2Br), 129.6 (C(9)), 129.5 (C(1)CC(9), C(8)CC(9)), 128.3 (C(1,8, 4,5)), 126.27 
(C(2,3,6,7)), 125.14 (C(10)), 31.2 (CH2S), 30.7 (CH2Br), 23.1 (o-CH2CH3), 22.9 (p-CH2CH3), 
16.6 (CH2CH3). 
ESI-MS calculated for C31H33N3S1Br2 [M+H+] 640.0788, found 640.0807. 
 
 








In an oven-dried, argon-purged two-necked round-bottomed flask connected to a condenser, 
compound 82 (0.100 g, 0.16 mmol) and compound 74 (0.061 g, 0.33 mmol) were dissolved in 
50 mL of dry acetonitrile. The reaction mixture was refluxed for 48 hours. After cooling to 
room temperature, the solvent was evaporated under reduced pressure and the product 
recrystallized from a mixture of chloroform/n-pentane to give the title compound as a yellow 
powder (0.141 g, 87%). 
1H NMR (400 MHz, DMSO-d6, 298 K) δ 11.65 (1H, s, CHNNH), 9.46 (2H, s, NCHN), 9.34 
(1H, s, C(10)H), 8.72 (1H, s, CHNNH), 8.58 (2H, d, J = 8.8 Hz, C(1,8)H), 8.16 (2H, d, J = 8.3 
Hz, C(4,5)H), 8.03, 7.97 (4H, bs, NCHCHN), 7.65 (4H, dt, J = 7.5, 2.5 Hz, C(2,3-6,7)H), 7.13 
(4H, s, Mes-CH), 5.70 (6H, s, CH2N, CH2S), 2.81 (6H, q, J = 7.1 Hz, CH2CH3), 2.33 (6H, s, 
Mes-p-CH3), 1.99 (12H, s, Mes-o-CH3), 1.33 (9H, s, C(CH3)), 0.95 (9H, t, J = 6.9 Hz, CH2CH3). 
13C NMR (125 MHz, DMSO-d6, 298 K) δ 177.9 (SCNHNH), 147.8 (C(9)CHN), 142.1 
(CCH2S), 140.2 (Mes o-CCH3), 136.8 (NCHN), 134.3 (C-p-CH2CH3), 134.1 (CCH2N), 131.6 
(C-o-CH2CH3), 131.3 (Mes C-o-CH3), 129.6 (C(1)CC(9), C(8)CC(9)), 129.6 (C(9)), 129.4 
(C(4)CC(10), C(10)CC(5)), 128.9 (Mes CH), 128.5 (Mes CN), 127.2 (C(1,8, 4,5)), 125.3 
(C(2,3,6,7)), 124.9 (C(10)), 124.1 (NCH=CHN), 123.1 (NCH=CHN), 47.7 (CH2N), 30.5 
(CH2S), 23.4 (CH2CH3), 21.0 (Mes p-CH3), 17.5 (Mes o-CH3), 16.1 (CH2CH3). 
ESI-MS calculated for C55H61N7S1 [M2+] 425.7349, found 425.7384. 




7.2.4. Synthesis of compounds from Chapter 5 
Re(CO)3 (2,4,6-trimethylbenzene-1,3,5-triyl)tris(methylene) (2,2',2'')-tris(2-(anthracen-9-
ylmethylene)hydrazine-1-carbimidothioate) (compound 84) 
 
In a 10 mL microwave vial equipped with a stirring magnet equimolar amounts of compound 
67 (0.115 g, 0.12 mmol) and chloropentacarbonylrhenium(I) (0.047 g, 0.12 mmol) were added. 
The reaction vessel was sealed and saturated with argon for 15 minutes, then 8 mL of dry 
toluene was added. The reaction mixture was heated at 150°C for 30 minutes under microwave 
irradiation, during which time an orange precipitate was formed. The suspension was filtered, 
and the filter cake washed with aliquots of fresh toluene, diethyl ether and dried to give the title 
compound as an orange solid (0.051 g, 34%). 
1H NMR (400 MHz, DMSO-d6, 298 K) δ 9.86 (3H, bs, C(10)H), 8.87 (3H, s, C(9)-CH=NNH), 
8.62 (6H, m, C(4,5)H), 8.28-8.22 (6H, m, C(1,8)H), 7.72-7.65 (12H, m, C(2,3-6,7)H), 4.92 (6H, 
bs, CH2S), 2.71 (9H, s, CH3). 
13C NMR (125 MHz, CDCl3, 298 K) δ 162.87 (SCNHNH), 151.3 (C(9)CHN), 138.1 (CCH2S), 
133.2 (CCH3), 131.0 (C(4)CC(10), C(10)CC(5)), 130.7 (C(1)CC(9), C(8)CC(9)), 128.1 (C(9)), 
127.5 (C(1,8)), 126.7 (C(4,5), 125.8 (C(10)) 125.3 (C(2,3,6,7), 31.0 (CH2S), 16.4 (CH3). 
ESI-MS calculated for C63H51N9O3S3Re [M+H+Na]+ 1286.3069, found 1286.3334. 
Solid-state (powder) FT-IR (cm-1) 2017, 1907, 1883. 
 





9-ylmethylene)hydrazine-1-carbimidothioate) (compound 85) 
 
Compound 85 was synthesised following the experimental procedure for compound 84. 
Compound 68 (0.050 g, 0.05 mmol) and bromopentacarbonylrhenium(I) (0.021 g, 0.05 mmol) 
were heated in toluene at 150°C for 30 minutes under microwave irradiation. The product was 
obtained as an orange solid (0.041 g, 62%). 
1H NMR (400 MHz, DMSO-d6, 298 K) δ 9.89 (3H, s, C(10)H), 9.32 (3H, s, C(9)-CH=NNH), 
8.86-8.59 (6H, m, C(4,5)H), 8.18-8.06 (6H, m, C(1,8)H), 7.63-7.57 (12H, m, C(2,3-6,7)H), 4.55 
(6H, s, CH2S), 3.03-2.98 (6H, m, CH2CH3), 1.37-1.33 (9H, m, CH2CH3). 
13C NMR (125 MHz, CDCl3, 298 K) δ 183.8 (CO), 164.5 (SCNHNH), 155.1 (C(9)CHN), 147.6 
(CCH2S), 144.5 (CCH2CH3), 131.7 (C(4)CC(10), C(10)CC(5)), 131.2 (C(9)), 130.8 
(C(1)CC(9), C(8)CC(9)), 129.6 (C(1,8)), 125.7 (C(4,5), 125.2 (C(10)) 124.8 (C(2,3,6,7), 30.7 
(CH2S), 24.0 (CH2CH3), 16.3 (CH2CH3). 
ESI-MS calculated for C66H57N9O3S3Re [M]+ 1306.3299, found 1306.3282. 
Solid-state (powder) FT-IR (cm-1) 2020, 1907, 1887. 
 
  





ylmethylene)hydrazine-1-carbimidothioate) (compound 86) 
 
Compound 86 was synthesised following the experimental procedure for compound 84. 
Compound 68 (0.050 g, 0.05 mmol) and triruthenium dodecacarbonyl (0.031 g, 0.05 mmol) 
were heated in toluene at 150°C for 30 minutes under microwave irradiation. A cloudy, deep 
red solution was obtained. The mixture was filtered, and the solution was evaporated under 
vacuum to give a red solid. The product was eluted with chloroform/hexane (60:40). After 
removal of the solvents, the title compound was afforded as a red solid. (0.027 g, 44%) 
1H NMR (400 MHz, DMSO-d6, 298 K) δ 9.62 (3H, s, C(10)H), 8.56 (3H, s, C(9)-CH=NNH), 
8.22-7.80 (6H, m, C(4,5)H), 8.18-8.06 (6H, m, C(1,8)H), 7.70-7.33 (12H, m, C(2,3-6,7)H), 1.31 
(6H, s, CH2S), 1.30-1.24 (6H, m, CH2CH3), 0.95-0.87 (9H, m, CH2CH3). 
ESI-MS calculated for C66H57N9O3S3Ru [M+H-CO]+ 1194.2929, found 1194.2958. 
UV-Visible (THF): 350, 370 and 390 nm 
Fluorescence emission (Maximum, THF): 441 nm 
Solid-state (powder) FT-IR (cm-1) 2041, 1972, 1579, 1494. 
 
  






hexafluorophosphate (compound 87) 
 
To a 50 mL round-bottomed flask compound 76·3PF6 (0.148 g, 0.12 mmol) and silver(I) oxide 
(0.034 g, 0.15 mmol), 20 mL acetonitrile was added. The resulting mixture was wrapped in 
tinfoil to prevent photodecomposition and stirred at room temperature for 48 hours. The 
reaction mixture was subsequently filtered through a Celite® pad and the solution was 
evaporated under reduced pressure. The final product was obtained via column 
chromatography, eluting with dichloromethane, as an off-white solid (0.074 g, 53%). 
1H NMR (400 MHz, CDCl3, 298 K) δ 9.22 (1H, s, NCHN), 8.01 (2H, s, NHC=CHN), 7.91 
(2H, s, NHC=CHN), 7.38 (2H, s, Mes-CH), 7.12 (4H, s, Mes-CH), 6.78 (1H, s, NHC=CHN), 
6.68 (1H, s, NHC=CHN), 5.63 (2H, s, CH2N+), 5.56 (4H, s, CH2N), 3.14-3.09 (2H, m, p-
CH2CH3), 2.82-2.74 (4H, m, o-CH2CH3), 2.30 (9H, s, p-CH3), 1.96 (18H, s, o-CH3), 1.18-1.15 
(3H, m, p-CH2CH3), 0.93-0.90 (6H, m, o-CH2CH3). 
13C NMR (125 MHz, CDCl3, 298 K) δ 186.7 (C) 147.3 (CH), 141.2 (CH), 134.2 (C), 134.1 
(C), 129.7 (C), 125.8 (CH), 124.4 (CH), 122.6 (CH), 54.2 (CH2), 47.1 (CH2), 26.0 (CH2), 22.3 
(CH2), 21.0 (CH3), 17.0 (CH3), 16.9 (CH3), 15.9 (CH3), 15.0 (CH3), 14.0 (CH3). 
ESI-MS calculated for C51H61N6PF6Ag+ [M+PF6]+ 1011.3645, found 1011.3786. 
  





imidazol-2-ide) silver(I) hexafluorophosphate (compound 88) 
 
In a 20 mL microwave vial equipped with a stirring magnet equimolar amounts of compound 
76·3PF6 (0.100 g, 0.08 mmol) and silver(I) oxide (0.023 g, 0.10 mmol) were added. The 
reaction vessel was sealed and saturated with argon for 15 minutes, then 15 mL of 
dichloroethane (DCE) were added. the resulting mixture was heated for 40 minutes at 150°C 
under microwave irradiation. The reaction mixture was subsequently filtered through a Celite® 
pad and the solution was evaporated under reduced pressure. The final product was obtained 
via column chromatography, eluting with dichloromethane, as a white solid (0.039 g, 48%). 
1H NMR (400 MHz, CDCl3, 298 K) δ 8.57 (3H, bs, NHC=CHN), 7.20 (3H, bs, NHC=CHN), 
6.94 (6H, bs, Mes-CH), 5.62 (4H, bs, CH2N), 5.20 (2H, s, CH2N+), 2.75-2.73 (2H, m, p-
CH2CH3), 2.63-2.58 (4H, m, o-CH2CH3), 2.29 (3H, s, Mes-p-CH3), 2.26 (6H, s, Mes-p-CH3), 
1.97 (6H, s, Mes-o-CH3), 1.96 (12H, s, Mes-o-CH3), 1.18-1.13 (6H, m, o-CH2CH3), 1.03-0.99 
(3H, m, p-CH2CH3). 
13C NMR (125 MHz, CDCl3, 298 K) δ 148.1 (CH), 140.4 (CH), 136.6 (C), 131.2 (C), 126.4 
(CH), 125.8 (CH), 56.7 (CH2), 25.1 (CH2), 23.0 (CH2), 21.0 (CH3), 17.0 (CH3), 16.9 (CH3), 
15.9 (CH3), 15.0 (CH3), 14.0 (CH3). 
ESI-MS calculated for C51H60N6Ag [M]+ 865.3925, found 865.3957. 
  





imidazol-2-ide) silver(I) bromide (compound 89) 
 
Compound 89 was synthesised following the experimental procedure for compound 89. 
Compound 75 (0.100 g, 0.09 mmol) and silver(I) oxide (0.066 g, 0.28 mmol) were heated in 
dichloroethane at 150°C for 40 minutes under microwave irradiation. The product was obtained 
as a pale yellow solid (0.058 g, 66%). 
1H NMR (400 MHz, CD3CN, 298 K) δ 7.40 (3H, s, NHC=CHN), 7.10 (3H, d, J = 1.7 Hz, 
NHC=CHN), 6.98 (6H, s, Mes-CH), 5.49 (6H, s, CH2N), 2.34 (9H, s, core-Ar-CH3), 2.32 (9H, 
s, Mes-p-CH3), 1.87 (18H, s, Mes-o-CH3). 
13C NMR (125 MHz, DMSO-d6, 298 K) δ 148.4 (CH2-p-Me), 135.9 (CCH3), 134.4 (CH2-o-
Me), 130.2 (CCH2N) 129.2 (CH Mes), 127.8 (CN), 123.1 (NCH=CHN), 122.8 (NCH=CHN), 
21.4 (CH3), 19.7 (p-CH3), 17.4 (o-CH3). 
ESI-MS calculated for C48H54N6Ag [M]+ 823.3455, found 823.3513. 
  





phenylene)bis(methylene))bis(1-tert-butyl-1H-imidazol-2-ide) silver(I) bromide 
(compound 90) 
 
Compound 90 was synthesised following the experimental procedure of compound 88. 
Compound 73 (0.100 g, 0.12 mmol) and silver(I) oxide (0.034 g, 0.15 mmol) were heated in 
dichloroethane at 150°C for 32 minutes under microwave irradiation. The product was obtained 
as a pale orange solid (0.061 g, 61%). 
1H NMR (300 MHz, DMSO-d6, 298 K) δ 7.57 (3H, s, NCH=CHN), 7.28 (3H, s, NCH=CHN), 
5.43 (6H, s, CH2N), 2.71 (6H, q, J = 8.2 Hz, CH2CH3), 1.62 (27H, s, C(CH3)3), 0.76-0.71 (9H, 
m, CH2CH3). 
13C NMR (75 MHz, DMSO-d6, 298 K) δ 147.7 (CCH2CH3 or CCH2N), 136.2 (NCHN), 122.3 
(CCH2CH3 or CCH2N), 128.9 (NCH=CHN), 120.8 (NCH=CHN), 60.1 (NC(CH3)3), 48.9 
(CH2N), 29.5 (C(CH3)3), 23.6 (CH2CH3), 15.2 (CH2CH3). 
ESI-MS calculated for C36H54N6Ag+ [M]+ 677.3455, found 677.3499. 
  






hexafluorophosphate (compound 91) 
 
In an oven-dried, argon-purged Schlenk flask, compound 87 (0.10 g, 0.09 mmol) and 
chloro(dimethylsulfide)gold(I) (0.026 g, 0.090 mmol) were dissolved in 20 mL of dry 
dichloromethane. The reaction mixture was stirred in the dark for 16 hours. The resulting cloudy 
solution was filtered through a Celite® pad, and the solution was treated with a saturated 
aqueous solution of ammonium hexafluorophosphate. After filtering off the precipitates, the 
clear solution was evaporated under reduced pressure to give the title compound as an off-white 
solid (0.068 g, 61%). 
ESI-MS calculated for C51H61N6AuPF6 [M+PF6]+ 1098.4181, found 1098.8146. 
UV-Visible (MeCN): 280 nm 
Fluorescence emission (Maximum, MeCN): 419 nm 
  






hexafluorophosphate (compound 92) 
 
Compound 92 was prepared following the experimental procedure for compound 91. 
Compound 87 (0.100 g, 0.09 mmol) and tetrakis(acetonitrile)copper(I) hexafluorophosphate 
(0.027 g, 0.09 mmol) were dissolved in dry dichloromethane. After recrystallization from a 
mixture of dichloromethane/n-pentane, the product was afforded as a white solid (0.057 mg, 
57%). 
1H NMR (400 MHz, CDCl3, 298 K) δ 8.82 (1H, s, N+CHN), 7.50 (2H, bs, N+HC=CHN), 7.29 
(4H, bs, N+HC=CHN), 7.00 (4H, s, yiliden-Mes-CH), 6.72 (6H, bs, Mes-CH), 5.81 (2H, bs, 
CH2N), 5.53 (2H, bs, CH2N), 5.32 (2H, s, CH2N+), 2.79-2.75 (6H, m, CH2CH3), 2.35 (6H, s, 
yliden-Mes-p-CH3), 2.18 (3H, s, Mes-p-CH3), 2.02 (12H, bs, yliden-Mes-o-CH3), 1.73 (6H, bs, 
Mes-o-CH3), 1.34-1.31 (3H, m, p-CH2CH3), 1.15-1.08 (6H, m, o-CH2CH3). 
ESI-MS calculated for C51H61N6CuPF6 [M+PF6]+ 965.3890, found 965.3866. 
UV-Visible (MeCN): 280 nm 
Fluorescence emission (Maximum, MeCN): 425 nm 
 
  




Reaction between compound 73 and Ru3(CO)12 to give compound 93 
 
1) One-pot reaction: Under anhydrous conditions with argon, triruthenium dodecarbonyl 
(0.039 g, 0.061 mmol), compound 73 (0.050 g, 0.061 mmol) and potassium tert-butoxide 
(tBuOK, 0.023 g, 0.20 mmol) were mixed in a Schlenk flask and solubilised in 8 mL of 
anhydrous THF. The reaction mixture was stirred for 48 hours until a dark orange solid 
precipitated. The solvent was removed and the solid was recrystallized from diethyl ether to 
give a brown solid (0.035 g). 
2) One-pot reaction: Same procedure as before, but with potassium bis(trimethylsilyl)amide 
(KHMDS) as base. The 1H NMR analysis performed on the dark red product showed no 
reaction had occurred between the Ru cluster and compound 73. 
3) Two step reaction:  
A) Formation of the free carbene: Under anhydrous conditions with argon, compound 73 (0.050 
g, 0.061 mmol) and potassium bis(trimethylsilyl) amide (0.038 g, 0.19 mmol) were dissolved 
in 10 mL of dry THF and stirred under anhydrous condition for 16 hours. During this time the 
white, cloudy reaction mixture turned to a pale-yellow solution. 
B) Formation of the metal complex: A solution of triruthenium dodecarbonyl (0.039 g, 0.061 
mmol) in 5 mL of dry THF was slowly cannulated into the reaction mixture from the previous 
passage. The solution turned orange and was stirred for a further 12 hours. After that time, the 
solid residue was separated from the solution by using a filter cannula and the resulting red 
solution was concentrated under vacuum. 20 mL of dry diethyl ether was added, then the two 
phases were separated and dried under vacuo. 1H NMR analysis performed on both fractions 
revealed the presence of large amounts of the starting compounds. 




4) Two step reaction:  
A) Formation of the free carbene: Under anhydrous conditions of argon compound 73 (0.050 
g, 0.061 mmol) and potassium bis(trimethylsilyl) amide (0.038 g, 0.19 mmol) were dissolved 
in 15 mL of dry THF and stirred under anhydrous condition for 16 hours. During this time the 
white, cloudy reaction mixture turned to a pale-yellow solution. 
B) Formation of the metal complex: The reaction mixture containing the carbene was cooled 
down to -78°C and a solution of Ru3(CO)12 (0.039 g, 0.061 mmol) in 5 mL of dry THF was 
slowly cannulated to the reaction mixture. The solution turned orange and was stirred for 16 
hours until the mixture reached room temperature. After that time, the solid residue was 
separated from the solution by using a filter cannula and the resulting red solution was 
concentrated under vacuum to .ca 1-2 mL before layering it with diethyl ether. The product was 
obtained as a red solid after filtration of the precipitated (0.032 g). 
1H NMR (400 MHz, CD3CN, 298 K) δ 7.59 (3H, s, N+CH=CHN), 7.08 (3H, s, NCH=CHN+), 
5.44 (6H, s, CH2N), 2.64 (6H, q, J = 7.5 Hz, CH2CH3), 1.61 (27H, s, C(CH3)3), 0.92 (9H, t, J = 
7.5 Hz, CH2CH3). 









imidazol-3-ium-2-ide) (compound 94) 
 
A Schlenk tube was charged with compound 72 (0.502 g, 0.65 mmol) and potassium 
bis(trimethylsilyl)amide (KHMDS) (0.388 g, 1.95 mmol). 15 mL of freshly distilled 
tetrahydrofuran was added, and the mixture was stirred at room temperature for 1.5 hours. The 
reaction mixture was filtered through a Celite® pad, the solvent removed under vacuum and 
the resulting oily yellow solid was washed with small aliquots of dry diethyl ether (3 x 5 mL) 
to give the desired product as a white powder (0.211 g, 74%). 
1H NMR (500 MHz, C6D6, 298 K) δ 6.63 (3H, s, NCH=CHN), 6.43 (3H, s, NCH=CHN), 5.20 
(6H, s, CH2N), 2.37 (9H, s, CH3), 1.47 (27H, s, C(CH3)3). 
13C NMR (125 MHz, C6D6, 298 K) δ 214.7 (NCN), 138.1 (Ar-C), 133.2 (Ar-C), 116.7 
(NCH=CHN), 115.0 (NCH=CHN), 55.4 (NC(CH3)3), 49.6 (CH2N), 31.2 (C(CH3)3), 16.4 (Ar-
CH3). 
Analysis consistent with literature data.9 
 
  




Reaction between compound 94 and Ru3(CO)12 
 
To a solution of triruthenium dodecarbonyl (0.041 g, 0.065 mmol) in 15 mL of dry THF, 
powdered compound 94 (0.050 g, 0.065 mmol) was added. The mixture immediately turned 
bright red. The reaction slurry was stirred for further 12 hours. After that time, the deep red 
solution was filtered and cooled to -30°C until formation of red crystals occurred (0.022 g).  
FT-IR (CH2Cl2, cm-1) 2071, 2027, 2006. 
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AAppendix A (Chapter 2) 
 
Figure A.1. 1H NMR (500 MHz, CDCl3, 298 K) spectrum of compound 60. For clarity, magnetically equivalent 
nuclei within the same NMR spin system are labelled once. * residual solvents and impurities traces. 
 
 
Figure A.2. 1H NMR (300 MHz, DMSO-d6, 298 K) spectrum of compound 65. For clarity, magnetically 







Figure A.3. 13C NMR (75 MHz, DMSO-d6, 298 K) spectrum of compound 65. § refers to aromatic C within the 
aromatic rings. For clarity, magnetically equivalent nuclei within the same NMR spin system are labelled once. 
 
 






Table A.1. Crystal data and structure refinement for compound 64. 
Identification code ox058 
Empirical formula* C44 H44 Br7 N7 O1 
Formula weight 926.59 
Temperature 293 K 
Wavelength 0.69110 Å 
Crystal system Triclinic 
Space group P-1 
Unit cell dimensions 
a = 11.4638(3) Å                 α = 93.770(1)° 
b = 13.5483(7) Å                 β = 105.543(1)° 
c = 16.9684(9) Å                 γ = 108.461(1)° 
Volume 2073.11(19) Å3 
Z 2 
Density 1.449 Mg/m3 
Absorption coefficient 2.962 mm-1 
F(000) 940 
Crystal size - 
Theta range for data collection 1.228 to 31.003° 
Index ranges -14<=h<=14, -19<=k<=19, -24<=l<=24 
Reflections collected 24216 
Independent reflections 12843 [R(int) = 0.064] 
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 1.00000 and 1.00000 
Completeness to theta = 67.684° 100% 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 8993 / 0 / 496 
Goodness-of-fit F2 1.0796 
Final R indices [I>2sigma(I)] R1 = 0.0500, wR2 = 0.0592 
R indices (all data) R1 = 0.0653, wR2 = 0.0665 
Extinction coefficient n/a 
Largest diff. peak and hole 1.15 and -0.80 e.Å-3 












BAppendix B (Chapter 3) 
 
Figure B.1. 13C NMR (75 MHz, DMSO-d6, 298 K) spectrum of compound 72. § refers to aromatic C within the 






Figure B.2. Mass spectrum of compound 75. Blue dotted box: ion species [M]3+ at m/z = 239.1537. 
 
 






Table B.1. Crystal data and structure refinement for compound 70. 
Identification code p18prr225_sq 
Empirical formula* C27 H39 F18 N6 P3 
Formula weight 882.56 
Temperature 150 K 
Wavelength 0.71073 Å 
Crystal system Trigonal 
Space group P-3 
Unit cell dimensions 
a = 11.6941(4) Å                 α = 90° 
b = 11.6941(4) Å                 β = 90° 
c = 16.2196(6) Å                 γ = 120° 
Volume 1920.90(15) Å3 
Z 2 
Density 1.526 Mg/m3 
Absorption coefficient 0.272 mm-1 
F(000) 900.0 
Crystal size 0.47 x 0.27 x 0.16 mm3 
Theta range for data collection 3.218 to 26.349° 
Index ranges -10<=h<=14, -14<=k<=12, -20<=l<=20 
Reflections collected 11040 
Independent reflections 2626 [R(int) = 0.0375] 
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 1.00000 and 1.00000 
Completeness to theta = 67.684° 100% 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 2626 / 15 / 189 
Goodness-of-fit F2 1.036 
Final R indices [I>2sigma(I)] R1 = 0.0396, wR2 = 0.0592 
R indices (all data) R1 = 0.1015, wR2 = 0.0923 
Extinction coefficient n/a 
Largest diff. peak and hole 0.277 and -0.331 e.Å-3 





Table B.2. Crystal data and structure refinement for compound 75·3PF6. 
Identification code s18p7 
Empirical formula* C50 H60 F18 N7 P3  
Formula weight 1193.96 
Temperature 150.0(2) K 
Wavelength 1.54184 Å 
Crystal system Monoclinic 
Space group P 21/c 
Unit cell dimensions 
a = 11.72750(10) Å             α = 90° 
b = 28.2893(3) Å                 β = 106.309(10)° 
c = 17.1865(2) Å                 γ = 90° 
Volume 5472.40(10) Å3 
Z 4 
Density 1.449 Mg/m3 
Absorption coefficient 1.926 mm-1 
F(000) 2464 
Crystal size 0.326 x 0.127 x 0.053 mm3 
Theta range for data collection 3.124 to 73.132° 
Index ranges -8<=h<=14, -32<=k<=34, -21<=l<=21 
Reflections collected 43265 
Independent reflections 10860 [R(int) = 0.0407] 
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 1.00000 and 0.69900 
Completeness to theta = 67.684° 100% 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 10860 / 0 / 753 
Goodness-of-fit F2 1.037 
Final R indices [I>2sigma(I)] R1 = 0.0455, wR2 = 0.1145 
R indices (all data) R1 = 0.0552, wR2 = 0.1210 
Extinction coefficient n/a 
Largest diff. peak and hole 0.386 and -0.342 e.Å-3 
* Moiety formula (estimated from “checkcif”): C48 H57 N6, 3(F6 P), C2 H3 N C48 H57 N6, 





Table B.3. Crystal data and structure refinement for compound 76·3PF6 in “closed arms” conformation”. 
Identification code e17sip1 
Empirical formula* C59 H75 F18 N10 P3 
Formula weight 1359.20 
Temperature 150.0(3) K 
Wavelength 0.71073 Å 
Crystal system Orthorhombic 
Space group Pnma 
Unit cell dimensions 
a = 24.1394(9) Å             α = 90° 
b = 21.1348(10) Å           β = 90° 
c = 12.8990(6) Å             γ = 90° 
Volume 6580.8(5) Å3 
Z 4 
Density 1.372 Mg/m3 
Absorption coefficient 0.187 mm-1 
F(000) 2824 
Crystal size 0.480 x 0.270 x 0.100 mm3 
Theta range for data collection 3.269 to 26.448° 
Index ranges -30<=h<=30, -26<=k<=26, -16<=l<=16 
Reflections collected 82739 
Independent reflections 6926 [R(int) = 0.0983] 
Absorption correction Analytical 
Max. and min. transmission 0.987 and 0.957 
Completeness to theta = 67.684° 99.8% 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 6926 / 72 / 532 
Goodness-of-fit F2 1.017 
Final R indices [I>2sigma(I)] R1 = 0.0545, wR2 = 0.1153 
R indices (all data) R1 = 0.0967, wR2 = 0.1331 
Extinction coefficient n/a 
Largest diff. peak and hole 0.368 and -0.363 e.Å-3 
* Moiety formula (estimated from “checkcif”): C51 H63 N6, F2.40 P0.40, 2(F6 P), 2(F1.80 





Table B.4. Crystal data and structure refinement for compound 76·3PF6 in “open arms” conformation”. 
Identification code e17sip3 
Empirical formula* C51 H63 F18 N6 P3 
Formula weight 1194.98 
Temperature 150.0(3) K 
Wavelength 0.71073 Å 
Crystal system Triclinic 
Space group P-1 
Unit cell dimensions 
a = 10.1987(4) Å             α = 110.980(4)° 
b = 16.8351(7) Å             β = 96.945(4)° 
c = 17.7222(9) Å             γ = 97.767(4)° 
Volume 2767.5(2) Å3 
Z 2 
Density 1.434 Mg/m3 
Absorption coefficient 0.210 mm-1 
F(000) 1236 
Crystal size 0.600 x 0.180 x 0.090 mm3 
Theta range for data collection 3.373 to 29.746° 
Index ranges -13<=h<=14, -23<=k<=22, -22<=l<=24 
Reflections collected 48157 
Independent reflections 13603 [R(int) = 0.0478] 
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 1.00000 and 0.86805 
Completeness to theta = 67.684° 99.8% 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 13603 / 0 / 735 
Goodness-of-fit F2 1.014 
Final R indices [I>2sigma(I)] R1 = 0.0691, wR2 = 0.1329 
R indices (all data) R1 = 0.1186, wR2 = 0.1537 
Extinction coefficient n/a 
Largest diff. peak and hole 0.460 and -0.427 e.Å-3 






Figure B.4. Crystal structure of compound 70 (generated from “checkcif”). 
 
 






Figure B.6. Crystal structure of compound 76·3PF6 in “closed arms” conformation (generated from “checkcif”). 
 






Figure B.8. Epi-fluorescence acquisition of PC3 cells incubated for 15 min with compound 76 (a-e), compound 
73 (f-j), and DMSO control (k-o). Final concentrations 50 × 10-6 M in 5:95 DMSO:serum-free medium at 37°C. 
a,f) DIC channel; b,g) blue channel, λem = 460.0 nm; c,h) green channel λem = 525.0 nm; d,i) red channel λem = 
629.5 nm; e,j) overlay of DIC-blue-green-red channels. Scale bars: 50 μm a-e) and k-o), 20 μm f-j). 
 
 
Figure B.9. Single-photon laser-scanning confocal microscopy of PC-3 cells incubated at 37°C for 15 min with 
compound 76 (a–d), and compound 73 (e–h) (50 × 10−6 M, in 5:95 DMSO:serum-free medium). a,e) blue channel 
(417–477 nm); b,f) green channel (500–550 nm); and c,g) red channel (570–750 nm); d,h) overlay of the blue–






CAppendix C (Chapter 4) 
 





DAppendix D (Chapter 5) 
Radiolabelling of tripodal ATSC-based ligands with zirconium-89 
The positron-emitter radiotracer zirconium-89 was generated at the Wales Research and 
Diagnostic Positron Emission Tomography Imaging Centre (PETIC) via the 89Y(p,n)-89Zr 
reaction using the cyclotron CYCLONE 18/9. 89Zr was obtained as a 1 M solution in oxalic 
acid, which was neutralised to pH 7 with a 1 M aqueous solution of sodium carbonate. To this, 
a 1 mM solution of compound 84 in 1:1 DMSO:water was added. The reaction mixture was 
stirred at 60°C for 16 hours. The radiolabelling activity was probed by radio-TLC using a 50 
mM solution of diethylenetriaminepentaacetic acid (DTPA) to chelate all the free 89Zr4+ ions. 
The chelate 89Zr-DTPA elute with the solvent front with a Rf > 0.9 (Figure D.1). 
 
Figure D.1. Radio-TLC chromatogram of the 89Zr-DTPA chelate (Region 2). 
Radio-TLC analysis of the reaction product (Figure D.2) showed that the radiolabelling 
efficiency was ≥ 99.9%. These preliminary data suggest that 84 may be a potential new chelator 






Figure D.2. Radio-TLC chromatogram of 84 with 89Zr. The radio-TLC was eluted using 50 mM DTPA solution 







Figure D.3. 13C NMR (75 MHz, DMSO-d6, 298 K) spectrum of the deprotonated compound 72. C: refers to the 
carbene, § refers to aromatic C within the aromatic ring. For clarity, magnetically equivalent nuclei within the 
same NMR spin system are labelled once. 
 
 






Table D.1. Crystal data and structure refinement for the reaction product between compound 94 and Ru3(CO)12. 
Identification code e17sip7 
Empirical formula* C181.80 H247.20 Br6 N24 O49.80 Ru12 
Formula weight 5257.91 
Temperature 149.97(10) K 
Wavelength 0.71073 Å 
Crystal system Trigonal 
Space group R-3 
Unit cell dimensions 
a = 20.5077(8) Å               α = 90° 
b = 20.5077(8) Å               β = 90° 
c = 43.7192(13) Å             γ = 120° 
Volume 15923.4(13) Å3 
Z 3 
Density 1.645 Mg/m3 
Absorption coefficient 2.035 mm-1 
F(000) 7927 
Crystal size 0.370 x 0.130 x 0.080 mm3 
Theta range for data collection 3.430 to 27.528° 
Index ranges -26<=h<=21, -22<=k<=25, -56<=l<=55 
Reflections collected 38075 
Independent reflections 8095 [R(int) = 0.0625] 
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 1.00000 and 0.76511 
Completeness to theta = 67.684° 99.7% 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 8095 / 62 / 541 
Goodness-of-fit F2 1.029 
Final R indices [I>2sigma(I)] R1 = 0.0498, wR2 = 0.1064 
R indices (all data) R1 = 0.0949, wR2 = 0.1254 
Extinction coefficient n/a 
Largest diff. peak and hole 0.679 and -0.638 e.Å-3 















Figure D.6. Single-photon laser-scanning confocal microscopy images of Chinese hamster ovary cells (CHO) 
incubated with compound 87 (10 µg/mL 1% : 99% DMSO : DMEM) at 37 ºC for 16 hours; λex = 405 nm (a1-a5), 
λex = 488 nm (b1-b5) and λex = 561 nm (c1-c5). Overlapping of the DIC, blue, green and red channels (a1, b1, c1), 
blue channel, λem = 420-480 nm (a2, b2, c2), green channel, λem = 516-530 nm (a3, b3, c3), red channel λem = 615-






Two-photon fluorescence lifetime imaging microscopy of tripodal metal complexes 
Fluorescence lifetime, defined as the average time in which a fluorescent molecule remains in 
an excited state before returning to the ground state by releasing a photon, is an intrinsic 
property of every fluorophore and is influenced by fluorescence intensity and concentration. 
Fluorescence lifetime imaging (FLIM) is an optical imaging technique that relies on the 
fluorescence lifetime of an individual fluorophore (e.g. in a biological sample) rather than its 
emission spectrum. 
Preliminary FLIM experiments were carried out on selected metal complexes (described in 
Chapter 5) in order to study their lifetime characteristics in solution and in human breast cancer 
cells (MCF7). Prior to in-vitro experiments, time-correlated single-photo counting (TCSPC) 
measurements were carried out to test the lifetime of the selected metal complexes in solution, 
using DMSO as solvent. TCSPC and FLIM experiments were carried out at the Rutherford 
Appleton Laboratory (RAL), in the Central Laser Facility (CLF) by Dr Fernando Cortezon 
Tamarit and Dr Haobo Ge. 
TCSPC decay curves were generated for compounds 85 (Figure D.7) and 87 (Figure D.8). In 
TCSPC, each photon detected was plotted to calculate the fluorescence lifetime. The results 
consist of three components: the quality of fit χ2, the lifetime τn (ns), and the lifetime percentage 
an (%). TCSPC results for 87 are shown below in Table D.2. 
 
Figure D.7. TCSPC decay and fitting curves for compound 85 (10 mM in DMSO, excited at 810 nm with a laser 






Figure D.8. TCSPC decay and fitting curves for compound 87 (10 mM in DMSO, excited at 810 nm with a laser 
power of 3 mW for 10 s). The data were collected from three repeated measurements on the same day. 
 
Table D.2. TCSPC data for compound 87. 
Compound χ2 τ1 (ns) a1 (%). τ2 (ns) a2 (%). τm (ns) 
87 1.16 0.69 51.63 5.30 48.37 2.92 
 
Two-photon FLIM mapping and intensities in MCF7 cells were produced for compounds 85 
and 86. From the two-photon fluorescence intensity diagrams (Figure D.9 (A) and Figure D.10 
(A)) and the fluorescence lifetime mapping in MCF7 cells (Figure D.9 (B) and Figure D.10 
(B)), it was possible to observe that the compounds are able to accumulate into the cell 
membrane and no emission appears to originate from the nuclei. From the fluorescence lifetime 
mappings, it was possible to generate fluorescence lifetime distribution curves (Figure D.9 (C) 
and Figure D.10 (C)), which represent the overall fluorescence lifetime of the compounds in 
MCF7 cells. The distribution of these curves is proportional to the individual lifetimes recorded 
for each lifetime component. For compound 85, the average lifetime distribution is around 1.5 






Figure D.9. (A) Two-photon intensity diagram; (B) fluorescence lifetime mapping of τm and (C) fluorescence 
lifetime distribution curve of MCF7 cells treated with 0.1 mM solution of 85 in DMSO (incubation time = 1h, 
laser power = 5.3 mW, acquisition time = 90 sec, λex = 810nm). 
 
 
Figure D.10. Two-photon intensity diagram; (B) fluorescence lifetime mapping of τm and (C) fluorescence lifetime 
distribution curve of MCF7 cells treated with 0.1 mM solution of 86 in DMSO (incubation time = 1h, laser power 







Experimental procedures for the fluorescence lifetime measurements 
Time-correlated single photon counting (TCSPC). Lifetime measurements were recorded 
using TCSPC with an excitation wavelength of 910 nm and the emission measured at 360-580 
nm. The measurement of compounds 85 and 87 were carried out in DMSO/ water solvent with 
concentration of 10 mM. Emission spectral detection was carried out using an Acton Research 
Component 275 spectrograph and an Andor iDus 740-BU CCD camera. 
Confocal microscopy. Fluorescence microscopy images were captured on a Nikon eclipse 
TE2000 epifluorescence or a Zeiss LSM510META microscope at University of Bath, whereas 
at the Rutherford Appleton Laboratory a modified Nikon TE2000-U was utilised. MCF7 cells 
were cultured and plated in a glass bottomed petri dish (35 mm diameter and 1.5 mm thickness) 
at 1.5×105 -2.5×105 cells per dish depending on the culture time. In general, MCF7 cells needed 
48 hours to adhere. Prior to the microscopy observation, cultured cells were washed with PBS 
three times and refilled with 990 μL of serum free medium. Subsequently, a small volume of 
compound (10 μL) in DMSO was loaded to make the final volume 1 mL at the appropriate 
concentration. The final concentration on the plate were usually at 100 μM with 1% - 5% 
DMSO depending on the compound solubility. After 1 hour of incubation at 37 °C, cells were 
washed with HBSS three times and refilled with fresh SFM (1 mL). Confocal images were 
captured immediately afterwards. 
Fluorescence lifetime imaging microscopy (FLIM). Cell uptake studies were performed 
using MCF7 cells. The cells were plated on a glass petri dishes and left to attach for 12-24 
hours, depending on the growth rate. Control FLIM were recorded before the addition of the 
compounds. Plates were then mounted on the microscope stage and kept at 37ºC. 
The compounds were dissolved in DMSO and added to cells to achieve final concentration of 
100μM in DMEM/RPMI medium containing 1% of DMSO. The cells were incubated for 1 
hour prior to confocal imaging, FLIM was carried out immediately after the microscopy 











Synthesis of the peptide fragment [7-13]-bombesin 
As already mentioned in Chapter 1, the possibility to develop nanotherapeutics that can also 
display specificity for the cancer cells is crucial for both diagnosis and therapy. Hence, we 
decided to develop a small targeting peptide that can be easily conjugated to the luminescent 
metal complex. Thus, we opted for the fragment 7-13 of the bombesin, a short peptide involved 
in cancer growth. The bombesin displays high affinity for the Gastrin-releasing peptide receptor 
(GRPR), a member of the family of the G-protein, which is found to be overexpressed in various 
types of prostate cancers. 
 
Figure E.1. Structural representation of the D-[7,13]-bombesin fragment. 
We decided to perform a solid phase synthesis of the sequence 7-13 of the bombesin peptide. 
Furthermore, we also chose to synthesise the D-[7-13]-bombesin fragment (Figure E.1) in order 
to achieve a targeting molecule less susceptible to proteolytic degradation and digestion 
compared to the natural L-version. A general scheme of the synthetic pathway for the synthesis 





Figure E.2. Synthetic steps for the [7-13]-bombesin peptide fragment. 
The characterisation of the D-[7-13]-bombesin fragment was performed using reverse phase 
HPLC and electrospray ionisation mass spectrometry (ESI-MS) techniques. The results, shown 
in Figure E.3 and Figure E.4, showed that the synthesis was successful, and the product was 
obtained with high purity. This work was carried out in collaboration under the supervision of 
Dr Ruggero Dondi, at the Department of Pharmacy & Pharmacology, University of Bath. 
 
Figure E.3. HPLC chromatogram of the purified D-[7-13]-bombesin fragment. 
 
















Experimental procedure for the synthesis of the [7-13]-bombesin 
The peptide fragment [7-13]-bombesin was assembled by Fmoc solid phase peptide synthesis on 
Rink Amide MBHA Resin (Novabiochem, 200-400 mesh, assumed 0.6 mmolg-1 loading) using 
an Activotec Activo-P11 automated peptide synthesizer. The first residue was attached to the 
resin manually as follows. The resin (250 mg, 0.15 mmol) was placed in a 10 ml plastic reactor 
and was swollen in dimethylformamide DMF (15 min). The Fmoc protection was removed by 
treatment with 20% piperidine/DMF (3 cycles, 12 minutes and two rounds of 3 minutes each). 
After washing thoroughly with DMF to remove traces of piperidine, the deprotection was 
confirmed by a positive Kaiser test. Fmoc-Gln-OH (251 mg, 0.59 mmol, 4 eq) in DMF (2.5 ml) 
was preactivated by treatment with N,N′-diisopropylcarbodiimide (DIC, 94 μL, 0.96 mmol, 6 
eq.) and HOBt (81 mg, 0.59 mmol, 4 eq). After 3 h, this solution was added to the deprotected 
resin, followed by DIEA (157 μL, 0.96 mmol, 6 eq) and the vessel was shaken for 45 min. The 
vessel was then transferred to the automated synthesiser, and the reaction vessel was fitted with 
a heating jacket (60ᵒC). Subsequent Fmoc deprotection steps were performed using 20% 
piperidine/DMF (3 ml, 5 + 10 min). Amino acid couplings were performed with 3 eq of each 
Fmoc-protected amino acid, 3 eq. of PyBop (0.2 M) and 6 eq. of DIEA (0.4 M) in DMF. No 
final Fmoc deprotection step was performed to allow for subsequent elaboration of the peptide 
on the resin. After the synthesis, cleavage of the peptide from the resin was performed by 
mixing a small amount of the resin with a mixture of TFA/TIS/H2O (95:25:25) for 2 h. The 
resin beads were removed by filtration and the peptide was precipitated by addition of 
anhydrous Et2O. The white precipitate was collected by centrifugation and washed with further 
Et2O (3 x 1.5 ml). The solvent was removed, and the product was obtained as a white solid 
Rt = 4.93 min; 
ESI-MS calculated for C38H56N12NaO8 m/z [M+H]+  831.4236, found 831.4277 
 
 
 
